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The presynaptic protein alpha-
synuclein (α-syn) plays a crucial role 
in dopamine neurotransmission and 
pathology of Parkinson’s disease. 
However, its precise functions in the 
dopaminergic system are unknown. 
This thesis shows that α-syn plays an 
important role in the dorsal region 
of the striatum, where it modulates 
striatal neurochemistry, short-term 
plasticity of dopamine release, and 
may mediate the pharmacological 
action of psychostimulants.
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ABSTRACT 
 
Alpha-synuclein (α-syn) is an important presynaptic protein regulating critical aspects of 
dopamine (DA) neurotransmission. Causative mutations in the SNCA gene that encodes α-
syn have been implicated in several neurological disorders including Parkinson’s disease 
and addiction. Despite the numerous functions of α-syn and interactions with important 
presynaptic proteins, the precise role of α-syn in the dopaminergic system is poorly 
understood. This work was undertaken to elucidate the role of α-syn in the striatal 
dopaminergic system using wild-type and two α-syn deficient mouse lines and in vivo 
electrochemical techniques.  
The first study focused on the role of α-syn in the dorsal striatum, the region most 
vulnerable to degeneration in PD. We found that absence of α-syn significantly increased 
evoked DA overflow and basal extracellular DA levels in two mouse lines lacking α-syn in 
comparison with wild-type mice. These changes were accompanied with a concomitant 
decrease in dopamine transporter (DAT) expression and DA re-uptake, highlighting that 
the absence of α-syn produces long-term changes in striatal neurochemistry and DAT 
protein expression.  
The second study investigated the subregion specific role of α-syn in the short-term 
plasticity of DA overflow dependent on redistribution of presynaptic vesicle pools. We 
found a peculiar dorsolateral-ventromedial gradient of alterations in the short-term 
plasticity of DA overflow in α-syn deficient lines, which correlates with the degeneration 
pattern of DA neurons in PD. This suggests that α-syn may play a subregion specific role in 
striatal DA neurotransmission, possibly through regulation of vesicle pools.  
Due to the common mechanisms of action between methylphenidate (MPD) and α-syn, 
such as re-uptake modulation and redistribution of vesicle pools, we hypothesized that α-
syn may mediate the effect of MPD on DA neurotransmission. We observed that MPD 
modulates overflow and compartmentalization of presynaptic DA via an α-syn dependent 
mechanism of vesicle mobilisation. MPD affects DA release but not re-uptake in an α-syn-
dependent manner by differentially altering DA release probability.  
A part of the work was also devoted to improving the technique for DA detection using 
fast-scan cyclic voltammetry. In this work, a 32 μm carbon fibre electrode with a 14-fold 
greater sensitivity than conventional electrodes and novel parameters of voltage 
application with 65% greater sensitivity for DA detection were developed.  
Overall, the findings of this thesis improve our understanding of the role of α-syn in 
regulating DA neurotransmission, and effects of therapeutic drugs in striatal subregions.  
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TIIVISTELMÄ 
 Alfa-synukleiini (α-syn) on tärkeä proteiini hermopäätteiden dopamiini (DA) -
välitteisen viestinnän säätelyssä. α-Syn:a koodaavan SNCA-geenin mutaatioita on löydetty 
Parkinsonin taudissa ja riippuvuudessa. α-Syn:n lukuisat tehtävät ja vuorovaikutus monien 
tärkeiden hermopäätteissä sijaitsevien proteiinien kanssa osoittavat sen keskeisen 
merkityksen hermoston rappeumasairauksissa ja psykiatrisissa sairauksissa. Kaikesta 
huolimatta α-syn:n tarkka fysiologinen ja patologinen merkitys tunnetaan vielä varsin 
huonosti. Tämän väitöskirjatyön tarkoitus oli selvittää α-syn:n merkitystä striatumin 
(aivojuovio) dopaminergisessa hermotuksessa. Käytimme kokeissa villityyppisten hiirten 
lisäksi myös kahta hiirilinjaa, joilta puuttuu α-syn:a koodaava geenialue, sekä 
sähkökemiallisia in vivo -tekniikoita.  
Ensimmäinen osatyö keskittyi striatumin dorsaaliseen osaan, joka on herkin Parkinsonin 
tautiin liittyvälle rappeutumiselle. Havaitsimme, että α-syn:n puute lisäsi merkitsevästi 
DA:n vapautumista ja solunulkoisia pitoisuuksia kahdella mutattihiirilinjalla villityyppisiin 
hiiriin verrattuna. Näihin muutoksiin liittyi samanaikainen DA-kuljetusproteiinin (DAT) 
määrän ja DA:n takaisinoton väheneminen, mikä osoittaa, että α-syn:n puute johtaa 
pitkäkestoisiin muutoksiin striatumin neurokemiassa.  
Toinen osatyö selvitti aluekohtaisesti α-syn:n merkitystä DA:n vapautumisen 
lyhytkestoisessa muovautuvuudessa striatumissa. Havaitsimme muovautuvuudessa 
dorsolateraalis-ventromediaalisen gradientin joka vastaa Parkinsonin taudissa esiintyvien 
hermosolujen rappeuman jakaumaa. Nämä havainnot viittaavat siihen, että α-syn:lla olisi 
eri merkitys DA-välitteiselle hermovälitykselle striatumin eri osissa, mikä mahdollisesti 
liittyy välittäjäainerakkuloiden liikkuvuuden säätelyyn hermopäätteissä.  
Metyylifenidaatti (MPD) on monilta vaikutusmekanismeiltaan samanlainen kuin α-syn. 
Se esimerkiksi muuntelee DA:n takaisinottoa ja välittäjäainerakkuloiden jakautumista 
hermopäätteessä. Havaintojemme mukaan MPD muuntelee DA:n vapautumista ja 
jakautumista hermopäätteessä α-syn:sta riippuvaisella mekanismilla. MPD vähensi DA:n 
vapautumista α-synukleiinittomilta hiiriltä alentamalla DA:n vapautumisen 
todennäköisyyttä, mutta ei vaikuttanut tähän mekanismiin villityyppisillä hiirillä.  
Kehitimme myös DA:n mittaustekniikkaa käyttämällä syklistä voltammetriaa. Tätä 
varten suunnittelimme uudenlaisen, halkaisijaltaan 32 μm olevan hiilikuituelektrodin, joka 
on 14 kertaa herkempi kuin perinteinen elektrodi. Kehittelimme myös elektrodin 
jännitevaihteluiden muuttujia ja pystyimme parantamaan menetelmän herkkyyttä 65 %.  
Yleisesti ottaen tämän väitöskirjan löydökset auttavat ymmärtämään α-syn:n merkitystä 
DA-välitteisen hermovälityksen säätelyssä ja tähän järjestelmään vaikuttavien lääkkeiden 
erilaisia vaikutuksia striatumin eri osissa. 
 
Luokitus: QV 126, WK 725, WL 102.8, WL 307, WL 359 
Yleinen suomalainen asiasanasto: aivot; hermosolut; neurotransmissio; välittäjäaineet; dopamiini; alfa-
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SAMMANFATTNING 
 
Alfa-synuklein (α-syn) är en viktig pre-synaptisk protein som reglerar kritiska aspekter 
av dopamin (DA) neurotransmission. Mutationer i genen för α-syn (SNCA) ökar risken för 
Parkinsons sjukdom (PD) och beroende. Forskning har påvisat att α-syn påverkar den 
dopaminerga neurotransmissionen, syntesen och utsöndringen av DA, vesikel organisation 
och nervcellens synaptisk plasticitet. Trots detta är α-syns exakta fysiologiska och 
patologiska funktioner fortfarande okända. I denna avhandling har jag studerat vilken roll 
α-syn spelar i det striatala dopaminerga systemet som blir störd i dopaminerga sjukdomar. 
Till detta ändamål har vi använt oss av möss som saknar α-syn tillsammans med 
elektrokemiska tekniker in vivo.  
I den första studien har vi fokuserat på den bakre delen av striatum, eller dorsal 
striatum, som är mest sårbar för degeneration i PD. Vi fann att möss som saknar α-syn har 
ökad DA utsöndring och högre extracellulära DA nivåer jämfört med kontrollgruppen 
samtidigt som DA transporterarens (DAT) nivåer och DA upptag blev nedsatta. Detta tyder 
på att avsaknad av α-syn medför långvariga förändringar i den striatala neurokemin och 
DAT protein uttryck. 
Den andra studien utreder α-syns regionspecifika roll i kort-tids plasticitet som beror på 
omfördelningen av presynaptiska vesikler. Hos möss som saknade α-syn var denna typ av 
plasticitet förändrad i dorsolaterala striatum, medan den dorsomediala och ventrala 
striatum var mindre drabbade, vilket liknar förändringarna inom PD. Den här studien visar 
att α-syn har regionspecifika effekter på den striatala DA neurotransmissionen, möjligtvis 
genom regleringen av presynaptiska vesikler. 
Metylfenidat (MPD) och α-syn har gemensamma mekanismer som till exempel 
regleringen av presynaptiska vesikler och modulering av DA upptag. Den tredje studien 
påvisar att MPD modulerar utsöndringen och sorteringen av presynaptisk DA genom 
mobiliseringen av dopaminfyllda vesikler, effekter som var beroende av α-syn. MPD 
minskar DA utsöndring men inte återupptag genom att selektivt minska DA utsöndrings 
sannolikheten. 
Studie fyra fokuserade på att förbättra våra tekniker för att detektera DA in vivo med 
hjälp av fast-scan cyklisk voltammetri. Vi har utvecklat en ny 32 μm kolfiber elektrod som 
är 14 gånger mer känslig för DA än vanliga elekrtoder och tillsammans med nya 
parametrar har 65% högre känslighet för DA.   
Sammanfattningsvis påvisar denna avhandling nya fynd kring de effekter som α-syn har 
i det dopaminerga systemet och vilka mekanismer som ligger bakom dessa effekter. 
Dessutom ger utvecklingen av en ny elektrod med högre känslighet för DA en viktig 
verktyg för framtida studier.       
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3-MT  3-methoxytyramine 
6-OHDA 6-hydroxydopamine 
α-syn  Alpha-synuclein  
AADC  Aromatic L-amino acid 
decarboxylase 
aCSF  Artificial cerebrospinal fluid 
AD  Alzheimer’s disease 
ADHD Attention deficit 
hyperactivity disorder 
AMPA 2-amino-3-(3-hydroxy-5-
methyl-isoxazol-4-yl) 
propanoic acid 
ANOVA Analysis of variance 
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b6─  C57BL/6JOlaHsd Harlan 
b6─ros B6;129X1-Sncatm1Rosl/J 
β-syn  Beta-synuclein 
CFE  Carbon fibre electrode 
CNS  Central nervous system 
COMT Catechol-O-methyl 
transferase 
CPA Constant potential 
amperometry 
CPu  Caudate-putamen 
CSP-α  Cysteine string protein α 
CV  Cyclic voltammogram 
DA  Dopamine 
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1 Introduction 
Dopamine (DA) is a crucial and one of the most intensively studied neurotransmitters in 
the brain. DA, chemically also known as 3-hydroxytyramine, was first identified as a 
neurotransmitter in the brain in 1958 (Carlsson and Waldeck, 1958; Carlsson, 1958). 
Subsequently, it was found that DA plays an important role in the mammalian central 
nervous system (Bertler and Rosengren, 1959a,b,c; Ehringer and Hornykiewicz, 1960), and 
in the gastrointestinal and peripheral nervous system (Maxwell et al., 1960).  
DA neurons are a population of cell bodies in the brain which synthesise, store, and 
release the neurotransmitter DA. Although DA neurons make up less than 1% of all the 
neurons in the brain, they play a pivotal role in modulating day-to-day functions and 
behaviours. DA is commonly described as a “reward” molecule, and plays an important 
role in social interactions. DA is essential for evolutionarily critical behaviours such as 
seeking food and sex (Zhou and Palmiter, 1995). Rewarding experiences such as success 
and positive social interaction induce the release of DA to encode the reward value of these 
experiences and reinforces the desire to repeatedly seek these rewarding experiences 
(Schultz, 2007). Consequently, DA plays a crucial role in motivation and goal-directed 
behaviour. DA facilitates learning of new behaviours and modulates memory and higher 
level cognitive and executive functions. Given the role of DA in encoding reward, it is also 
a target of numerous drugs of abuse including cocaine, amphetamines, and alcohol. These 
drugs are known to increase DA levels in certain brain regions and produce feelings of 
pleasure, euphoria, and psychomotor stimulation (for a review, see Di Chiara and Bassareo, 
2007). Another critical function of DA is the regulation of movement. DA regulates key 
aspects of voluntary and involuntary movement, and dopaminergic stimulation is essential 
for the maintenance of motor function (Filion et al., 1991; Schultz et al., 1989a,b).  
The primary reason for extensive interest in studying the dopaminergic system is the 
role of DA in neurodegenerative and neuropsychiatric disorders. Dopaminergic neurons 
innervate several brain structures, and dopaminergic dysfunction can give rise to a host of 
debilitating diseases. Impaired dopaminergic function has been implicated in, for example, 
Parkinson’s disease (PD), addiction, attention deficit hyperactivity disorder (ADHD), and 
schizophrenia. Currently, PD remains a highly untreatable disease causing progressive and 
irreversible loss of functions while addiction and schizophrenia are treatment resistant, 
frequently resulting in relapse. The neurobiological basis of ADHD also remains poorly 
understood. DA is also implicated in certain less prevalent disorders such as personality 
disorders, bipolar disorder, and restless leg syndrome. Considerable amount of research 
has been directed towards understanding dopaminergic disorders and finding appropriate 
therapeutic targets. Wide ranging investigations of genetic polymorphisms and molecular 
factors affecting different aspects of DA neurotransmission including DA release, re-
uptake, synthesis and storage, enzymatic breakdown, expression of DA transporters and 
receptors, have been performed using various techniques and genetically-modified animal 
models to improve our understanding of dopaminergic disorders.  
In the late 1990s, a series of discoveries on the presynaptic protein known as alpha-
synuclein (α-syn) attracted scientists’ attention with regards to its role in PD and the 
dopaminergic system. α-Syn was found to be a major component of the pathological 
hallmark of PD known as the Lewy bodies (Spillantini et al., 1998). Around the same time, 
causative mutations in the SNCA gene, which encodes the presynaptic protein α-syn, were 
discovered in familial as well as sporadic forms of PD (Polymeropoulos et al., 1997; Krüger 
et al., 1998). Aggregations and misfolding of α-syn were also found in other 
neurodegenerative disorders such as Alzheimer’s disease (AD) (Spillantini et al., 1998). PD 
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is the second most prevalent neurodegenerative disease affecting nearly 1% of the 
population over 60 and 4% over the age of 80. The precise causes leading to the 
development of PD are unknown. Therefore, studies showing the involvement of α-syn in 
PD attracted immense interest in exploring the physiological and pathological role of this 
protein. Subsequently, α-syn was shown to regulate fundamental aspects of DA 
neurotransmission such as DA synthesis (Perez et al., 2002), release (Abeliovich et al., 2000), 
re-uptake (Lee et al., 2001), synaptic plasticity (Cabin et al., 2002; Yavich et al., 2004; Martin 
et al. 2004), and survival of DA neurons (Chandra et al., 2005; Gorbatyuk et al., 2008; 
2010a,b). Consistent with the extensive involvement of α-syn in DA neurotransmission, it 
was found to play a role in neuropsychiatric disorders. A study showed that genetic 
variation in α-syn expression could be a predisposing factor for alcoholism and drug abuse 
(Liang et al., 2003; Bönsch et al., 2004; Foroud et al., 2007). Furthermore, recreational use of 
cocaine, heroin, and morphine was shown to affect α-syn expression levels in the brain 
(Mash et al., 2008; Ziolkowska et al., 2005; Dürsteler-Macfarland et al., 2011).  
Despite clear evidence on the importance of α-syn in physiological and 
pathophysiological processes in the dopaminergic system, the precise functions of this 
protein are still poorly understood. This study was aimed at examining the physiological 
role of α-syn in the striatal dopaminergic system, which is the key DA system affected in 
PD, addiction, and other dopaminergic disorders such as ADHD. The study used wild-type 
mice and two mouse lines lacking the expression of α-syn to understand its functions in the 
striatum, which is densely innervated by DA. DA neurotransmission was studied using 
several techniques, with a primary focus on in vivo voltammetric methods. The findings 
suggest that α-syn plays a crucial role in regulating DA neurotransmission in the dorsal but 
not ventral regions of the striatum. Significant neurochemical alterations were observed in 
the striatum in the absence of α-syn. Further, α-syn may play a crucial role in modulating 
the pharmacological effects of psychostimulants such as methylphenidate, which is the 
most widely prescribed medication to treat ADHD. A part of this work was devoted to 
improve the electrochemical technique for in vivo detection of DA, which is currently being 
used to further our understanding of the dopaminergic system and the role of α-syn in it.  
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2 Review of the literature 
 
2.1 ANATOMY OF THE DOPAMINERGIC SYSTEM 
Dopamine (DA) belongs to the catecholamine family of neurotransmitters. The 
dopaminergic system consists of neurons which synthesize and release DA. The 
dopaminergic pathways consist of cell bodies and topographic axonal projections 
originating primarily from the substantia nigra (SN), ventral tegmental area (VTA), and the 
arcuate nucleus of the hypothalamus. These axons project the terminal fields in different 
brain areas of the basal ganglia and cortex (Lindvall et al., 1977a,b; Lindvall and Björklund, 
1978; Lindvall et al., 1979; Björklund and Skagerberg, 1979a). Depending on the origins of 
ascending axonal projections and their innervation targets, DA pathways are divided into 
the following 4 major pathways: 
 
1. Nigrostriatal pathway  
2. Mesolimbic pathway 
3. Mesocortical pathway 
4. Tuberoinfundibular pathway 
However, it must be noted that these pathways are not distinct and a significant overlap 
exists between them. A large proportion of the ascending DA fibres exiting the SN and 
VTA pass through an anatomical tract called the medial forebrain bundle (Moore and 
Bloom, 1978). 
The nigrostriatal pathway consists of A8 and A9 subpopulations of DA neurons 
originating primarily from the retrorubral area and substantia nigra pars compacta (SNc) 
(Dahlström and Fuxe, 1964). These neurons project to two main structures known as 
caudate nucleus and putamen in humans and primates (Madras and Kaufman, 1994). In 
rodents, the two structures are largely indistinguishable and are collectively referred to as 
caudate-putamen or dorsal striatum (Fig. 1) (Franklin and Paxinos, 2007). A subset of 
nigrostriatal neurons also branches to other structures of the basal ganglia such as the 
globus pallidus external (GPe) and internal segment (GPi) and the subthalamic nucleus 
(STN) (Lindvall and Björklund, 1977a,b; 1979; Hassani, 1997), forming an important part of 
the sensorimotor pathway (for a review, see Björklund and Dunnett, 2007a). The SN 
receives efferent projections from the caudate-putamen as a feedback mechanism to 
regulate the firing activity of SN DA neurons (Lindvall and Björklund, 1977a,b). There is 
also direct innervation of the GPi, GPe, and STN from a subpopulation of striatal gamma-
aminobutyric acid (GABA) neurons (also known as the striatopallidal pathway). A large 
population of GABA neurons present in the SN locus exert inhibitory control over the firing 
rate of the SN DA neurons. The nigrostriatal dopaminergic pathway is primarily 
responsible for regulating motor function in cooperation with different structures within 
the basal ganglia (Schultz et al., 1998). This pathway is particularly vulnerable to 
degeneration in the pathogenesis of PD, and its selective vulnerability has remained one of 
the most intensely studied topics in the field of PD. This pathway plays a critical role also in 
goal-directed behaviour, learning, novelty, gambling, and decision making (for a review, 
see Schultz, 2001). This pathway is the key target for treatment of movement disorders such 
as PD and Huntington’s disease and regulates psychomotor activation induced by 
psychostimulants (for a review, see Obeso et al., 2008).  
The mesolimbic pathway is also known as the reward pathway. It consists of the A10 
and a part of the A9 subpopulations of DA neurons originating from the VTA (Ungerstedt, 
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1971). The VTA is divided into 4 subregions of which paranigral nucleus (PN) and 
parabrachial nucleus (PBN) are known to be particularly rich in the density of 
dopaminergic neurons (for a review, see Björklund and Dunnett, 2007a,b). Approximately 
60% of the VTA neurons have been identified as dopaminergic neurons (Margolis et al., 
2006). The primary efferent target of these neurons is the nucleus accumbens (NAc) or the 
ventral striatum (Ungerstedt, 1971). In addition, these neurons project to the olfactory 
tubercle (OT) and other structures in the limbic system such as hippocampus, amygdala 
and locus coeruleus (Lindvall and Björklund, 1978), serving as an important link between 
the limbic system and the basal ganglia (Fig. 1). However, it must be noted that the density 
of DA innervation is significantly lower in these limbic regions than in the striatal regions. 
The remaining neuronal population in the VTA is made primarily of GABA and 
glutamatergic neurons (for a review, see Björklund and Dunnett, 2007a). The mesolimbic 
pathway is primarily associated with modulation of reward and motivation (Schultz, 1997).  
 
Figure 1. A simplified schematic illustration of major ascending dopaminergic pathways in 
mouse brain. The blue line shows the nigrostriatal pathway originating from the substantia nigra 
(SN) to the dorsal striatum (DS). The mesolimbic pathway (green line) originates from the 
ventral tegmental area (VTA) and innervates primarily the ventral striatum (VS). This pathway 
also innervates the olfactory tubercle (OT) and to a lesser extent hippocampus (HC) and 
amygdala (AMG). The third major pathway, known as the mesocortical pathway (shown by the 
orange line), innervates the prefrontal cortex (PFC) from the axons originating primarily in the 
VTA. This pathway is also known as mesocorticolimbic pathway. The fourth pathway (purple 
line) is known as the tuberoinfundibular pathway that originates in the arcuate nucleus of the 
hypothalamus (HT-ARC) and projects onto the median eminence (ME) and pituitary gland (PIT).  
 
The mesocortical DA pathway comprises A9 and A10 subpopulations of DA neurons 
originating from the VTA and projecting to the frontal lobe (Lindvall et al., 1977b). These 
neurons mainly innervate the cortical regions in the frontal lobe (Fig. 1) (Thierry et al., 
1973a,b; Fallon and Moore, 1978a,b,c; Lindvall et al., 1977b; Williams and Goldman-Rakic, 
1998). This pathway is vital for executive function, impulse control, cognition, memory, 
planning, and modulates motivation and reinforcement learning along with the mesolimbic 
and nigrostriatal pathways. Impairment in the mesocortical pathway has been linked to 
ADHD, schizophrenia, and uncontrolled drug seeking because of the loss of 
“discretionary” control over reward seeking. There are also descending neuronal 
projections from the frontal cortex to the striatum, which plays an important role in 
instrumental learning and reward-oriented behaviour (for a review, see Wickens, 2009). In 
reality, the nigrostriatal, mesolimbic, and mesocortical pathways are all interconnected and 
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their coordination is key for wide spectrum of DA-mediated functions (for a review, see 
Voorn et al., 2004).  
The fourth DA pathway, known as the tuberoinfundibular pathway, is made of the A12 
and A14 DA neurons. These neurons originate in the region called arcuate nucleus in the 
hypothalamus and project to the median eminence, the infundibular stem, and the pituitary 
gland (Björklund et al., 1973; Ajika and Hökfelt, 1973). These neurons are classified as 
neuroendocrine neurons and secrete DA directly in the portal blood circulation, which 
reaches the anterior pituitary gland and regulates prolactin secretion (Björklund et al., 1973; 
Ajika and Hökfelt, 1973). This pathway primarily mediates the secretion of sex hormones, 
and has been implicated in abnormal lactation, menstrual cycle, migraine, and sexual 
dysfunction. 
In addition to these pathways, there are A11 and A13 subpopulations of DA neurons 
that regulate the sympathetic nervous system through diencephalospinal neurons 
(Björklund and Skagerberg, 1979b). There are also dopaminergic cells in the retina 
(Malmfors, 1963; Dowling and Ehringer, 1975), which modulate multiple functions of 
retinal cells such as cell growth, light excitation and modulation of vision (Witkovsky et al., 
2005). 
2.2 FUNCTIONS OF THE DOPAMINERGIC SYSTEM 
DA performs a host of functions in the mammalian nervous system including the 
regulation of movement, mood, motivation, learning and memory (for a review, see 
Schultz, 2007). The major functions of DA are discussed below.  
2.2.1 Dopaminergic modulation of motor function 
Regulation of motor function is one of the most vital roles of DA in the mammalian central 
nervous system. One of the earliest experimental evidence regarding the role of DA in 
motor function came from animal studies employing DA depletion using drugs or lesions 
in the nigrostriatal regions. These studies demonstrated that loss of DA function in the 
striatum, globus pallidus, and motor cortex in rats and monkeys resulted in severe deficits 
in voluntary movement initiation and execution (Carlsson et al., 1958; Burns et al., 1983; 
Filion et al., 1991; Schultz et al., 1989a). Lesions of the nigrostriatal pathway (Burns et al., 
1983) or blockade of DA receptors using antagonists (Poirier, 1960) also mimic motor 
deficits similar to those observed in PD (Carlsson et al., 1958; Ehringer et al., 1960; 
Birkmayer and Hornykiewicz, 1961). Although the precise circuitry of motor function is not 
fully understood, current understanding suggests that DA regulates motor function 
through a series of interconnected, feedback-loop mechanisms between different structures 
in the basal ganglia (for reviews, see Obeso et al., 2008; Rodrigeuz-Oroz et al., 2009; Smith et 
al., 2012).  
The motor circuitry can mainly be subdivided into direct and indirect pathways. The 
direct pathway produces net excitation of motor function while the indirect pathway 
produces net inhibition of motor function. The striatum receives its excitatory input from 
the nigrostriatal pathway in form of afferent DA projections originating primarily in the 
SNc but also in the SNr and VTA. These neurons are tonically active (Williams et al., 1998) 
and maintain a constant basal level of DA in the striatum to enable movement (Smith et al., 
1994; Garris et al., 1997a,b; Schultz et al., 1989b; Bergstrom et al., 2011) by stimulating D1 
and D2 receptors (Crossman et al., 1987). D2 receptors provide inhibitory input to the 
indirect pathway while D1 receptors provide excitatory input to the direct pathway. 
Depending on this input, direct and indirect pathways further regulate motor function by 
interacting with other structures in the basal ganglia. As part of the direct pathway, striatal 
GABAergic neurons provide a direct inhibitory output to the STN, GPe, GPi, and SNr 
(Sanchez-Gonzalez et al., 2005). This inhibition prohibits GPi, GPe and STN from inhibiting 
the centromedian and ventral nuclei, which promotes an excitatory input from the 
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contromedian and ventral nuclei (CM/VL) to the motor cortex to initiate and facilitate 
motor function (Sanchez-Gonzalez et al., 2005). In the striatum, DA also exerts finer control 
over movement by inhibiting “excessive” glutamate (Bamford et al., 2004) and 
acetylcholine release (Calabresi et al., 2000a,b). 
 
Figure 2. Role of the dopaminergic system in motor circuitry. Striatum and SNc play key roles in 
initiating the cascade of motor function. Following input from the motor cortex, the striatum 
activates motor circuitry through direct and indirect pathways. Striatal input provided by D2 
receptors acts on the indirect pathway by producing inhibition of the GPe, SNr and STN. The 
direct pathway is modulated by the stimulation of D1 receptors, which excites the GPi and SNr. 
The inhibition of the centromedian and ventral (CM/VL) produces a net excitation of the motor 
cortex allowing initiation of motor function.  
 
In the case of the indirect pathway, a different set of striatal neurons provide inhibitory 
input to the GPe, STN and SNr. However, this input does not prevent the GPe and STN 
from inhibiting the excitatory output of ventromedial nucleus required for excitation of the 
motor cortex. Thus, the net result is a suppression of excitatory input to the motor cortex 
from centromedian and ventral nuclei, producing inhibition of motor function. Adequate 
motor function requires a fine balance between the direct and indirect pathways and their 
excitatory and inhibitory connections. The primary cause of loss of movement in PD is the 
absence of nigrostriatal dopaminergic input to the striatum, which is the first key step in 
initiating movement through the motor circuitry. The loss of striatal input causes an 
imbalance between the direct and indirect pathways leading to the motor cortex, eventually 
causing overinhibition of movement (Schultz et al., 1989a,b).  
2.2.2 Role of dopamine in reward, motivation and goal-oriented behaviour 
DA plays an important role in modulation of motivation, reward, and goal-oriented 
behaviour. DA signalling in the striatum is essential for the maintenance of basic 
behaviours such as feeding and movement. DA deficient mice display a complete lack of 
feeding behaviour and die of starvation at the age of three weeks (Zhou and Palmiter, 
1995). Merely 5% restoration of DA in the dorsal striatum restores basic feeding behaviour 
while the restoration in the ventral striatum restores exploratory behaviour (Szczypka et al., 
2001). DA also regulates feelings of reward by exhibiting firing activity of the VTA neurons 
in response to presentation of unexpected reward (Schultz, 1999; Robinson and Wightman, 
2002). Activation of DA neurons (Schultz, 2001; Kobayashi and Schultz, 2008; Hyland et al., 
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2002) and evidence of DA release in the terminal fields of the striatum (Robinson and 
Wightman, 2002; Phillips et al., 2003; 2005) have been reported following presentation or 
acquisition of reward. The timing of DA release (Robinson and Wightman, 2002; Clark et 
al., 2010) or firing of DA neurons (Schultz et al., 1998) shows a high correlation with the 
time course of reward delivery or reward-associated cue (Ljungberg et al., 1991; 1992). 
More evidence on the highly rewarding nature of striatal DA release can be seen in studies 
using intracranial self-stimulation (Yavich and Tiihonen, 2000a,b). Mice with an implanted 
stimulating electrode, which produces DA release in the striatum, actively seek DA release 
by self-administering intracranial stimulation (Yavich and Tiihonen, 2000a,b). Classical 
behavioural paradigms using Pavlonian conditioning show that DA plays a critical role at 
various stages of learning, acquisition and execution of performance in goal-oriented tasks 
(Wise, 2004; Schultz, 2010a; Berridge, 2007; for a review, see Clark et al., 2012). DA release 
following a rewarding stimulus encodes reward-value driven learning and acquisition of 
behaviour to repeatedly seek reward (for reviews, see Dayan and Balleine, 2002; Schultz, 
2007; 2010). DA also modulates the quality of performance and effort required to achieve 
the reward in a behavioural task (for a review, see Salamone et al., 2009). Recent studies 
provide direct voltammetric evidence that changes in striatal DA release drive drug-
seeking behaviour (Owesson-White et al., 2009; Aragona et al., 2009; Wheeler et al., 2011), 
implicating dysfunction of the dopaminergic system in the development of addiction. DA 
also modulates reward prediction, error associated with reward prediction, and the cost of 
effort required to achieve reward (for a review, see Glimcher, 2011). DA is known to 
regulate these behaviours by activating postsynaptic DA receptors and producing 
downstream changes in synaptic plasticity (Calabresi et al., 2000b). In addition to DA 
receptors, DA also interacts with GABA, glutamate, and acetylcholine interneurons to 
produce plasticity-dependent changes in the striatum and cortex (for reviews, see Calabresi 
et al., 2007; Wickens, 2009; Horvitz, 2009). The role of DA in reward, motivation, and goal-
directed behaviour is closely linked with its functions in learning and memory since these 
functions involve common pathways and molecular mechanisms (as reviewed by Wickens, 
2009). The rewarding effect produced by DA release acts as an incentive for goal-directed 
behaviour necessary for learning, cognition, and memory (Horvitz, 2009; Lammel et al., 
2012; Clark et al., 2013; for a review, see Schultz, 2010a,b).  
2.2.3 Role of dopamine in cognition, learning and memory 
DA plays an important role in learning, memory, and cognition. It facilitates motor learning 
as well as stimulus-reward and action-outcome learning (reviewed by Costa, 2007). DA has 
also been credited for modulating working memory and mental agility (Mehta et al., 2000; 
2004; Volkow et al., 2005; Berridge et al., 2006). Low-dose psychostimulants, which increase 
the availability of DA in the corticostriatal areas, significantly improve cognition and 
working memory (Volkow et al., 2005). DA also modulates attention and latent inhibition. 
For instance, DA enhancing drugs such as methylphenidate and d-amphetamine improve 
the symptoms of attention deficit by increasing attention span and decreasing distractibility 
and hyperactivity in individuals with ADHD (Volkow et al., 1992a,b; for a review, see 
Volkow et al., 2005). On the other hand, deficits in cognitive function, memory, and 
learning are common symptoms in disorders resulting from loss of DA such as PD (for a 
review, see Schultz, 2007). Studies from rodent and primate models using different 
behavioural paradigms show that DA mimicking agents, depending on the appropriate 
dose, accelerate the rate of learning and task acquisition, and improve performance in tasks 
(Horvitz, 2001; Nelson and Killcross, 2006). On the contrary, DA blockade or lesions impair 
performance in behavioural tasks (Costa, 2007; Cheer et al., 2007a,b). Apart from these, DA 
also regulates highly sophisticated executive functions such as decision making (Rogers et 
al., 1999), timing behaviour (Artieda et al., 1992), strategy generation (Taylor et al., 1986) 
and mental flexibility (Jaspers et al., 1984; for an extensive review, see Schultz, 2001). DA 
facilitates these behaviours through DA-induced changes in neuronal plasticity (Sigala et 
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al., 1997; Horvitz, 2001; for a review, see Calabresi et al., 2007). Stimulation of D1 and D2 
family of DA receptors primarily in the corticostriatal pathway is required for NMDA (N-
methyl-D-aspartate) and AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic 
acid) mediated long-term potentiation (LTP). Similarly, DA also facilitates memory and 
learning by potentiating LTP or long-term depression (LTD) between cholinergic, 
glutamatergic, and GABAergic interneurons (for a review, see Calabresi et al., 2007; Dalley 
and Everitt, 2009).  
2.2.4 Role of dopamine in aversion and pain 
In addition to regulating reward and pleasure, DA plays an important role in aversion and 
pain. DA encodes aversive stimuli by briefly pausing the baseline firing of VTA DA 
neurons (Romo and Schultz, 1989; Ungless et al., 2004). However, some other studies show 
both excitation and inhibition of VTA DA neurons in response to footshock and physical 
restraint stress (Valenti et al., 2011). DA also plays a role in predicting aversive outcome 
and is necessary for modulating avoidance behaviour in response to aversive stimuli 
(Zweifel et al., 2011). It has been shown that presentation of aversive and fear-inducing cues 
increase DA release in the nucleus accumbens shell (NAcSh) and decrease it in the nucleus 
accumbens core (NAcC) (Badrinarayan et al., 2012). DA neurotransmission is important in 
modulating behaviours following acute or chronic stress (Cao et al., 2010, Miczek et al., 
2011). Studies on social defeat stress, a commonly used model for stress and behavioural 
despair, show that firing of mesolimbic DA neurons modulates defeated behaviour, and 
excitation of these neurons is important for recovery from social defeat stress (Chaudhury 
et al., 2013). Increased frequency of DA transients is observed following an aggressive 
encounter in the social defeat stress paradigm (Anstrom et al., 2009). DA mediated 
anhedonia has been proposed as one of the mechanisms underlying depression (for a 
review, see Nestler and Carlezone, 2006). 
DA has been shown to modulate the sensation of pain (Jensen and Yaksh, 1984). It 
modulates the perception of pain through the stimulation of D2 receptors (Romo and 
Schultz, 1989; Hagelberg et al., 2002). DA depletion increases the sensation of pain, which is 
the most common complaint in patients suffering from PD (for a review, see Barceló et al., 
2012). Levodopa treatment decreases pain sensitivity and increases pain threshold 
(Gerdelat-Mas et al., 2007). In healthy humans, variations in DA receptor availability 
following exposure to sensory and emotional pain have been shown using positron 
emission tomography (Scott et al., 2007). Both phasic and tonic levels of DA modulate 
sensitivity to pain (Scott et al., 2006; Wood et al., 2007). However, disruption in phasic DA 
release, which is more common in psychiatric disorders such as depression (Rosetti et al., 
1993; Di Chiara et al., 1999), has been particularly implicated in increased pain sensitivity in 
psychiatric patients (for a review, see Finan and Smith, 2012). The role for DA in pain is 
further supported by recent advances in pharmacotherapy, which indicate efficacy of DA 
agonists and re-uptake blockers in the treatment of fibromyalgia, restless leg syndrome, 
and chronic pain syndrome (for a review, see, Barceló et al., 2012). Treatments with DA 
agonists and re-uptake blockers have shown to produce significant improvement in the 
severity of chronic pain. Furthermore, a recent study showed that genetic polymorphisms 
in the gene encoding catechol-O-methyltransferase (COMT), which degrades extracellular 
DA, may predict the severity and chronicity of pain, and therapeutic efficacy of pain 
medication in humans (Kambur et al., 2011; Loggia et al., 2011; for a review, see Belfer and 
Segal, 2011). It has been hypothesized that DA may play an important role in suppressing 
pain and overcome aversion in order to maximise effort and reward in case of a positive 
experience (reviewed by Leknes and Tracey, 2008). Overall, the role of DA in pain and 
aversive conditioning works in tandem with its role in reward, motivation and goal-
directed behaviour to facilitate learning, adaptive behaviour, and higher level executive 
functions (for a review, see Schultz, 2007).  
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2.3 PRESYNAPTIC DOPAMINE NEUROTRANSMISSION  
2.3.1 Dopamine biosynthesis, metabolism and storage 
DA is synthesized by DA neurons in the CNS primarily from the readily available amino 
acid L-tyrosine. DA is also synthesized from L-phenylalanine, which is converted to L-
tyrosine to be used as a precursor for DA biosynthesis. In the second stage, L-tyrosine is 
converted to L-DOPA (L-3,4-dihydroxyphenylalanine) by the enzyme tyrosine hydroxylase 
(TH) in the presence of tetrahydropholic acid, O2 and ferrous iron (Fe2+) as cofactors. In the 
third step, L-DOPA is converted to DA by aromatic L-amino acid decarboxylase (AADC) in 
the presence of pyridoxal phosphate as a cofactor (Kuhn and Lovenberg, 1983). In the 
cytoplasm, free DA is highly unstable and prone to autoxidation (Fornstedt et al., 1989). 
Due to the unstable catechol ring, DA can be rapidly oxidised to produce hydrogen 
peroxide, superoxide, and dopamine-o-quinone (Graham, 1978), all of which can cause 
severe damage to cellular organelle and death of DA neurons.  
In order to prevent DA from unleashing a chain of toxic reactions, cytosolic DA is 
rapidly sequestered into vesicles or broken down by enzymatic degradation (Wang et al., 
1997). After synthesis, DA is rapidly transported into vesicles mainly by vesicular 
monoamine transporter-2 (VMAT2) and stored for release (Nirenberg et al., 1998a,b). The 
vacuolar ATPase pumps two H+ ions inside the vesicle. VMAT2, which is an antiporter 
protein, then exchanges one molecule of DA for two H+ ions in the presence of a 
concentration gradient (Rudnick et al., 1986; Peter et al., 1995). The low pH and absence of 
other reactive compounds inside vesicles guards DA from oxidation (Weihe and Eiden, 
2000; for a review, see Caudle et al., 2008). Therefore, most of the presynaptic DA is stored 
inside vesicles (Wang et al., 1997). Normal functioning of VMAT2 in sequestering DA in 
vesicles is a critical factor in mitigating intracellular cytotoxicity of DA (Liu and Edwards, 
1997).  
Metabolic breakdown of DA can be carried out mainly by two enzymes, monoamine 
oxidase (MAO) and COMT. MAO catalyses DA both intracellularly and extracellularly 
(Holschneider et al., 2001) while COMT degrades DA primarily in intracellular 
compartments of non-dopaminergic neurons (Kaakkola et al., 1987; Schendzielorz et al., 
2013; for a review, see Männistö and Kaakkola, 1999). The two types of MAO enzymes 
present in DA neurons are MAO-A and MAO-B (Berry et al., 1994). MAO-A is more closely 
associated with catecholaminergic neurons (Vitalis et al., 2002). While both isoforms can 
metabolise DA, MAO-B has a higher preference for metabolising DA making it an 
important target in PD (Youdim and Weinstock, 2004). MAO removes the amine group 
from DA with the help of a cofactor flavin adenine dinucleotide (FAD), and reduces DA to 
3,4-dihydroxyphenylacetaldehyde (DOPAL). DOPAL is further converted to 3,4-
dihydroxyphenylacetic acid (DOPAC). COMT further breaks down DOPAC to 
homovanillic acid (HVA). COMT also directly metabolises DA into 3-methoxytyramine (3-
MT). In humans and primates, HVA is the most abundant metabolite of DA while DOPAC 
is present in greater quantities in rodent brains (Wilk and Stanley, 1978). The function of 
COMT is of greater importance in brain regions with slower clearance of DA due to a 
comparatively lower expression of DAT (Yavich et al., 2007). Therefore, COMT plays a 
greater role in regulating extracellular DA levels in the prefrontal cortex than the striatum 
where re-uptake of DA is very efficient (Yavich et al., 2007).  
DA synthesis and breakdown are important processes under tight regulation for healthy 
function of the dopaminergic system. DA synthesis can be upregulated in response to 
changing demand. For instance, increase in DA synthesis and TH expression in the early 
stages of PD has been reported (Zigmond et al., 1984; Wolf et al., 1989). Similarly, certain 
drugs and disorders can also alter the rate of DA synthesis (for a review, see Sulzer and 
Pothos, 2000). However, since excessive DA in the cytosol is toxic to neurons, it can also be 
detrimental to neurons as in the case of methamphetamine abuse (Larsen et al., 2002). DA 
also serves as a precursor for norepinephrine (NE) synthesis. Therefore, factors affecting 
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DA synthesis are also critical for proper functioning of the noradrenergic system, especially 
in areas with dense catecholaminergic innervation such as prefrontal cortex, amygdala, and 
locus coeruleus (Masserano and Weiner, 1983). DA may also serve to replace NE in case of 
NE depletion (Goodall and Alton, 1969).  
2.3.2 Dopamine transporter (DAT) 
Dopamine transporter (DAT) is a membrane protein encoded by the DAT1 gene. DAT 
performs the crucial role of inactivating DA neurotransmission by removing DA from the 
extracellular space via re-uptake (Horn, 1974; Horn et al., 1974; Garris and Wightman, 
1994). The DAT is a symporter protein that actively transports DA across the membrane by 
exchanging one DA molecule for two Na+ ions and one Cl- ion. For this action, the DAT 
relies on ionic concentration gradient generated by the plasma membrane Na+/K+ ATPase 
(For a review, see Torres et al., 2003). DAT is under constant dynamic regulation by kinases 
to facilitate the recruitment and internalisation of DAT in response to changing demand 
(Mortensen and Amara, 2003). DAT is expressed by dopaminergic neurons only and has 
been shown to be located away from the synapse towards the perisynaptic area, and also on 
non-synaptic sites (Nirenberg et al., 1996a; Hersch et al., 1997). DAT is widely expressed 
throughout the nigrostriatal, mesocortical, and mesolimbic pathways (Ciliax et al., 1999). 
Dense DAT expression has been reported in areas such as the striatum which receives the 
densest innervation of dopaminergic neurons (Nirenberg et al., 1996a,b; Nirenberg et al., 
1997a,b,c). Dense DAT expression is also found in the VTA and SN where DA neurons 
originate (Nirenberg et al., 1996a,b; Nirenberg et al., 1997a,b,c). Further, DAT expression in 
the striatum is heterogeneous such that the dorsal-dorsolateral areas of the striatum show 
maximal DAT expression consistent with the fact that these regions also receive denser 
dopaminergic projections. DAT expression in the dorsomedial striatum is comparatively 
lower and even lower in the ventral striatum.  
The DAT is the primary mechanism to control the extracellular life of DA and terminates 
its function in the synaptic cleft (Wightman and Zimmerman, 1990). Re-uptake by the DAT 
is highly efficient in contrast to diffusion, which happens at much slower time-scales 
(Ewing and Wightman, 1984). DA is also removed from the extracellular space by the 
norepinephrine transporter (NET) (Morón et al., 2002; Carboni et al., 2006) and to a lesser 
extent by the serotonin transporter (SERT) (Shen et al., 2004; Kannari et al., 2006) in certain 
brain regions. However, these transporters bind DA at much lower affinities than the DAT. 
The crucial role of the DAT has been highlighted in studies on DAT knockout and 
heterozygote mice (Giros et al., 1996; Jones et al., 1998; Spielewoy et al., 2000). Mice lacking 
the DAT display a 5-fold increase in the extracellular levels of DA and a 4-fold reduction in 
evoked DA release (Jones et al., 1998). These mice also display 95% reduction in striatal 
tissue DA content and are spontaneously hyperactive. DAT knockout mice also exhibit 
significant adaptations in the organisation of neuronal network (Zhang et al., 2010).  
Given the importance of the DAT in DA neurotransmission, factors which interfere with 
normal DAT function can have serious implications for the dopaminergic system. DAT is 
the main target of several commonly abused drugs such as cocaine, amphetamine, 
methamphetamine, and MDMA. Most of these drugs are competitive inhibitors of the DAT 
and block DA re-uptake from the synapse. Amphetamines on the other hand reverse the 
DAT and produce massive spillover of DA into the synaptic cleft by depleting 
intraneuronal DA storage (Jones et al., 1999b; for a review, see Sulzer et al., 2005). DAT is 
also known to play an important role in PD. It has been shown that DAT knockout mice are 
resistant to MPTP-induced toxicity, and inward transport of MPTP through the DAT is 
necessary for its cytotoxicity (Gainetdinov et al., 1998). A similar phenomenon has been 
reported in the case of neurotoxin 6-OHDA (Glinka et al., 1997). DAT also provides 
compensation for loss of DA neurons by slowing re-uptake of DA in the course of PD 
(Garris et al., 1997a,b; Bergstrom et al., 2011). Dysfunction in the DAT has been implicated 
in ADHD and it is the main therapeutic target of methylphenidate in the treatment of 
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ADHD (for a review, see Viggiano et al., 2004; Gainetdinov et al., 2010). These studies 
highlight that DAT is one of the most crucial proteins regulating DA neurotransmission. 
2.3.3 Role of dopamine autoreceptors in presynaptic dopamine release 
DA receptors are broadly classified into D1 and D2 families of receptors based on G-protein 
receptor based coupling (Zou et al., 1996; Lachowicz and Sibley, 1997; Missale et al., 1998; 
Zhuang et al., 2000). The D1-like family is coupled to the Gs subunit of the heterotrimeric G-
protein while the D2-like family receptors are coupled to Gi subunit of the G-protein. The 
D1 family comprises D1 and D5 receptors, and the D2 family comprises D2, D3, and D4 
types of receptors. DA receptors are the crucial binding sites for DA and regulate the 
functions and behaviours mediated by DA (Schmitz et al., 2002; Horvitz, 2001). DA 
receptors are primarily expressed postsynaptically but are also located presynaptically 
(Charuchinda et al., 1987; Gonon and Buda, 1985). The striatum consists of dense 
expression of D1 and D2 receptors while the cortical and limbic regions consist of D1, D2, 
D3, D4, and D5 receptors (for a review, see Cave and Baker, 2009). The expression pattern 
of D2 autoreceptors follows the gradient of dopaminergic innervation in the striatum, such 
that D2 autoreceptor expression is much greater in the dorsal areas of the striatum than 
ventral areas (Lindvall and Björklund, 1978; Charuchinda et al., 1987). 
Among DA receptors, presynaptically located D2 receptors are referred to as 
autoreceptors. These receptors are present on the neuronal membrane and play the most 
direct role in regulating DA release (Meiergerd et al., 1993) by producing autoinhibition of 
DA release through a G-protein-coupled receptor mediated negative feedback mechanism 
(Gonon and Buda, 1985; Stamford et al., 1988a,b; May and Wightman, 1989). D3 receptors, 
which belong to the D2 family, are also located presynaptically and inhibit DA release in a 
manner similar to that of D2 autoreceptors. However, their contribution is significantly 
smaller (Joseph et al., 2002). The primary function of D2 autoreceptor is to maintain a 
constant extracellular level of DA. D2 autoreceptors achieve this by directly modulating 
both release and re-uptake. D2 autoreceptors are primarily known to inhibit DA release 
following repetitive stimulation (Benoit-Marand et al., 2001; Schmitz et al., 2002). Studies in 
rodents have revealed that D2 autoreceptors inhibit DA release stimulated at inter-stimulus 
intervals between 0.4 to 5 s (Schmitz et al., 2002; Phillips et al., 2002). This phenomenon has 
been described as paired-pulse depression (PPD), in which D2 autoreceptors inhibit further 
DA release due to the presence of DA molecules released by an earlier stimulation. The 
autoinhibition disappears almost completely at 5 s inter-stimulus interval (Kita et al., 2007). 
Furthermore, the autoinhibition is dependent on stimulation frequency and intensity. The 
effect of D2 antagonist on the short-term dynamics of evoked DA overflow disappears with 
increasing frequencies (>30 Hz) (Wu et al., 2002) and duration of stimulation (Kita et al., 
2007). However, it has been shown that D2 autoreceptors can also facilitate DA release, 
which can be reversed by the D2 antagonist raclopride (Kita et al., 2007). This phenomenon 
is seen following prior activation of DA neurons by electrical stimulation, possibly 
suggesting a role in activity dependent bidirectional modulation of DA release (Kita et al., 
2007).  
D2 receptor activation by DA or D2 receptor agonists produces a rapid increase in 
membranal DAT expression by activating extracellular regulated kinases 1 and 2 (ERK1/2) 
and phophoinositide 3 kinase (PI3K) through D2-receptor coupled G-protein receptors 
(Bolan et al., 2007; Zapata et al., 2007). Quantitative data on DA re-uptake also show that D2 
receptor agonists accelerate re-uptake (Meiergerd et al., 1993; Schmitz et al., 2002; Rouge-
Pont et al., 2002: Joseph et al., 2002) while D2 receptor blockade by haloperidol slows down 
DA re-uptake in the striatum (Wu et al., 2001). For instance, DAT knockout mice with 5-
fold increase in the extracellular DA levels display a complete loss of D2 autoreceptor 
function due to desensitisation of DA autoreceptors (Jones et al., 1999a). Although the 
precise mechanism is not fully understood, D2 autoreceptors can attenuate further release 
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by inhibiting the opening of calcium channels and preventing Ca2+ entry required for 
neurotransmitter release (Neve et al., 2004  
D2 receptor knockout mice display significant alterations in DA neurotransmission in 
the striatum. While the absence of receptors does not alter DA release per pulse, re-uptake 
is enhanced by approximately 80% in these mice (Schmitz et al., 2002). D2-mediated 
autoinhibition of DA release is greater in the ventral striatum than the dorsal striatum 
(Cragg and Greenfield, 1997). D2 receptors known as “heteroreceptors” are expressed also 
by non-DA neurons which receive afferent DA input, and indirectly regulate DA release 
through modulating release of glutamate (Bamford et al., 2004), acetylcholine (Cragg, 2003; 
Rice and Cragg, 2004) or GABA (Centonze et al., 2002a,b; Cheer et al., 2005), primarily in 
the dorsal striatum (Anzalone et al., 2012). 
In the striatum, D1 and D2 postsynaptic receptors are the primary sites that carry out the 
function of DA (Schultz et al., 1989, Doudet et al. 1990). As described earlier in section 2.2, 
stimulation of these receptors is required for the downstream action of DA to initiate 
movement or to mediate reward, goal-oriented behaviour, learning, and memory (Horvitz, 
2001; Eyny and Horvitz, 2003; Centonze et al., 2002a,b; for reviews, see Horvitz, 2001).  
2.3.4 Subregional dynamics and short-term plasticity of dopamine neurotransmission in 
the striatum  
The striatum is broadly divided into dorsal and ventral regions. In rodents, these regions 
are also referred to as caudate-putamen (CPu) and nucleus accumbens (NAc), respectively. 
The NAc is further subdivided into the nucleus accumbens core (NAcC) and nucleus 
accumbens shell (NAcSh). Although NAcC and NAcSh share certain similarities, 
heterogeneity in DA neurotransmission in these two regions has been reported 
(Cacciapaglia et al., 2011). Dopaminergic neurotransmission in striatal subregions has been 
intensively studied due to its importance in PD and addiction (Garris and Wightman, 1994, 
1995; Jones et al., 1995a,b; Cragg et al., 2000, 2002).  
Advances in voltammetric techniques have allowed a detailed characterisation of 
subsecond, real-time DA release and re-uptake in rodent and primate brains. The first 
prominent study (Garris and Wightman, 1994), which reported differences between the 
dorsal and ventral striatum in the rat brain, showed that electrically evoked DA overflow 
per stimulation pulse is greater in the dorsal striatum than the ventral striatum. 
Furthermore, the rate of DA re-uptake is also significantly faster in the dorsal striatum than 
ventral striatum (Garris and Wightman, 1994; 1995; Jones et al., 1995a; Cragg, 2003). Most 
studies employing voltammetric techniques have reported values of the maximal rate of re-
uptake (Vmax) in the dorsal striatum between 4-6 μM/s (Garris and Wightman, 1995; Jones et 
al., 1995a,b) while the values in the ventral striatum range from 2.5-3.5 μM/s (Garris and 
Wightman, 1994; 1995; Jones et al., 1995a,b; Wu et al., 2001). Similarly, DA release per pulse 
is much greater in the dorsal striatum (~100 nM) than the ventral (~65 nM) (Garris and 
Wightman, 1994). Studies in primates revealed more closely the gradient of DA release in 
the dorsal striatum. One study (Cragg et al. 2001) showed that the dorsolateral areas of the 
striatum exhibit the highest DA release, with a progressive decrease towards the medial 
and ventromedial CPu. DA release decreases further in the ventral striatum (Cragg et al., 
2001). This variation showed a weak correlation with local DA tissue content (Garris and 
Wightman, 1994; Cragg et al., 2001). The rates of DA re-uptake also followed a similar 
pattern with re-uptake being the fastest in the dorsolateral striatum (Cragg et al., 2001). It 
has been shown that these differences primarily emerge from variation in dopaminergic 
innervation density and number of re-uptake sites (Lindvall and Björklund, 1978; Madras 
and Kaufman, 1994; Garris and Wightman, 1994; Cragg et al., 2002). It has been proposed 
that DA neurotransmission in the dorsal striatum is more “uptake-dependent” than in the 
ventral striatum since re-uptake inhibition by nomifensine produces significantly larger 
increase in DA overflow in the dorsal striatum than in the ventral striatum (Garris and 
Wightman, 1994; Jones et al., 1995). These findings were also validated in studies using in 
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vivo microdialysis (Kuczenski et al., 1991). Further studies demonstrated that the NET 
inhibitor desipramine and the selective SERT inhibitor fluoxetine had no effect on DA re-
uptake in the striatum (Jones et al., 1995a; Mateo et al., 2004), indicating that DAT is solely 
responsible for DA re-uptake in striatal subregions. Studies have also shown differences in 
activity-dependent, short-term plasticity of DA overflow in dorsal and ventral regions. 
Electrical stimulation-dependent increase in DA overflow, described as the facilitation of 
DA overflow, following repetitive stimulation of the ascending DA pathways is much 
greater in the dorsal striatum than in the ventral stratum (Yavich and MacDonald, 2000). A 
similar gradient has been reported in paired-pulse facilitation/depression in the primate 
brain (Cragg, 2003), indicating that the pattern of subregional differences in striatal DA 
release are highly conserved in rodent and primate brains (Cragg et al., 2000; Calipari et al., 
2012).  
The differences observed in the terminal fields in dorsal and ventral striatum are also 
reflected in their axonal origins of SN and VTA, respectively. Although distinguishing the 
firing of SN and VTA is neurons is technically extremely challenging, differences in the 
activation of these neurons have been reported. Nearly 60% of the VTA neurons display 
synchronous firing activity in response to a rewarding stimulus (Schultz et al., 1998). In 
contrast, SN neurons display more tonic, low-frequency firing (Zhang et al., 2009a,b). The 
two regions also display different responses to drugs of abuse like cocaine (Zhang et al., 
2009a,b) and differential alterations during behavioural conditioning (Cacciapaglia et al., 
2011; Budygin et al., 2012; Willhun et al., 2012). Moreover, DA neurotransmission in the 
ventral striatum is relatively intact even after nearly 85% loss of DA in the dorsal striatum 
(Bergstrom et al., 2011), at least in the experimental models of PD. These studies indicate 
that although dorsal and ventral striatum share many similarities, they also play distinct 
roles in behaviours and diseases. These differences may hold the key to understanding 
crucial aspects of dopaminergic neurotransmission.  
2.4 DISORDERS ASSOCIATED WITH DOPAMINERGIC DYSFUNCTION 
Because of the wide spectrum of functions of DA in the central nervous system, 
dopaminergic dysfunction can have serious pathological consequences and lead to 
debilitating neurodegenerative and psychiatric disorders. The primary brain regions 
affected in dopaminergic disorders are the basal ganglia and cortical regions (Lindvall and 
Björklund, 1978). Dysfunction in the basal ganglia, primarily in the nigrostriatal pathway, is 
known to be responsible for PD (Carlsson et al. 1958; Schultz et al., 1989a). On the other 
hand, both striatal and cortical regions are known to be involved in the neurobiology of 
addiction, ADHD, and schizophrenia (For a recent review, see Maia and Frank, 2011). The 
most prominent disorders associated with dopaminergic dysfunction are discussed below. 
2.4.1 Parkinson’s disease 
PD is the second most common neurodegenerative disorder affecting approximately 1% of 
the population over 60. PD is a movement disorder caused by the destruction of mainly DA 
neurons. The primary symptoms of PD are tremor, bradykinesia, and rigidity of muscles 
eventually causing a complete loss of motor function and paralysis in the later stages. 
Individuals suffering from PD also exhibit cognitive and psychiatric abnormalities and 
symptoms of dementia. The precise causes underlying the pathogenesis of PD are still 
unknown. Although several causative genetic mutations in genes such as SNCA, PINK1, 
Parkin, and DJ-1 have been implicated in PD, most PD cases are sporadic in nature (for a 
review, see Tofaris and Spillantini, 2007). Exposure to environmental toxins, heavy metals, 
and drugs of abuse has also been implicated in PD. Lewy bodies are one of the major 
hallmarks of PD and aggregated α-syn forms the major component of the Lewy bodies. 
Therefore, PD is also classified as a synucleinopathy. 
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The most direct evidence of DA dysfunction in PD has come from studies using animal 
models employing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP). MPTP, when metabolised to 1-methyl-4-
phenylpyridinium (MPP+), selectively destroys DA neurons (for reviews, see Snyder and 
D’Amato, 1986; Kopin, 1992) while 6-OHDA selectively destroys catecholaminergic 
neurons (Jonsson and Sachs, 1975). Animals with targeted lesions of the motor regions 
display significant deficits in motor function (Schultz et al., 1989a; Schneider et al., 1992), 
which can be partially rescued by DA mimicking agents such as l-DOPA or DA agonists.  
The primary cause underlying PD is the destruction of DA neurons in the SNc. However, 
the symptoms of PD do not appear until nearly 80-90% of DA neurons are destroyed (Agid, 
1991; Hornykiewicz and Kish, 1987). Similar to the causes of pathogenesis of PD, it is poorly 
understood how the dopaminergic system maintains adequate function despite such a 
drastic loss of DA neurons. Studies have shown that extracellular DA levels in the striatum 
are not different between lesioned and untreated animals until 80% of DA neurons are lost 
(Abercrombie et al., 1990). Increase in DA turnover (Hefti et al., 1985; Stachowiak et al., 
1987) and rate of re-uptake proportional to the extent of degeneration have been observed 
in animal models of PD (Bergstrom and Garris, 2003; McCallum et al., 2006). These studies 
suggest that increased DA turnover may compensate for the overall decline in striatal DA 
content while decreased re-uptake may allow DA to linger in the extracellular space longer 
in order to maintain tonic DA levels for adequate function (Garris et al., 1997a,b; Bergstrom 
and Garris, 2003; 2011; McCallum et al., 2006). Furthermore, studies have reported 
heterogeneity in striatal subregions prone to PD. The nigrostriatal DA neurons originating 
from the SNc and projecting to the CPu are most vulnerable in PD (Kish et al., 1988; 
Morrish et al., 1996). Consistent with this, alterations in DA neurotransmission in animal 
models mimicking PD have been reported primarily in the SNc and caudate-putamen (or 
dorsal striatum), especially the lateral parts of the dorsal striatum (Bergstrom et al., 2001; 
Bergstrom and Garris, 2003; McCallum et al., 2006). The underlying cause for the selective 
vulnerability of the dorsal striatum is still poorly understood, and several molecular 
mechanisms involving interactions between mitochondrial proteins and enzymes, α-syn, 
and cytosolic DA storage are being investigated (for a comprehensive review, see Sulzer, 
2007). 
Currently, the major themes being studied in the pathogenesis of PD are the mechanisms 
contributing to increased oxidative stress, misfolding and aggregations of presynaptic 
proteins, failure of protein degradation pathways, mechanisms disrupting presynaptic DA 
storage, and deficits in mitochondrial respiratory system (for reviews, see Sulzer, 2007; 
Caudle et al., 2008; Venda et al., 2010). Presence of genetic mutations and environmental 
toxins further increases the vulnerability in the above mechanisms to predispose one to PD 
(for a review, see Lotharius and Brundin, 2002a,b). Oxidative stress produces free radicals 
and superoxides, which can cause severe damage to cellular organelle. Age-dependent 
increase in oxidative stress-induced damage in the brain is common in humans (Smith et 
al., 1991; Mecocci et al., 1993; Sohal and Weindruch, 1996). DA neurons in the dorsal 
striatum are particularly vulnerable to oxidative stress due to the high rate of DA turnover 
in this region (Graham, 1978; Wightman and Zimmerman, 1990). As discussed in section 
2.2.1, DA can be oxidised to form hydrogen peroxide, superoxides, and other highly 
reactive compounds such as hydroxyl radicals and quinones (Maker et al., 1981; Hastings et 
al., 1996). These reactive molecules cause serious damage to proteins, lipids, and DNA. For 
example, damage to lipids can alter the membrane permeability of neurons, and lead to 
enhanced Ca2+ influx or DA leakage from vesicles further increasing oxidative stress (Volles 
et al., 2001; Volles and Lansbury, 2002). In particular, increases in superoxides and 
peroxidation have been reported in nigrostriatal neurons in PD brains (Saggu et al., 1989; 
Dexter et al., 1989; Floor and Wetzel, 1998). Moreover, increased iron levels which itself is a 
result of oxidative stress (Dexter et al., 1989) have also been reported in the substantia nigra 
of humans in PD (Sofic et al., 1988; Jenner, 1998).  
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One of the most critical factors contributing to PD is believed to be DA itself given its 
vulnerability to oxidation. Consequently, factors which disrupt proper handling and 
storage of DA inside the cytosol can be key contributors to PD (For reviews, see Lotharius 
and Brundin, 2002b; Caudle et al., 2008). Excess accumulation of DA both inside and 
outside the nerve terminal is highly toxic and can cause apoptotic death of the neurons 
(Lotarium and O’Malley, 2001; Larsen et al., 2002). Studies show that mice lacking VMAT2, 
which is primarily responsible for cytosolic DA handling, show age-dependent 
degeneration of DA neurons and signs of PD (Colebrooke et al., 2006). The primary 
consequence of loss of DA storage is the resulting oxidative stress. Certain drugs of abuse 
such as methamphetamine have also been shown to increase the vulnerability to develop 
PD by disrupting DA storage. Methamphetamine disrupts the functioning of VMAT2 and 
DAT and causes accumulation of DA and increased oxidative stress (Sulzer and Rayport, 
1990). Intriguingly, if the cells treated with methamphetamine are depleted of DA before 
treatment, its neurotoxic effect is significantly attenuated (Vergo et al., 2007). This 
highlights that DA itself plays a crucial role in determining vulnerability of DA neurons. 
The role of α-syn is also critical in DA storage and pathogenesis of PD (discussed in detail 
in section 2.5.4). 
Impairment in mitochondrial complex I hampers the ability of neurons to fight oxidative 
stress, and deficits in mitochondrial complex I have been reported in PD (Schapira et al., 
1998; Swerdlow et al., 1998). Several pesticides and environmental toxins such as rotenone 
and paraquat inhibit complex I activity and cause death of DA neurons (Sherer et al., 
2003a). Impairment in the ubiquitin-proteosome system, which degrades misfolded 
proteins, has also been implicated in PD, especially in the case of neurodegenerative 
disorders involving genetic mutations (Chung et al., 2001).  
2.4.2 Addiction 
Addiction to psychoactive substances is a potentially devastating disorder characterised by 
compulsive drug seeking that is difficult to reverse and causes significant harm to an 
individual’s health, and social and financial status (Diagnostic and Statistical Manual of 
Mental Disorders; APA 2000). Most of the commonly abused drugs directly or indirectly 
target the dopaminergic system by acting on the mesolimbic reward pathway and 
positively reinforcing drug-seeking behaviour. Drugs such as cocaine, amphetamine, and 
methamphetamine increase the synaptic availability of DA, which produces rewarding 
effects such as euphoria, increased self-confidence, psychomotor activation, and sexual 
arousal (Wise and Bozarth, 1987; Kuhar et al., 1991; Robinson et al., 2002). The two most 
commonly abused drugs, ethanol and nicotine, also exert their addictive properties by 
acting on the dopaminergic system. Hence, the interaction of these drugs with the 
dopaminergic system has been a subject of intense research in the field of addiction. 
Cocaine is a widely abused and one of the most potent drugs affecting the dopaminergic 
system. It increases extracellular DA levels in the striatum by primarily inhibiting DA re-
uptake (Ritz et al., 1987; Wise et al., 1995a,b; Rouge-Pont et al., 2002), although it also blocks 
NE and serotonin re-uptake with lower potencies (Rocha et al., 1998). Cocaine also 
enhances subsecond DA release in the NAc, which is known to play a critical role in the 
shift from recreational use to compulsive drug seeking of cocaine (Phillips et al., 2003; 
Owesson-White et al., 2009; Wheeler et al., 2012). However, the precise mechanism 
underlying the shift from recreational use to addiction is poorly understood. Alterations in 
synaptic plasticity (Saal et al., 2003; Argilli et al., 2008) and overexpression of α- and γ-syn 
(Brenz-Verca et al., 2003) have been reported in response to repeated exposure to cocaine. 
Chronic cocaine abuse produces profound changes in striatal morphology and function, 
mimicking pre-motor symptoms of PD (Little et al., 1993; 1998; Staley et al., 1994a,b).  
Amphetamine and methamphetamine also enhance dopaminergic neurotransmission 
however by a different mechanism. Amphetamines are known as DA releasers (Heikkilä et 
al., 1975), and act as substrates for the DAT. They can be actively transported inside the 
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nerve terminal via the DAT (Liang and Rutledge, 1982; Zaczek et al., 1991) or can passively 
diffuse through the membrane by lipophilic diffusion (Mack and Bonisch, 1979). 
Amphetamines disrupt the proton gradient necessary for DA transport via VMAT2 inside 
synaptic vesicles (Sulzer and Rayport, 1990; Schmitz et al., 2002). The large cytosolic 
accumulation of DA reverses the gradient-driven DAT and causes DA efflux into the 
synaptic cleft (for a review, see Sulzer et al., 2005). Methamphetamine shares the 
mechanism of action of amphetamine, although it is known to be far more neurotoxic than 
amphetamine (Volz et al., 2007b). Alterations of striatal DA neurotransmission have also 
been reported in the addictive effects of cannabis (Cheer et al., 2004) and nicotine (Zhang 
and Sulzer, 2004; Rice and Cragg, 2004). Nicotine, for example, amplifies phasic DA release 
via interaction between DA and cholinergic interneurons (Zhang and Sulzer, 2004; Cragg 
and Rice, 2004). Ethanol has also been shown to increase accumbal DA release following 
acute administration (Jones et al., 2006) while its chronic effects could be attributed to 
disruption of glutamatergic and GABAergic modulation of VTA DA neurons (Theile et al., 
2011; Mishra et al., 2012). Similarly, the most commonly abused prescription drugs, 
benzodiazepines, also exert addictive effects by increasing the firing rate of VTA DA 
neurons (Tan et al., 2010). Moreover, chronic abusers of psychostimulants often display 
preclinical symptoms of PD or even early stage motor impairment (Bauer, 1996). 
Methamphetamine abuse, for example, has been linked to an increased risk of developing 
PD (for reviews, see Volz et al., 2008b; Cruickshank and Dyer, 2009). These studies 
highlight that striatal DA neurotransmission plays a key role in the development of 
addiction, and further research is required to investigate the underlying factors and 
therapeutic intervention in addiction. 
2.4.3 Attention-deficit hyperactivity disorder 
Attention-deficit hyperactivity disorder (ADHD) is characterised by the inability to sustain 
concentration, impulsivity, and/or hyperactivity. It is among the most prevalent childhood 
disorders affecting 2-5% of school-age children (Zoëga et al., 2012). A substantial 
proportion of children diagnosed with ADHD continue to experience the symptoms into 
adulthood and face difficulties in professional and personal lives. Hence, investigation of 
the treatment of ADHD and its underlying causes remains of substantial interest. The main 
brain regions implicated in ADHD pathology are the prefrontal cortex and striatum (for a 
recent review, see Durston et al., 2011). The primary cause underlying ADHD is believed to 
be the dysfunction of the dopaminergic system (reviewed by Gainetdinov, 2010). 
Noradrenaline also plays a key role and NET inhibitors such as reboxetine are widely used 
for treating ADHD. Polymorphisms in the genes encoding DAT, DA receptor, and 
synaptosomal-associated protein, 25 kDa (SNAP-25) (Barr et al., 2000; Mill et al., 2002) have 
been linked to vulnerability to ADHD, all of which affect normal dopaminergic functioning 
by modulating DA release and re-uptake. In addition to genetic, prenatal and 
developmental factors have been linked to ADHD. 
Although dopaminergic dysfunction has been implicated in ADHD, the precise 
mechanisms underlying ADHD are still poorly understood. Studies have reported that both 
hypo- and hyperdopaminergic states can produce symptoms of ADHD. A U-shaped 
relation between extracellular DA levels and symptoms of ADHD has been proposed 
(Vrshek-Schallhorn et al., 2006). The two commonly used animal models of ADHD, DAT 
knockout mice and spontaneously hyperactive rats, both display elevated extracellular DA 
levels (Jones et al., 1998; Viggiano et al., 2003). At the same time, decreased DA levels may 
also contribute to some of ADHD symptoms (Russell, 2003). One of the most intriguing 
questions in ADHD is the therapeutic effects of methylphenidate (MPD) and amphetamine 
commonly used to treat ADHD. Both MPD and amphetamine belong to the 
psychostimulant class of drugs and increase extracellular DA levels, yet they produce 
calming effects in humans as well as in animal models of ADHD with elevated striatal DA 
levels (Volkow et al., 2012). Therefore, investigating the mechanisms of therapeutic efficacy 
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of these drugs is important for better understanding of the neurobiological mechanisms of 
ADHD. Further, genetic association ofsingle-nucleotide polymorphisms in the SNAP-25 
gene with the phenotype of ADHD in SNAP-25 heterozygous mice suggests that 
dysfunction in presynaptic proteins involved in exocytosis may also play a part in ADHD 
pathology (Russell, 2011). Since MPD interacts with several intracellular molecules such as 
VMAT2, its interaction with other presynaptic proteins such as α-syn deserves further 
attention.  
2.4.4 Schizophrenia 
Schizophrenia is a well-known psychiatric disorder in which patient suffers from altered 
perception of reality, hallucinations, delusions, cognitive dysfunction and poor emotional 
control. The main predisposing factors for schizophrenia have been reported to be heredity 
(Hall et al., 2006), social isolation (Hall et al., 2006), head trauma (Molloy et al., 2011), a 
history of drug abuse (Picchioni and Murray, 2007), and developmental problems 
(Malhotra et al., 2006). Schizophrenia manifests itself in two phases – the positive phase 
includes symptoms such as delusions, psychomotor agitation, and psychosis while the 
negative phase involves symptoms of apathy, lack of motivation, decreased cognitive 
function, and anhedonia (for review, see Moore et al., 1999). It has been proposed that 
increased DA levels in the frontal lobe may contribute to the positive symptoms of 
schizophrenia (Lundberg et al., 1989; for review, see Moore et al., 1999). The mainstay of 
treatment of schizophrenia includes the use of typical and atypical antipsychotics such as 
haloperidol and quetiapine, respectively, which primarily block the activation of DA 
receptors (Lieberman, 2004). However, these treatments are effective mainly in the positive 
phase and the treatment of the negative phase remains a considerable therapeutic challenge 
(Ventura et al., 2012). Studies have also shown the involvement of NMDA receptors and 
serotonergic and GABAergic systems in the pathology of schizophrenia (for a review, see 
Gray and Roth, 2007). Overall, the underlying mechanisms responsible for schizophrenia 
remain poorly understood and role of the corticostriatal dopaminergic pathways remains 
an area of active research to further our understanding of schizophrenia.  
2.4.5 Major depressive disorder 
Anhedonia and lack of motivation are predominant features of depression and dopamine is 
intricately involved in mediating these behaviours (for a review, see Nestler and Carlezone, 
2006). Alterations in DA neurotransmission have been reported following exposure to 
stress, which is implicated in susceptibility to depression (Dziedzicka-Wasylewska et al., 
1997). Depletion of DA has been linked to lower effort in tasks requiring effort to achieve 
reward, which can play an important role in depression (for a review, see Salamone, 2009). 
Polymorphisms in dopamine-associated genes encoding DAT, DA receptors, and COMT 
have been investigated in the context of depression. Although these have not been 
implicated in depression, their synergistic interaction with other polymorphisms and 
stressful events in life have been suggested to play a role in susceptibility to depression (for 
a review, see Dunlop and Nemeroff, 2007). Pharmacological evidence from preclinical and 
clinical studies has however been more supportive for the role of DA in depressive 
disorders. Recent studies have revealed efficacy of dopamine agonists (Hori and Kunigi, 
2012) and atypical antipsychotics (Vieta et al., 2013) as adjunct treatments for major 
depression. Further, the DAT and NET blocker bupropion is now a widely used drug to 
treat major depression (Moreira, 2011). Studies have also shown that dopaminergic drugs 
can decrease the latency of therapeutic efficacy of selective serotonin re-uptake inhibitors 
(SSRIs) or augment their effects in treatment-resistant depression (Sporn et al., 2012; Chen 
et al., 2012). Two recent studies (Chaudhury et al., 2013; Tye et al., 2013) showed that 
specific activation of the midbrain DA neurons rapidly resolves the symptoms of 
depression in mice. Therefore, the dopaminergic reward pathway is emerging as an 
important therapeutic target for treatment of depression. 
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2.5 ALPHA-SYNUCLEIN 
2.5.1 Introduction to alpha-synuclein (α-syn) 
Alpha-synuclein (α-syn) attracted the attention of researchers after the discovery of its 
presence in amyloid plaques in Alzheimer’s disease and (Iwai et al., 1995) and causative 
mutations in the SNCA gene locus in familial forms of PD (Polymeropoulos et al., 1997; 
Spillantini et al., 1998). Inclusions containing α-syn were also found in sporadic forms of 
PD (Spillantini et al., 1998). α-Syn has since been intensively studied to understand its 
physiological and pathological roles.  
α-Syn is a presynaptic protein belonging to the synuclein family of proteins. The 
presence of synuclein-like proteins was first reported in the electric lobe of Torpedo 
californica (Maroteaux et al., 1988), and the presence of its homologs was soon reported in 
rat (Maroteaux and Scheller, 1991) and human brains (Jakes et al., 1994; Irizarry et al., 1996). 
The homologous family of proteins reported in these and a few other studies (Nakajo et al., 
1990, George et al., 1995) was later categorised into alpha (α), beta (β) and gamma (ϒ) 
synucleins (For a review, see Clayton and George, 1998). Due to its involvement in 
neurodegenerative disorders, α-syn has been the most widely studied protein among the 
synucleins so far.  
α-Syn is a 19 KDa presynaptic protein made of 140 amino acids (for a review, see George, 
2002). It is a highly conserved protein whose genetic sequence can be divided into three 
distinct regions: acidic tail, non-amyloid-β component (NAC) domain, and amphipathic 
region (Beyer, 2006). Over half of the α-syn molecule (7-87 amino acids) consists of 
imperfect repeat sequences of 11 amino acids with a core sequence motif of KTKEGV (for 
reviews, see Sidhu et al., 2004a,b; Venda et al., 2010). The synucleins share a considerable 
structural homology, mainly a highly conserved α-helix (residues 7-87), a hydrophobic 
NAC domain (residues 61-95) and carboxyl terminal acidic tail (residues 95-140) (Lavedan, 
1998; Petersen et al., 1999; for a review, see Sidhu et al., 2004b). The three missense 
mutations implicated in PD, i.e., A30P, A53T and E64K, are found in the amphipathic 
region of the SNCA gene (Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz et al., 
2004). Duplication (Charteir-Harlin et al., 2004; Ibáñez et al., 2004) and triplication 
(Singleton et al., 2003) of the SNCA gene linked to autosomal dominant inheritance of PD 
have also been found. Moreover, the linkage of single nucleotide polymorphisms (Simon-
Sanchez et al., 2009; 2011; Satake et al., 2009) and other variations (Farrer et al., 2001; 
Maraganore et al., 2006) in the SNCA gene have been discovered, which increase the risk of 
developing PD. In addition to underlying genetic abnormalities, involvement of α-syn in 
Lewy bodies and intracellular inclusions validate its role also in sporadic forms of PD (for a 
recent review, see Pihlstrøm and Toft, 2011). 
The primary difference between α- and β-syn is the presence of 11 residues at the core of 
the NAC binding domain (Giasson et al., 2001a,b; Du et al., 2003; 2010). On the other hand, 
the γ-syn lacks the conserved C-terminal domain (Buchman et al., 1998). There is also a 
significant overlap in the expression patterns of the three synucleins. β-Syn expression is 
relatively more widespread than the other two synucleins (Galvin et al., 2001; Skarnes et al., 
2011). The expression of γ-syn is denser in the medulla, pons, and hypothalamus while the 
expression of α-syn is higher in the olfactory system. α- and γ-synucleins are expressed at 
roughly similar levels in the CPu, pallidum, and cortex (Brenz Verca et al., 2003). Abundant 
expression of α-syn is observed in the CPu, ventral striatum, hippocampus, thalamus, 
amygdala, olfactory bulb, and the cortical regions (Brezn Verca et al., 2003). Its expression is 
relatively moderate in the SN and very low in the VTA (Brenz Verca et al., 2003). Although 
α-syn is best known for its presence in the central nervous system, it is also present the 
peripheral nervous system (Martinez-Navarrete et al., 2007), retina (Surgucheva et al., 2002) 
and haematopoietic cells (Shin et al., 2000). 
α-Syn is abundantly expressed in the cytosol (Maroteaux et al., 1988; Iwai et al., 1995; 
Fortin et al., 2005), and is richly expressed in the vesicular fractions of nerve terminal and in 
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close proximity to the membrane (Irizarry et al., 1999; Kahle et al., 2000). It is a natively 
unfolded protein (Eliezer et al., 2001), and although it is described as a highly soluble and 
mobile protein, it is commonly found in membrane-bound form (Lee et al., 2002a,b).  
2.5.2 Role of α-syn in dopamine biosynthesis 
Since TH-mediated synthesis of DA from L-DOPA is the rate-limiting step of DA synthesis, 
molecules which affect TH activity can have an important effect of DA synthesis (Goldstein, 
1984). For DA synthesis to take place, phosphorylation of TH is the key step (Goldstein, 
1984). α-Syn negatively regulates TH activity by preventing the phosphorylation of TH 
(Perez et al., 2002). The absence of α-syn leads to increased phosphorylation and greater 
activity of TH (Liu et al., 2008). α-Syn is further capable of reducing TH activity by 
inhibiting calcium-calmodulin-dependent kinase, MAP kinases, and protein C kinase, all of 
which regulate TH function (Lee et al., 2002a). α-Syn has also been shown to interact with 
the enzyme AADC, which converts L-DOPA to DA (Tehranian et al., 2006).  
α-Syn overexpression has been shown to decrease TH activity (Gao et al., 2007) and 
mRNA levels (Yu et al., 2004) in neurons. Studies using animal models with α-syn 
overexpression reveal a significant downregulation of DA synthesis (Masliah et al., 2000; 
Kirik et al., 2002). Mutated forms of α-syn (A30P and A53T) also downregulate TH activity 
and DA synthesis (Perez et al., 2002). This is especially relevant in the pathology of PD 
involving aggregations containing α-syn, since these aggregations can further reduce DA 
synthesis (for a review, see Lotharius and Brundin, 2002a). Despite the role of α-syn in DA 
biosynthesis, the consequences of loss of α-syn on striatal DA content are unclear. 
Abeliovich et al. (2000) reported an 18% reduction in striatal DA content while Chandra et 
al. (2004) reported no such change. However, a significant loss of tissue DA content and 
DAT expression has been reported in aged mice lacking α-syn (Robertson et al., 2004; Al-
Wandi et al., 2008) in comparison with wild-type mice.  
2.5.3 Role of α-syn in synaptic vesicles 
α-Syn was initially shown to play a role in the modelling of neuronal networks during song 
learning (Clayton and George, 1998). Furthermore, α-syn expression is known to increase 
during postnatal period when new synapses are being formed (Jakowec et al., 2001; 
Murphy et al., 2000). This early evidence hinted at a role for α-syn in synaptic formation. 
The first study by Abeliovich et al. (2000) showed that mice lacking α-syn do not display 
alterations in the number of synapses in the striatum. However, ultrastructural analysis of 
synaptic structure showed an approximately 50% reduction in the number of vesicles in the 
reserve pool (Murphy et al., 2000; Cabin et al., 2002), indicating an important role in the 
compartmentalisation of synaptic vesicles.   
Despite evidence in vesicular function, how α-syn performs these functions is still not 
clearly understood and several explanations have been proposed. Mice lacking α-syn 
display significant reduction in synapsin which redistributes vesicles in different pools 
(Cabin et al., 2002; Greengard et al., 1993; Hilfiker et al., 1999). Further, the amino-terminal 
end of α-syn actively binds with phospholipids in the cytosol (Davidson et al., 1998; Eliezer 
et al., 2001), and thus modulates and inhibits the activity of phospholipase D2 (PLD2) (Ahn 
et al., 2002). PLD2 enables the recruitment of binding proteins to vesicular membranes and 
may regulate the recruitment and recycling of vesicles in cooperation with α-syn (for 
reviews, see Lotharius and Brundin, 2002a,b; Sidhu et al., 2004b). α-Syn also interacts with 
several intracellular protein kinases which phosphorylate α-syn (Okochi et al., 2000; Pronin 
et al., 2000). Phosphorylated α-syn further promotes vesicle redistribution and recycling 
during increased synaptic activity (reviewed by Sidhu et al., 2004b) and protects against 
neurotoxicity (Chen and Feany, 2005). Studies suggest that α-syn may transfer fatty acids, 
which are present in high quantities in synaptic vesicles, and thus assist in vesicle 
formation (Schmidt et al., 1999) and recycling (Sharon et al., 2001). One study (Fortin et al. 
2005) showed interesting evidence on the role of α-syn in exocytosis and endocytosis. The 
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study revealed that α-syn binds with vesicles and modulates exocytosis. α-Syn is richly 
present in the vesicles in close proximity to the membrane and facilitates vesicle movement 
towards the membrane. It does not fuse with the membrane but rapidly dissociates and 
moves away from the membrane inside the cytosol (for a review, see Fortin et al., 2010). α-
Syn may also indirectly modulate vesicle trafficking by regulating the levels of polymerised 
actin filaments inside the nerve terminal which promotes vesicle translocation inside the 
cytosol (Sousa et al., 2009). Additionally, α-syn modulates intracellular trafficking by 
interacting with other cytoskeletal proteins such as tubulin and tau (Jensen et al., 1999; 
2000; Alim et al., 2004). α-Syn also cooperates with cysteine string protein α (CSP-α) 
(Chandra et al., 2004), which facilitates exocytosis by interacting with soluble NSF 
attachment protein receptor (SNARE) (Graham and Burgoyne, 2000) and ameliorates 
neurotoxicity by regulating intracellular Ca2+ influx (Umbach et al., 1998). More recently, α-
syn was shown to modulate exocytosis directly by interacting with the SNARE complex, 
and clear deficits in exocytosis are seen in the absence of α-syn (Burré et al., 2010). 
Differential expression of α-syn in vesicle subpopulations raises an interesting question on 
whether α-syn distinguishes vesicles participating in release. It has been shown to regulate 
the size of vesicles in the readily releasable pool (RRP) and reserve pool (Murphy et al., 
2000; Cabin et al., 2002; Fortin et al., 2005), and is expressed only in a subpopulation of DA 
vesicles (Lee et al., 2008), in an activity-dependent manner (Fortin et al., 2005). A study 
showed a direct interaction between α-syn and VMAT2 (Guo et al., 2008). Therefore, in 
addition to vesicle recycling, α-syn may directly participate in vesicular transport of DA 
(Choi et al., 2005), a potentially important function to prevent autoxidation of DA.  
Several studies using overexpression or mutant forms of α-syn complement the evidence 
on the role of α-syn in synaptic vesicles. Transgenic mice with A30P mutation display 
altered compartmentalisation of DA vesicles (Yavich et al., 2009). Mutant forms of α-syn 
disrupt vesicle mobilisation and reclustering due to the loss of α-syn as a trafficking 
protein. Similar results were obtained in a recent study (Nemani et al. 2010) which showed 
that even a modest overexpression of α-syn inhibits vesicle recycling after exocytosis. 
Because of these numerous functions of α-syn in synaptic vesicles, it is not surprising that 
vesicular organization has emerged to be one of the most prominent functions of α-syn 
(Abeliovich et al., 2000; Murphy et al., 2002; Cabin et al., 2002; also see reviews, Lotharius 
and Brundin, 2002a,b; Venda et al., 2010; Fortin et al., 2010).  
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Figure 3. Schematic summary of the major functions of α-syn inside the cytosol. The green 
arrows indicate the cellular processes under the modulation of α-syn. For instance, α-syn binds 
with and mobilises vesicles towards the membrane for release by binding the vesicular 
membrane. α-Syn facilitates this mobilisation by interacting with microtubules and other 
trafficking proteins, and assists in exocytosis in cooperation with the SNARE complex. After 
vesicle fusion with the membrane, α-syn diffuses away from the membrane and binds new 
vesicles in order to sustain DA release in response to high demand. α-Syn also aids in recycling 
fused vesicles by acting as a tethering protein. Further, α-syn transports the DAT towards and 
away from the membrane, binds with TH and inhibits DA synthesis, and binds VMAT2 and may 
play a role in refilling vesicles. 
2.5.3.1 Short-term plasticity of neurotransmitter release 
Before elucidating the role of α-syn in the short-term plasticity of neurotransmitter release, 
it is important to first look at the evidence which has shaped our understanding of 
vesicular organisation and the short-term plasticity of neurotransmitter release. 
Mobilisation and recruitment of vesicles is a highly adaptive process designed to maintain 
neurotransmitter release in response to changing demand (for a review, see Rizzoli and 
Betz, 2004). When a neuron fires an action potential, the voltage-gated calcium channels 
open and the ensuing calcium influx initiates a chain of reactions to facilitate 
neurotransmission through vesicle mobilisation and exocytosis (for a review, see Südhof, 
1995). It has now been convincingly shown that there exist three different types of vesicle 
pools in presynaptic terminals which are recruited at different stages of neurotransmission, 
depending on the intensity and duration of neuronal firing (for reviews, see Rizzoli and 
Betz, 2004; Stevens, 2004; Voglmaier and Edwards, 2007). In the particular case of DA, 
indirect evidence from stimulated DA release has long indicated a presence of more than 
one vesicle storage pool (Javoy and Glowinski, 1971; Ewing et al., 1983b; Yavich, 1996). 
These studies showed using pharmacological tools and electrical stimulation of DA 
neurons that not all of the DA storage is emptied following an electrical stimulation. In fact, 
high-frequency stimulation at a few second intervals successively enhances DA release in 
the dorsal striatum until all DA storage is exhausted (Ewing et al., 1983b; Yavich, 1996). 
Later studies in non-dopaminergic systems provided direct molecular evidence that indeed 
different vesicle pools are recruited during neurotransmission (Stevens and Wesseling, 
1999a,b; For reviews, see Rizzoli and Betz, 2004; 2005).  
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The three vesicle pools have been defined as readily releasable pool (RRP), reserve pool, 
and recycling pool (Rizzoli and Betz, 2005). The RRP serves as the immediate source of 
neurotransmitter release upon arrival of an action potential. Studies in frog neuromuscular 
junction have displayed that stimulation at low frequencies of 2-10 Hz recruit DA from 
vesicles almost exclusively from the RRP (Stevens and Wesseling, 1999a,b; Richards et al., 
2000; 2003). Stimulation at middle frequencies (10-30 Hz) mobilises vesicles from the 
recycling pool to meet greater demand for neurotransmitter release (Wang and Kaczmarek, 
1998; Stevens and Wesseling, 1999a,b; Richards et al., 2003). Stimulation at frequencies 
higher than 50 Hz recruits vesicles from the reserve pool in addition to RRP and recycling 
pool (Wang and Kaczmarek, 1998; Stevens and Wesseling, 1999b). Although no anatomical 
separation between different vesicle pools has been found (for a review, see Rizzoli and 
Betz, 2005), it was recently shown that vesicles belonging to different pools exhibit different 
composition of membrane proteins (Hua et al., 2011).  
More recently, two studies have confirmed the presence of distinct vesicle pools in DA 
neurons similar to those of glutamate (Wang and Kaczmarek, 1998) and GABA 
(Rosenmund and Stevens, 1996; 1997). The first study (Mani and Ryan, 2009), which 
monitored the activity of DA vesicles in neurons using optical imaging, showed that DA 
neurons indeed have three distinct vesicle pools which are recruited at different stimulation 
frequencies. The study indicated that the recycling pool maintains DA neurotransmission 
during prolonged stimulation between 5-30 Hz. Another study (Daniel et al. 2009) showed 
that the size of the recycling pool is the main limiting factor for sustaining DA release 
following prolonged stimulation. Thus, these studies strongly substantiate similar 
suggestions regarding the roles of the recycling pool in DA neurons (Yavich, 1996; Yavich 
and MacDonald, 2000; Yavich et al., 2004).  
2.5.3.2 Role of α-syn in vesicular mobilisation and redistribution 
Given the role of α-syn in vesicular organization, it is not surprising that α-syn affects the 
short-term plasticity of DA overflow. Mice lacking α-syn do not display overt deficits in 
DA overflow following weak electrical stimulation (Senior et al., 2008). It has been argued 
that functional redundancy between the synucleins may provide compensation for the loss 
of α-syn. However, it is also possible that mice born with the absence of α-syn may not 
display dramatic phenotype due to compensatory mechanisms. In contrast, postnatal local 
silencing of α-syn in the SN neurons in mice has been shown to dramatically decrease 
neurotransmitter release (Liu et al., 2004). Furthermore, more “demanding” protocols 
which tested neurotransmitter release following intense or prolonged stimulation clearly 
unmask deficiencies in neurotransmitter release in mice lacking α-syn (Abeliovich et al., 
2000; Murphy et al., 2000; Cabin et al., 2002; Yavich et al., 2004; Fortin et al., 2005).  
Abeliovich et al. (2000) showed that paired-pulse stimulation of DA release produces 
short-term depression of DA release. However, this depression was much less in mice 
lacking α-syn, indicating a faster recovery of DA release in these mice. Consistent with this 
role, α-syn deficient mice exhibit enhanced facilitation of DA overflow following repetitive, 
high-frequency stimulation (Yavich et al., 2004). These studies suggested that mice lacking 
α-syn may display an increased rate of refilling of DA vesicles, which enables them to 
replenish the vesicle pools faster than wild-type mice. Altered interaction between RRP and 
recycling pool was also proposed as an explanation behind this phenomenon (Abeliovich et 
al., 2000; Yavich et al., 2004; See Fig. 4 for the working hypothesis of the short-term 
plasticity of DA overflow in mice with and without α-syn). Similar alterations attributable 
to impaired vesicular dynamics have also been observed in norepinephrine (Yavich et al., 
2006) and glutamate (Gureviciene et al., 2007) release in α-syn deficient mice indicating a 
universal role for α-syn in neurotransmitter release.  
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Figure 4. Working model of the short-term plasticity of DA overflow following repeated burst 
stimulation in mice with and without α-syn (Reprinted from Study III with permission from the 
American Society for Pharmacology & Experimental Therapeutics). Mice lacking α-syn display 
enhanced facilitation of DA overflow due to altered compartmentalization of DA overflow. 
Studies show that the rate of refilling of vesicles may be greater (Abeliovich et al., 2000; Yavich 
et al., 2004). As a compensation for decreased vesicles in the active zone (Murphy et al., 2000; 
Cabin et al., 2004), the recycling pool may play a greater role in release in these mice. 
Therefore, these mice may display enhanced facilitation of DA overflow.  
2.5.3 Trafficking and regulation of DAT activity by α-syn 
Regulation of the DAT is a potentially important function of α-syn given its importance in 
PD and a host of other disorders. DAT is trafficked from the cytosol and inserted into the 
membrane in an activity-dependent manner (for a review, see Mortensen and Amara, 
2003). DAT function is constantly modulated by kinases in response to changing demand, 
and α-syn interacts with and modulates the activity of these kinases (for a review, see 
Sidhu et al., 2004a). The first evidence of direct binding of α-syn with the DAT was 
provided in a study using cultured neurons (Lee et al., 2001). α-Syn promotes DAT 
trafficking away from the plasma membrane, and attenuates DAT activity and DA re-
uptake by 30-50% (Wersinger and Sidhu, 2003). Decreased membrane binding of the DAT is 
observed in the presence of α-syn. Similarly, A30P mutant α-syn also decreased DAT 
trafficking inside the cytosol (Wersinger et al., 2003). α-Syn mediated attenuation has been 
suggested to play a protective role by decreasing DA re-uptake and cytosolic accumulation 
of DA (Wersinger et al., 2003). Intriguingly, the neurotoxin MPP+, which is transported 
inside the cytosol solely through the DAT (Gainetdinov et al., 1997), reverses the α-syn 
mediated attenuation of DAT activity and increases cytosolic accumulation of DA 
(Wersinger et al., 2003). However, in vivo studies using α-syn knockout mice have reported 
no changes in DAT activity (Dauer et al., 2002; Senior et al., 2008). As in the case of 
vesicular organisation, it is possible that mice with a genetic loss of α-syn develop 
compensatory mechanisms that can mask the true role of α-syn in modulating re-uptake. 
Another possibility for this discrepancy could be the differences between the modulation of 
DAT activity in cell cultures or ex vivo preparations and in the intact brain. In addition to 
DAT, α-syn modulates the trafficking of serotonin (Wersinger et al., 2006a) and 
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norepinephrine (Wersinger et al., 2006b) transporters, suggesting a broader role in 
transport and protein trafficking. 
Overall, disruption of DA re-uptake by α-syn during the pathogenesis of PD remains a 
relevant question. Several other proteins implicated in PD such as PINK, DJ-1, Parkin also 
modulate re-uptake and determine the vulnerability of DA neurons in a DAT-dependent 
manner (Jiang et al., 2004; Goldberg et al., 2005). 
2.5.4 Role of α-syn in Parkinson’s disease 
Because of the prominent involvement of α-syn, the associated neurodegenerative 
disorders have been collectively referred to as synucleinopathies, which include PD, 
Dementia with Lewy body (DLB) and multiple system atrophy (Spillantini et al., 1998; 
1999). Alzheimer’s disease also exhibits a significant overlap with synucleinopathy with 
regards to the involvement of α-syn (Iwai et al., 1995; Rockenstein et al., 2001).  
The evidence for the presence of α-syn in neurofibrillary tangles and inclusions in the 
brain were the first to provoke investigation of α-syn in neurodegenerative disorders 
(Spillantini et al., 1997). Later studies (Spillantini et al., 1997; Polymeropoulus et al., 1997) 
found evidence of mutations in the α-syn gene in familial forms of PD. The A53T mutation 
caused by A to G transition at position 209 was identified in an Italian-Greek family 
(Polymeropoulus et al., 1997). Another mutation at position 88 resulting from G to C 
transition was reported in a German kindred (Krüger et al., 2001). Individuals carrying the 
mutations in the SNCA gene exhibit autosomal dominant inheritance and display a 
significantly elevated risk for developing PD than non-carriers (Polymeropoulos et al., 1997; 
Bostantjopoulou et al., 2001). Inclusions with the presence of α-syn have been demonstrated 
also in sporadic, non-familial PD patients (Spillantini et al., 1997). A strong presence of the 
LB containing α-syn was observed in the SN, brainstem, and cingulate cortex in human 
brains of PD patients (Spillantini et al., 1997).  
Despite the link between genetic mutations and presence in Lewy bodies, how α-syn 
leads to pathogenesis is still not fully understood. Structural changes in α-syn have 
attracted particular attention in this context. Elevated concentration of α-syn has been 
shown to increase its tendency to form protofibrils, which have proven to be highly 
neurotoxic (Conway et al., 2000a,b; Shtilerman et al., 2002). Furthermore, presence of A53T 
(Lee et al., 2002b; Giasson et al., 2003) or A30P (Fortin et al., 2005) mutations exacerbates the 
propensity of α-syn to form protofibrils. The interaction of α-syn with tau protein may also 
contribute to a higher probability of aggregation (Giasson et al., 2003). The presence of 
genetic mutations has been shown to accelerate α-syn oligomerisation, suggesting a link 
between other PD-related genetic mutations and the role of α-syn in PD (Conway et al., 
2000a,c; 2001). For instance, the A53T mutation is known to be far more toxic than other 
alterations in α-syn (Lee et al., 2002b). MPTP and 6-OHDA models of PD also show that 
administration of these neurotoxins significantly increases the expression of α-syn in nigral 
neurons (Kholodilov et al., 1999; 2004; Vila et al., 2000). 
As discussed in section 2.4.1, oxidative stress is a major contributor to PD. α-Syn has 
been shown to both increase (Ischiropoulos, 2001) and mitigate (Hashimoto et al., 2002; Liu 
et al., 2008) oxidative stress by interacting with numerous proteins. Disruption of 
mitochondrial complex I has been shown to promote aggregation and accumulation of α-
syn (Manning-Bog et al., 2002; Sherer et al., 2003a,b). α-Syn is particularly prone to 
oxidative stress, as revealed by selective nitration of α-syn in the sporadic cases of PD 
following increased oxidative stress (Giasson et al., 2000; Giasson and Lee, 2000). 
Neurotoxins paraquat and rotenone also promote intracellular accumulation of aggregated 
α-syn (Manning-Bog et al., 2002; Betarbet et al., 2003). Overexpression of α-syn increases 
cytosolic concentration of DA (Mosharov et al., 2006; 2009), which in itself can be highly 
toxic to DA neurons. Membrane bound α-syn has also been shown to be highly prone to 
protofibril formations (Perrin et al., 2001; Sharon et al., 2003; Roberti et al., 2007). 
Overexpression of α-syn has been shown to play a protective role by reducing oxidative 
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stress and promoting regeneration (Kholodilov et al., 1999; Hashimoto et al., 2002). Some 
studies have suggested that α-syn aggregations may in fact be a protective strategy of the 
cell (Hashimoto and Masliah, 1999; Iwai et al., 2000; Lashuel et al., 2002) and promote cell 
survival.  
Another mechanism implicated in potential toxicity of α-syn is the loss or disruption of 
ubiquitin-proteosome system which degrades α-syn (Paxinou et al., 2001). The ubiquitin-
proteosome system has an important regulatory role in degrading malformed or excessive 
levels of proteins. Given the fact that an overabundance of α-syn is toxic to dopaminergic 
neurons, the failure of the ubiquitin-proteosome system to degrade excessive or misfolded 
α-syn can indeed threaten the survival of DA neurons (Lee et al., 2002a). In support of this 
argument, α-syn aggregations have been shown to bind directly with the proteasome and 
inhibit its function (Stefanis et al., 2001; Snyder et al., 2003), leading to severe toxicity inside 
the cell. α-Syn can also be degraded by chaperone-mediated autophagy (Massey et al., 
2006), and the blockade of chaperone-mediated autophagy can induce cell death. It has 
been shown that A30P and A53T mutations or overexpression of α-syn (Massey et al., 2006) 
inhibits the lysosomal translocation of α-syn and other proteins to chaperone-mediated 
autophagy, making neurons more vulnerable to apoptosis. This has been suggested as an 
explanation as to why a gene duplication in the SNCA gene may predispose one to PD (for 
a review, see Sulzer, 2007). A recent study showed that microinjection of preformed 
protofibrils of recombinant α-syn in the mouse brain? produced a PD-like pathology 
causing death of DA neurons and marked impairment of motor performance (Luk et al., 
2012).  
PD is also commonly referred to as a DA dysregulation disorder, and given the role of α-
syn in DA vesicular storage, this function of α-syn may be critical in the context of PD (for 
reviews, see Lotharius and Brundin, 2002a; Caudle et al., 2008). One of the most intriguing 
questions regarding the role of α-syn in PD is the specific vulnerability of DA neurons 
despite the abundant presence of α-syn in other types of neurons (for a review, see Sulzer, 
2007). An important explanation suggested is the toxicity of DA itself. It has been shown 
that DA promotes the oxidation and protofibril formation of α-syn, causing its aggregation 
and accumulation (Conway et al., 2001). Toxic forms of α-syn can permeabilize vesicle 
membranes and cause DA leakage from vesicles to the cytosol (Volles et al., 2001; Volles 
and Lansburry, 2002; Mosharov et al., 2006). Thus, accumulation of cytosolic DA or toxic 
forms of α-syn may set in a progressive chain of reactions synergistically exacerbating the 
function and survival of DA neurons (for a review, see Caudle et al., 2008). The role of α-
syn in DA storage is highlighted by the findings in VMAT2 knockout mice. Studies have 
shown that VMAT2 knockout mice, with dysregulated DA storage, display significant loss 
of DA neurons. However, a progressive loss of nigrostriatal DA neurons mimicking 
conditions observed in PD is seen only in the presence of α-syn (Colebrooke et al., 2006; 
Caudle et al., 2007). These studies show that the function of α-syn as a guardian of DA 
vesicular storage may be the key factor in the pathogenesis of PD (Venda et al., 2010). 
These findings are backed by a number of studies on α-syn in humans. Post-mortem 
studies from human brains have shown that α-syn expression is 4-fold greater in sporadic 
cases of PD (Rockenstein et al., 2001; Chiba-Falek et al., 2006). On the other hand, several 
studies have reported decreased mRNA levels of α-syn in PD brains (Neystat et al., 1999; 
Kingsbury et al., 2004). However, these studies report that since these expression levels 
were found at the end stage of PD with very few or no viable DA neurons, it is hard to 
draw a direct correlation between α-syn levels and loss of DA neurons. However, the 
evidence from animal models and genome-wide association studies in humans is much 
more unequivocal. Animal models with decreased or no expression of α-syn do not exhibit 
signs of PD (Abeliovich et al., 2000; Cabin et al., 2002). However, animals with 
overexpression of α-syn show significant degeneration of the nigrostriatal dopaminergic 
neurons (Masliah et al., 2000; Kirik et al., 2002). Similarly, humans carrying the triplication 
of the SNCA gene display early-onset PD with significantly worse motor and cognitive 
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deficits and a faster rate of degeneration (Singleton et al., 2003; Farrer et al., 2004). A recent 
study by Lundblad et al. (2012) provides further proof for this by reporting that α-syn 
overexpression produces a significant decline in tissue DA content, release and re-uptake as 
early as 10 days after delivery of human α-syn in the substantia nigra. The study showed 
presence of extensive axonal damage, synaptic dysfunction, and α-syn aggregates in the 
striatum (Lundblad et al., 2012).  
2.5.5 Role of α-syn in neuropsychiatric disorders 
Because of the numerous functions of α-syn in the dopaminergic system, α-syn and its 
genetic polymorphisms have been widely investigated in neuropsychiatric disorders 
including substance abuse (Liang and Carr, 2006), schizophrenia (Gray et al., 2010), 
depression (Jeannotte et al., 2007; 2009a,b), eating disorders (Frieling et al., 2008), and 
psychosis (Kobayashi et al., 2008). Similarities between psychostimulant-induced 
neurotoxicity and preclinical symptoms in PD (Bartzokis et al., 1996; Volkow et al., 1992a,b) 
initially prompted an investigation of the role of α-syn in psychostimulant action. In this 
area, Mash et al. (2003) reported for the first time that cocaine abuse alters α-syn expression 
in the human brain. Overexpression of α-syn is observed in the midbrain DA neurons of 
cocaine abusers, especially in the SN and VTA (Mash et al., 2003; 2008). Rats with an 
overexpression of α-syn in the NAc display a nearly two-fold increase in cocaine self-
administration, which can be reversed by lentiviral silencing of α-syn (Boyer and Dreyer, 
2007). α-Syn has also been implicated in mediating vulnerability to ethanol abuse (Liang et 
al., 2003). A study showed that increased expression of α-syn may be a predisposing factor 
in ethanol preference in alcohol-preferring rats (Liang et al., 2003; Liang and Carr, 2006). 
This suggestion was further substantiated by studies in both monkeys (Walker and Grant, 
2006) and humans (Bönsch et al., 2004, 2005a,b,c), which linked elevated mRNA levels of α-
syn in blood to alcohol craving. Apart from cocaine and ethanol, α-syn has also been 
associated with modulation of the effects of heroine (Dürsteler-Macfarland et al., 2011) and 
methamphetamine dependence (Kobayashi et al., 2004). Alterations in expression levels of 
α-syn in several brain regions were reported following chronic antidepressant treatment 
(Jeonnotte et al., 2009a,b). These studies provide firm evidence on the overall importance of 
α-syn in the midbrain dopaminergic system and in the pathology of addiction and other 
psychiatric disorders.  
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Table 1. Functions of α-syn, and the effects of deletion and overexpression of wild-type or 
mutant forms on different parameters of the dopaminergic system. The upward arrows indicate 
an increase while the downward arrows indicate a decrease of the particular parameter. 
 
 Function of  
α-syn 
 
α-syn deletion/ 
knockdown/silencing 
Overexpression or 
mutant 
α-syn expression 
DA synthesis Binds and 
regulates TH 
activity 
  TH activity, synthesis(Perez et al., 
2008, Liu et al., 2008) 
  TH activity, synthesis 
(Kirik et al., 2002; Gao et al., 2007) 
DA innervation   No change(Abeliovich et al., 2000; Cabin et 
al., 2002; Murphy et al., 2000) 
Silencing induces cell 
death(Gorbatyuk et a., 2008) 
Progressive decrease (Kirik 
et al., 2002; Lundblad et al., 2012) 
Lewy Body pathology(Luk 
et al., 2012) 
DA release    Release(Abeliovich et al., 2000; Yavich et 
al., 2004) 
No change(Senior et al., 2008) 
Release(Cabin et al., 2002) 
   Release(Yavich et al., 2004; 
Nemani et al., 2010; Lundblad et al., 
2012) 
Slower release(Kirik et al., 
2003) 
DAT 
activity/expression 
Transports and 
attenuates DAT 
trafficking to 
the membrane 
(Wersinger and Sidhu, 
2003) 
No change(Abeliovich et al., 2000; Dauer et 
al., 2002; Senior et al., 2008) 
  Expression(Fountaine et al., 2008) 
Disruption of α-syn/DAT 
interaction increased re-
uptake(Wersinger and Sidhu, 2005) 
  Re-uptake(Kirik et al., 2002; 
Lundblad et al., 2012) 
    Expression(Luk et al., 2012) 
DA tissue content    of 18%(Abeliovich et al., 2000) 
No change(Chandra et al., 2004) 
  of 40-90%(Kirik et al.,2002; 
2003; Lundblad et al., 2012) 
Vesicular 
organization 
Redistribution 
and trafficking 
of vesicles(Cabin 
et al., 2002; Fortin et 
al., 2005; Nemani et 
al., 2010) 
No change(Abeliovich et al., 2000; Chandra 
et al., 2004) 
 Vesicles in RRP and reserve 
pool(Murphy et al., 2000; Cabin et al., 2002)  
 Reserve pool(Scott and Roy, 2012) 
 Density in reserve 
pool(Nemani et al., 2010; Scott and 
Roy, 2012) 
 
VMAT2 Binds with 
VMAT2(Guo et al., 
2008) 
  Expression(Fountaine et al., 2008)  
SNARE complex Promotes 
SNARE complex 
assembly(Burré et 
al., 2010) 
N & C-terminal sequences 
required for formation(Burré et al., 
2012) 
No effect of mutant α-syn 
on physiological 
function(Burré et al., 2012) 
Motor deficits  No gross abnormalities (Abeliovich et 
al., 2000; Dauer et al., 2002) 
Slight impairment in Rotarod 
test(Pelkonen and Yavich, 2011) 
Moderate to severe motor 
deficits(Kirik et al., 2002; 2003; 
Lundblad et al., 2012; Luk et al., 
2012) 
Effects of 
neurotoxins 
 Resistant to MPTP(Dauer et al., 2002) 
Partial resistance to 6-
OHDA(Alvarez-Fischer et al., 2008) 
Exacerbation of MPTP 
(Nieto et al., 2006) but not 6-
OHDA toxicity(Zhou et al., 
2006) 
 
As summarised in the table above, data on the effects of deletion or overexpression of α-
syn on presynaptic functions are largely complementary. It can be seen that only 
overexpression or mutant α-syn expression leads to pathological effects mimicking PD-like 
symptoms. Therefore, to specifically investigate α-syn dependent-mechanism underlying 
pathology of PD, animal models overexpressing α-syn are best suited. On the other hand, 
mice carrying deletion of α-syn gene locus are useful to investigate the physiological 
functions of α-syn, as these can reveal the consequences of α-syn deletion in the absence of 
any pathology. Since the primary aim of this thesis was to investigate the physiological role 
of α-syn in the striatum, two mouse lines lacking α-syn were employed.  
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2.6 IN VIVO VOLTAMMETRY 
2.6.1 Introduction to in vivo voltammetric techniques 
Since the discovery of neurotransmitters in the early 20th century, development of in vivo 
techniques to measure the changes in neurotransmitter levels and their functions in the 
brain became an area of prime focus for neuroscientists. One of the first breakthroughs in 
this direction was the use of in vivo microdialysis in rodent brain (Bito et al., 1966) which 
allowed detection and measurement of neurochemicals in vivo. Although enormously 
useful, this technique suffered from two main limitations. The first was poor time 
resolution in scales of minutes, and the second was a relatively large microdialysis probe 
causing significant local tissue damage. These limitations demanded development of 
techniques with faster time resolution and smaller microsensor dimensions. Development 
of carbon fibre microsensor and advances in voltammetric electroanalytical methods 
eventually paved the way for the use of in vivo voltammetry in rodent brains (Kissinger et 
al., 1973; Wightman et al., 1978; Gonon et al., 1981).  
One of the earliest techniques used for in vivo DA detection include differential pulse 
voltammetry, high-speed chronoamperometry, fast-scan cyclic voltammetry and constant 
potential amperometry (Gonon et al., 1978; Wightman et al., 1978; Marcenac and Gonon, 
1985; Gerhardt, 1986). All of these techniques share a common principle; they rely on 
application of constant or varying voltage to the working electrode to force the 
neurochemical of interest to undergo oxidation and/or reduction. These techniques have 
proved to be highly valuable for studying the rapid dynamics of catecholamine 
neurotransmission, especially DA, in intact brain since DA readily undergoes oxidation and 
reduction. Furthermore, the simplification and advances in the fabrication of carbon fibre 
microelectrodes have allowed fabrication of working electrodes with high electrochemical 
stability, biocompatibility, and excellent subsecond temporal resolution. These advances 
have enabled the use of in vivo voltammetry not only in anaesthetised (Wightman, 2006) but 
also in freely moving animals (Robinson and Wightman, 2002; Wightman, 2006) and 
humans (Kishida et al., 2011). Increased sophistication of electronic equipment combined 
with improved microsensors now allows the detection of DA in the range of 10-20 nM in 
intact brain (Keithley et al., 2011).  
2.6.2 Electrochemical methods for in vivo dopamine detection 
In order to detect DA in vivo, a carbon fibre electrode (CFE) is positioned in the desired 
brain region with presence of DA. Appropriate voltage, depending on the specific 
technique, is applied to the CFE to force DA to undergo oxidation. When DA molecules 
diffuse and adsorb on the surface of the working electrode, they undergo oxidation by 
donating two electrons to the recording electrode (Clark et al., 2010). The resulting electron 
transfer kinetics produces faradaic current that is directly proportional to the number of DA 
molecules present at the electrode surface (Phillips et al., 2003). Therefore, the faradaic 
current measured at the recording electrode is directly proportional to the number of DA 
molecules in the electrode microenvironment (Clark et al., 2010). Voltammetric techniques 
are ideal to detect phasic DA release produced by electrical stimulation or a natural 
stimulus producing a rapid, transient elevation in the extracellular concentration of DA in 
time scales of milliseconds to seconds (Robinson and Wightman, 2002). Tonic changes in 
DA levels cannot be detected using in vivo voltammetry since the changes in concentrations 
are relatively small (in scales of nanomolar) and happen over a period of minutes to hours. 
Furthermore, voltammetric techniques are known as differential techniques, i.e., they 
determine change in concentration in reference to the concentration at a previous time point 
(Phillips et al., 2003). Therefore, changes in concentration over a period of only a few 
seconds can be reliably detected whereas absolute levels of extracellular DA cannot be 
reliably measured using voltammetric methods. Currently, the two most commonly used 
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voltammetric techniques for DA detection are constant potential amperometry (CPA) and 
fast-scan cyclic voltammetry (FSCV).  
2.6.3 Constant potential amperometry 
Constant potential amperometry (CPA) is a commonly used electrochemical technique for 
in vivo detection of DA. CPA provides the fastest temporal resolution amongst all 
electrochemical methods available for DA detection (Kawagoe and Wightman, 1993; 
Chergui et al., 1994). In CPA, a CFE is held at a potential of +0.4-+0.6 V against an Ag/AgCl 
reference electrode (Chergui et al., 1994; Yavich, 1996). DA molecules which come in 
contact with the CFE get oxidised at this potential and thus generate faradaic current. 
However, all molecules which get oxidised at or below this potential contribute to the 
electrical signal measured by the electrode (Michael and Borland, 2007). Therefore, CPA is 
not a selective technique. CPA is ideal to detect DA when a substantial proportion of the 
compound present in the brain region is known to be DA, and it has been verified 
anatomically, histologically and pharmacologically following specific stimulation of 
ascending dopaminergic pathways (Michael and Borland, 2007). The striatum consists of 
primarily dopaminergic innervation from the ascending axons in SNc and VTA (Lindvall 
and Björklund, 1978). It is well known that electrical stimulation of the medial forebrain 
bundle (MFB) produces primarily DA release in the striatum (Stamford et al., 1988a,b; 
Kawagoe and Wightman, 1994; Dugast et al., 1994). Further, compounds such as ascorbic 
acid, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) are present 
at much greater concentrations than DA (Rebec et al., 1985; 1997; Kuhr et al., 1986). These 
compounds are easily oxidised at the potential used to oxidise DA, and thus contribute to 
electrochemical signal. However, the dynamic changes in DA concentration are 
significantly more rapid than those of ascorbic acid or DA metabolites (Rebec et al., 1985; 
1997; Kuhr et al., 1986, Stamford et al., 1988a,b). Therefore, CPA is a highly suitable and 
reliable method to detect electrically evoked DA levels in the striatum (Gonon et al., 1988; 
Dugast et al., 1994; Yavich, 1996). 
 
 
 
Figure 5. Illustration of constant potential amperometry in rodent brain (brain schematic 
adapted from Honkanen, 1999). A carbon fibre working electrode (W.E.) of 30 μm diameter is 
introduced in the caudate-putamen which receives afferent dopaminergic projections from the 
SN through the medial forebrain bundle (MFB). An Ag/AgCl reference electrode (R.E.) is kept on 
the skull via saline bridge anterior to the working electrode. Constant voltage of 0.4 V is applied 
to the working electrode using a potentiostat. A stimulating electrode (S.E.) is lowered into the 
MFB and a current of 200-250 μA is delivered at varying stimulation frequencies, pulse lengths 
and intervals using a current stabilised isolation stimulator. This stimulation of the MFB 
produces DA release in the terminal fields of the striatum. When DA molecules are present at 
the surface of the working electrode, they get oxidised at 0.4 V and the resulting faradaic 
current is detected by the working electrode to indicate the presence of DA.  
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2.6.4 Fast-scan cyclic voltammetry 
Fast-scan cyclic voltammetry (FSCV) is also commonly used for the in vivo detection of 
neurochemicals, especially DA. The main advantage of FSCV over CPA is that it provides a 
unique chemical signature of the compound of interest in the form of a cyclic 
voltammogram (CV) (Ewing et al., 1982; Stamford et al., 1984; Kawagoe et al., 1992). In 
order to detect DA using FSCV, the typical voltage applied to an electrode is cyclically 
scanned from ─0.4 V to +1.0 or +1.2 V and returned to ─0.4 V in a triangular waveform (Fig. 
5; for a review, see Robinson et al., 2008). Typically, the resting potential is held at ─0.4 V 
between scans to allow the adsorption of DA molecules on the surface of the electrode and 
the scans are repeated every 100 ms (Phillips et al., 2003).  
In FSCV, when DA is present at the surface of an electrode, it is oxidised to dopamine-o-
quinone during the anodic sweep of the scan with the peak oxidation current appearing at 
approximately +0.7 V (against Ag/AgCl reference electrode) (Clark et al., 2010). The applied 
voltage is then scanned backward from 1.2 V to ─0.4 V (Fig. 5). During this cathodic phase 
of the scan, dopamine-o-quinone regains the two electrons and reduces back to DA. The 
peak reduction current is observed at approximately ─0.15 V (Clark et al., 2010). The 
faradaic current generated during the redox reaction can be plotted against applied voltage 
to obtain a CV. The CV is obtained by subtracting background current from part of the 
signal where change in DA concentration is to be analysed. Since the shape of the CV is 
influenced by changes in several electroactive compounds, it is important to choose the 
signal immediately prior to the signal to be analysed as background (Phillips et al., 2003). 
The CV obtained by this approach is unique for catecholamines which includes both DA 
and NE (Hermans et al., 2006). However, the striatum is primarily innervated by 
dopaminergic neurons, with little contribution of NE (Wightman and Zimmerman, 1990). 
The CVs of other contaminants which contribute to electrochemical signals such as ascorbic 
acid, DOPAC and HVA can be easily distinguished from that of DA (Baur et al., 1988). 
Therefore, FSCV can detect dynamic changes in extracellular DA concentration with high 
specificity in the striatum. However, certain limitations of FSCV over CPA include 
comparatively slower temporal resolution (100 ms) and greater sensitivity to pH shifts, 
which commonly occur during neurotransmitter release in vivo (Kawagoe and Wightman, 
1994). 
 
Figure 6. Detection of DA using fast-scan cyclic voltammetry. Fast-scan cyclic voltammetry 
relies on the ability of DA to undergo oxidation and reduction upon applied voltage. In FSCV, 
the applied voltage (Vapp) is scanned forward and backward from ─0.4 to 1.2 V at a rate of 300-
400 V/s. During the positive sweep or the oxidation phase of the scan (indicated by red lines), 
DA oxidises to donate two electrons to form DA-o-quinone. The oxidation reaction is nearly 
complete at ~ +0.7 V producing a rise in current that reaches peak value at +0.7 V (see the red 
line in voltage vs current plot on the upper right corner). During the cathodic scan (indicated by 
green line), DA-o-quinone starts to regain the electrons to form DA. The reduction reaches its 
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peak at ~ ─0.15V and the current returns to baseline at the end of the scan at ─0.4 V. The 
voltage vs current plot in the upper right corner is a unique chemical signature of 
catecholamines, allowing the detection of DA with high specificity. 
2.6.5 Michaelis-Menten based kinetic analysis of dopamine neurotransmission 
One of the most important advantages of voltammetric techniques is their ability to capture 
subsecond changes in extracellular DA concentrations (Garris and Wightman, 1994; Phillips 
et al., 2003). This fast time resolution allows real-time analysis of the dynamics of DA 
release and re-uptake. The extracellular levels of DA in different brain regions are 
determined by the balance between release and re-uptake (Wightman and Zimmerman, 
1990). When an action potential arrives, DA from the presynaptic terminal is released in the 
synapse by means of exocytosis. The basal extracellular levels of DA in the striatum have 
been reported to be in the range of 4 to 10 nM in rat (Parsons and Justice, 1992) and mouse 
(Jones et al., 1998; Salahpour et al., 2008) striatum, and are constantly maintained at those 
levels by a balance between release and re-uptake. The fate of DA after release is 
determined by three factors – diffusion, breakdown, and re-uptake (Wightman and 
Zimmerman, 1990; Cragg and Rice, 2008). However, diffusion and breakdown of DA occurs 
at much slower time scales than re-uptake (Ewing and Wightman, 1984). In the striatum, re-
uptake is the primary mechanism for DA removal from the extracellular space.  
In experimental conditions in vivo or ex vivo, stimulus-evoked DA levels increase since 
the rate of DA release is greater than DA re-uptake (Wightman and Zimmerman, 1990; 
Kawagoe et al., 1994). Therefore, the rate of increase of DA signal is reflective of how fast 
DA is being released into the extracellular space. When stimulation is stopped, DA release 
ceases and re-uptake is more dominant than release. This causes the measured signal to 
decline to baseline levels (Wightman and Zimmerman, 1990; Kawagoe et al., 1994). Thus, 
the decay phase of DA signal is reflective of how rapidly DA is being removed by the DAT, 
especially at higher concentrations (Wu et al., 2001). This dynamics of DA release and re-
uptake can be modelled on the basis of Michaelis-Menten kinetics.  
Since the extracellular concentration of DA is a balance between release and re-uptake of 
DA (Wightman and Zimmerman, 1990), the change in extracellular DA levels during 
stimulation can be expressed broadly as  
 
d[DA]EC/dt = d[DA]release/dt – d[DA]re-uptake/dt      1 
where d[DA]EC/dt indicates the extracellular concentration of DA with respect to time, 
d[DA]release/dt indicates the change in DA concentration due to release, and d[DA]re-uptake/dt 
indicates change in DA concentration due to DAT-mediated re-uptake (Kawagoe et al., 
1994). The two components of release and re-uptake can be further broken down. For 
instance, in electrically evoked DA overflow, release is a function of the intensity of 
electrical stimulation, which is determined by the frequency, duration, and the number of 
electrical pulses delivered to the MFB (Wightman et al., 1988a,b; Kawagoe et al., 1992; Wu 
et al., 2001). Since the transient increase in extracellular DA levels is the result of 
accumulation of DA released per pulse of electrical stimulation, DA release component can 
be expressed as 
                d[DA]release/dt = [DA]p × f             2 
where [DA]p is the concentration of DA released per pulse of electrical stimulation and f 
is the frequency of stimulation (Kawagoe et al., 1994; Wu et al., 2001). The rate of DA re-
uptake is known to depend on the rate of binding of DA molecules to the DAT. Hence, the 
process can be described by Michaelis-Menten equation as 
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                                      d[DA]re-uptake/dt = –Vmax/(Km/[DA] + 1)                      3 
where Vmax is the maximal rate of DA re-uptake, Km is the Michaelis-Menten constant of 
at which the reaction rate is half of Vmax, and [DA] is the instantaneous concentration of DA 
(Wu et al., 2001). The Km is also used as an indicator of the apparent affinity of DA for the 
DAT in the Michaelis-Menten based analysis of DA neurotransmission (Jones et al., 1995). 
Thus, the dynamics of DA release and re-uptake can be expressed as follows in terms of the 
three key parameters of Vmax, Km and [DA]p 
                            d[DA]/dt = [DA]p × f  − Vmax/(Km/[DA] + 1)              4 
The kinetic parameters of DA release and re-uptake can be extracted by a computational 
model based on the above equations. The model can be used to simulate DA signals and 
can be fitted onto actual experimental recordings of DA signals. The first step in estimating 
these parameters is the estimation of Vmax. As discussed earlier in sections 2.3.2 and 2.3.3, 
the clearance of DA from the extracellular space depends primarily on DAT-mediated 
active re-uptake or diffusion of DA in the extracellular space (Wu et al., 2001). When high 
levels of DA overflow are evoked by electrical stimulation (in excess of 2 μM), the decline 
in DA levels is almost entirely dependent on DAT-mediated re-uptake (Garris and 
Wightman, 1994; Wu et al., 2001). Hence, the slope of the descending part of the curve is 
directly proportional to the velocity of DA re-uptake and can be taken as a direct measure 
of DAT activity (Kawagoe et al., 1992). Therefore, the maximal velocity of re-uptake (Vmax) 
can be calculated from the slope of a linear regression fit to the descending part of DA 
curve as 
                          Vmax = − d[DA]re-uptake/dt                  5 
When stimulation ceases, some diffusion of DA towards the electrode continues during 
which the peak plateaus (Garris et al., 1993), which may interfere with the re-uptake 
component and yield an incorrect estimation of Vmax. Hence, only the portion of the decay 
curve from 80% to 20% of the peak amplitude is used in this calculation. Similarly, the rate 
of rise in DA signal is directly proportional to the rate of DA release, i.e., [DA]p. Since the 
extracellular DA level is a balance between DA release and re-uptake, [DA]p can be 
calculated by subtracting the slope of the descending part of DA curve from the slope of the 
ascending part of DA curve (Wu et al., 2001) from equations 1 and 2 as follows 
       [DA]p = {d[DA]EC/dt – d[DA]re-uptake/dt} / f   6 
Once the values of Vmax and [DA]p are obtained, the value of Km can be calculated from 
the equation as follows 
                         Km =(Vmax/([DA]p × f − 1) × [DA]                   7 
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where [DA] is the steady state concentration of DA (Wu et al., 2001).   
 
Figure 7. Estimation of the parameters of DA release and re-uptake using Michaelis-Menten 
based kinetic analysis. The figure shows DA overflow evoked by a 100 Hz, 2 s stimulation of the 
MFB in the dorsal striatum. Extracellular DA levels are a balance between release and re-
uptake. The rate of rise of DA signal is directly proportional to how fast DA is released from the 
presynaptic terminals. Therefore, DA release per pulse of stimulation ([DA]p) can be obtained by 
calculating the slope of the rising phase of DA signal (dashed green line). Linear regression 
analysis can be used to fit a line to the rising part of the signal. The actual value of [DA]p 
depends on the total increase in DA concentration from baseline, the duration and frequency of 
stimulation. Overflow of DA continues for some time after the end of stimulation due to diffusion 
of DA towards the electrode. The DA signal begins to decline as a result of DAT-mediated re-
uptake. At concentrations greater than 2 μM, this decline is entirely dependent on DAT-
mediated rate of DA re-uptake. Therefore, the slope of the decay phase of DA signal can be 
considered as direct measure of how fast DA is being removed by the DAT and can be 
calculated by fitting a linear regression line (dashed blue line).  
This process can be automated by using a computer program and can provide valuable 
information about the dynamics of DA release and re-uptake in different brain regions. This 
approach has also advanced our understanding of the mechanisms of action of several 
pharmacological agents. For example, classic re-uptake inhibitors such as cocaine, 
GBR12909 and nomifensine block re-uptake and increase only the Km, i.e., the apparent 
affinity for re-uptake (Garris and Wightman, 1994). Classic re-uptake inhibitors produce no 
change in [DA]p. On the other hand, DA releasers and D2 autoreceptor inhibitors increase 
DA overflow by increasing DA release probability, i.e., [DA]p without producing any 
change in Km (Wu et al., 2001). Neither DA releasers nor re-uptake inhibitors alter the Vmax 
but Vmax is directly proportional to the number of DAT molecules available on the 
membrane (Garris and Wightman, 1994). Alterations that affect the number of active 
transporters also affect the Vmax accordingly (Salahpour et al., 2008). For instance, repeated 
cocaine exposure downregulates DAT surface recruitment and protein expression, which is 
also reflected in decreased Vmax in these mice (Ferris et al., 2011).   
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Figure 8. Fitting of simulated DA signals to actual in vivo amperometric recordings from the 
dorsal striatum at varying frequencies of stimulation. The thick black line at the bottom of each 
recording shows the duration of stimulation, which was 2 s in each case. The black thin line 
indicates simulated DA signal and the dashed line show actual amperometric recording of 
evoked DA overflow. Simulated DA signal showed higher correlation (r2) with experimental 
recordings with increasing frequency of stimulation. The model can accurately fit actual 
recordings and can be successfully used to determine the parameters of DA release and re-
uptake.  
 
Although the model is useful in studying the kinetics of DA release and re-uptake, the 
estimated parameters must be interpreted keeping in mind the limitations of the model. 
The first important consideration is the assumption of initial values for best fit parameters. 
The initial value of Km is typically fixed at 0.2 μM while the maximum value of Vmax is fixed 
at values between 6-10 μM/s (Wu et al., 2001). The initial value of [DA]p is typically set to 
200 nM. In this work, the initial values were set to those similar to that used in the 
literature. Further, if the best-fit parameters for Vmax reached 6 μM/s before a reliable fitting 
(r2 > 0.97) of the simulated curve to the actual recording was obtained, the model was rerun 
by increasing the upper limit of Vmax by 1. This process was repeated until an excellent fit (r2 
> 0.97) was obtained. Similarly, the upper limit of Km was set at 2 μM and increased further 
in case of poor fit. Increasing the upper limits of Vmax and Km did not affect or increase the 
values of estimated parameters if the obtained quality of fit was already of high quality (r2 > 
0.97). For example, if the model estimated Km at 0.23 μM with maximum Km set at 2 μM, 
then further increasing the maximum Km to 3 μM still yielded a best fit value of 0.23 μM. 
However, the approach to find best-fit values within the confines of initial and maximal 
values may introduce a distortion in estimating best-fit parameters. Further, the precision 
used while running iterations also influences the best-fit values. The smaller the step size 
used for each iteration, the higher the precision, as evaluated by the r2 value. In this study, 
the minimum step size for Vmax and Km was 0.01 μM while that for [DA]p was 0.005 μM. 
Although such low step sizes significantly increased computation time for fitting, larger 
step sizes of (e.g. 0.05 μM for Km) significantly overestimated Km in comparison with the 
values in literature.  
In addition to these limitations, electrical artifacts commonly present in voltammetric 
recordings may also lead to incorrect estimation. It has been reported that presence of 
electrical artifacts, which occurs more towards the lower end of descending peaks (Wu et 
al., 2001), may overestimate Km and underestimate Vmax. Therefore, partial curve fit 
approach which disregards the lower end of the descending curve has been proposed (Wu 
et al., 2001). Several studies employ Nafion coated carbon fibre electrodes to eliminate the 
contribution of interferents to DA measurement. However, Nafion increases the response 
time of CFEs and may introduce a distortion in the curve, which can be partially eliminated 
by using deconvoluted data for fitting. Slower sampling rate may also contribute a similar 
error, which can be eliminated by using higher sampling rate. In this work, we used CPA 
with a 5 kHz sampling rate and uncoated CFEs, which minimised distortions due to slower 
temporal resolution. However, since the surface of the CFE was not coated with Nafion, we 
cannot rule out that accumulation of ascorbic acid and DA metabolites towards the end of 
the descending part of DA signal may have influenced the estimation of Km. 
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3 Aims 
 
The main objective of this work was to investigate the role of α-syn in the presynaptic 
mechanisms of DA neurotransmission in the striatal dopaminergic system.  
 
The study was divided into following four studies: 
 
1.  To investigate alterations in DA release and re-uptake in the dorsal striatum in wild-
type and two α-syn deficient mouse lines (Study I). 
 
2.  To determine α-syn-dependent alterations in the short-term plasticity of DA overflow 
in striatal subregions (Study II).  
 
3.  To investigate the possible role of α-syn in modulation of pharmacological effects of 
psychostimulants such as methylphenidate (Study III). 
 
4.  To improve the technique of in vivo DA detection by employing a 32 μm carbon fibre 
electrode and the parameters of fast-scan cyclic voltammetry (Study IV). 
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4 Materials and Methods 
4.1 ANIMALS (STUDY I-IV) 
Three mouse lines were used in this study. The C57BL/6J subpopulation that originated 
from Charles River Wiga (Sulzfeld, Germany) was employed as wild-type controls 
(referred to as b6+). The C57BL/6JOlaHsd mouse line from Harlan Olac (Bicester, UK, 
referred to as b6–) with a spontaneous chromosomal deletion of α-syn (snca) and 
multimerin-1 loci (Specht and Schoepfer, 2001, 2004), and B6;129X1-Sncatm1Rosl/J line 
(obtained from Charles River) with targeted deletion of the α-syn gene (Abeliovich et al., 
2000) served as α-syn deficient mouse lines. All three lines were bred at the Laboratory 
Animal Center of the University of Eastern Finland (Kuopio, Finland). Effects of gene 
deletions on the dopaminergic system have been shown to vary according to the genetic 
background of mice (Morice et al., 2004). To overcome this challenge, we used two mouse 
lines lacking α-syn, which permitted us to corroborate that the alterations in the 
dopaminergic system could indeed be attributed to the absence of α-syn. Animals were 
housed in controlled conditions at 21°C, 50-60% humidity, and 12-h day/night cycle. Food 
and water were provided ad libitum. All experiments were conducted according to the 
guidelines of the Council of Europe (Directive 86/609) and Finnish guidelines approved by 
the State Provincial Office of Eastern Finland. 
4.1.1 Behavioural and neurochemical phenotype of α-syn knockout mice 
Most studies using α-syn knockout mice have not reported a drastic behavioural or 
neurochemical phenotype in these mice (Abeliovich et al., 2000; Specht and Schoepfer, 2001; 
2004; Chandra et al., 2004). α-Syn deficient mice appear to have a normal life span, weight, 
and normal development with no gross abnormalities in motor function (Abeliovich et al., 
2000; Cabin et al., 2002). α-Syn is not essential for neuronal development, and mice lacking 
α-syn display normal TH activity and the density of dopaminergic terminals (Abeliovich et 
al., 2000; Dauer et al., 2002; Chandra et al., 2004). No gross morphological deficits were 
observed in the brain structures such as the basal ganglia, cortex, and the limbic system 
(Abeliovich et al., 2000; Dauer et al., 2002; Chandra et al., 2004). Similarly, no change in the 
expression of TH or other presynaptic proteins which interact with α-syn has been reported 
(Abeliovich et al., 2000; Chandra et al., 2004). Similar to the mice with targeted inactivation 
of SNCA gene, mice with a spontaneous deletion of the α-syn gene locus also do not 
display gross behavioural or neurological deficits (Specht and Schoepfer, 2001; 2004). 
Although it has been proposed that functional redundancy may exist between the 
synucleins, no studies have so far reported compensatory changes in the expression or 
function of β- and γ-syn in mouse models (Abeliovich et al., 2000; Specht and Schoepfer, 
2001; Chandra et al., 2004). 
The study by Abeliovich et al. (2000) reported that mice lacking α-syn (generated from a 
cross of 129SV/J and C57BL/6J) display normal habituation and locomotor response in the 
open-field test. However, in the same test these mice showed significantly attenuated 
locomotor response to d-amphetamine (Abeliovich et al., 2000). On the other hand, the 
study by Cabin et al. (2002) reported that α-syn deficient mice (bred on 129/SvEvTac 
background) showed no difference in amphetamine-induced locomotion in the open-field 
test. C57Bl/6JOlaHsd mice with spontaneous deletion of the SNCA gene display normal 
anxiety response (Janitzky et al., 2007; Peña-Oliver et al., 2010). However, these mice 
display significantly increased intracranial self-stimulation in operant nose-poke task 
(Oksman et al., 2006). Some of these discrepancies have been attributed to different genetic 
backgrounds of the animals used in these studies. Furthermore, mice used by Abeliovich et 
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al. (2000) were generated by deleting exon 1 and 2 while the mice used by Cabin et al. 
(2002) were generated by deleting exons 4 and 5. It has been suggested that these may have 
influence downstream gene transcription differently (Chandra et al., 2004; Venda et al., 
2010). 
4.2 DAT IMMUNOHISTOCHEMISTRY (STUDY I) 
Striatal DAT expression was determined by immunohistochemistry. Four animals from 
each genotype of 3 to 5 months of age were anaesthetized with Equithesin at a dose of 0.2 
ml. Animals were first perfused with 0.9% NaCl for 5 min and later with 4% 
paraformaldehyde (PFA) for 9 min. Brains were removed from the skull and stored in 4% 
PFA fixative for 4 h. The brains were later stored in 30% sucrose overnight in a 
cryoprotectant at –20°C. The brains were cut into 35 μm coronal sections using a freezing-
sliding microtome and sections were immunostained by free floating technique. The 
sections were pretreated with endogenous peroxidase (0.3% H2O2, 30 min) before staining 
and blocked in 1.5% normal goat serum (NGS) for 1 h. They were later transferred to a 
solution containing the primary rat monoclonal antibody recognising DAT (MAB369, 
Millipore, Temecula, CA, USA, dilution 1:10000) in Tris-buffered saline (TBS) with addition 
of 0.5% Triton X-100 (TBS-T). After incubating for 48 h on a shaker table at +4°C in the dark, 
the sections were rinsed three times in TBS-T and transferred to the solution containing 
biotinylated anti-rat IgG as the secondary antibody. The antibody dilution was performed 
at 1:500 (AAR10B, Serotec, Dusseldorf, Germany). After 2 h, the sections were rinsed three 
times with TBS-T and transferred to a solution containing streptavidin-horseradish 
peroxidase (diluted 1:1000) (RPN1231V; GE Healthcare, Little Chalfront Buckinghamshire, 
UK) for 2 h. After rinsing, the sections were incubated for approximately 3 min in 3,3-
Dimainobenzidine (DAB). The stained sections were mounted on slides and coverslipped. 
Sections from all genotypes were stained at the same time and all sections went through 
exactly the same process. The immunostaining intensity for DAT was determined 
bilaterally from 4 striatal sections selected at 35 μm interval. In order to eliminate the 
gradient due to uneven illumination, background subtraction was performed using the 
NIH-IMAGE program (NIH, Bethesda, MD, USA). Mean optical density was quantified 
using Photoshop elements 7 (Adobe Photoshop, Adobe Systems Inc., San Jose, CA, USA). 
The experimenter quantifying the mean optical density was blinded to the genotypes. 
4.3 ELECTROCHEMICAL TECHNIQUES FOR IN VIVO MEASUREMENT OF 
DOPAMINE (STUDY I-IV) 
4.3.1 Preparation and calibration of carbon fibre electrodes 
All carbon fibre electrodes (CFEs) were prepared by inserting a carbon fibre in a pulled 
glass capillary. The carbon fibres were insulated using epoxy glue and a metal shaft was 
inserted in the glass capillary using two component silver epoxy glue (WPI, Sarasota, FL, 
USA). In studies I-III, the diameter of the carbon fibre used was 30 μm (WPI, Sarasota, FL, 
USA) while the exposed length was in the range of 300-350 μm (Study I-III). In study IV, the 
diameter of the carbon fibre was 7 μm (Goodfellow Corp., Cambridge, UK) for the 
conventional electrode and 32 μm (Invilog Research, Kuopio, Finland) for the improved, 
higher sensitivity CFE. The electrodes were calibrated before experiments in phosphate 
buffered saline (PBS, pH 7.4) in the presence of 200-400 μM ascorbic acid (Study I-III) 
(Benoit-Marand et al., 2001; Yavich et al., 2004). DA was added in increments of 1 μM in 
each step up to 3 μM. DA oxidation current produced by each addition was plotted as a 
concentration vs current plot (Invilog Voltammetry Software). Calibration factor was 
obtained by fitting linear regression analysis to this plot. For CPA, only CFEs with 
sensitivities greater 0.12 nA/μM were used in experiments. Since the sensitivity of CFEs 
drops exponentially after in vivo implantation (Michael et al., 1987), CFEs were removed 
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from brains after experiments and postcalibrated. The concentrations of DA overflow 
evoked in vivo were estimated based on the sensitivity obtained after postcalibration (Study 
I, III, IV). In Study II however, at the end of each recording session, an electrolytic lesion 
was made (6 V, 10 s) to verify the position of the working electrode, which irreversibly 
modified the properties of CF. Therefore, only sensitivity obtained by precalibration was 
used to estimate the extracellular concentrations of DA.  
In Study IV, the 32 μm CFEs were calibrated using artificial cerebrospinal fluid (aCSF) 
instead of PBS. Studies have shown that in FSCV due to rapid cycling of voltage, Ca2+ and 
Mg2+ ions also contribute to the electrochemical signal (Jones et al., 1994; Kume-Kick and 
Rice, 1998). The aCSF was prepared in the concentrations commonly used for FSCV (124 
mM NaCl, 3.7 mM KCl, 26 mM NaHCO3, 2.4 mM CaCl2, 1.3 mM MgSO4, 1.3 mM KH2PO4, 
and 10 mM glucose). For calibration of 32 μm CFE, DA concentrations in increments of 100 
nM were added to the solution up to 1 μM and 1 μM increments up to 3 μM. For the 7 μm 
CFE, 100 nM increments were added up to 500 nM concentration, and 1 μM up to 3 μM 
concentration. Calibration factor was obtained by fitting linear regression analysis to the 
concentration vs oxidation current plot using Invilog voltammetry software. Detection 
limits of 7 and 32 μm CFEs were compared by adding 5 nM DA in each step in the solution 
containing aCSF and 200 μM ascorbic acid. Responses to shifts in pH were compared by 
testing the response of CFEs to acidic (pH 7.2) and basic (pH 7.6) shifts in pH of the aCSF. 
Further, the clarity of CV in the presence of pH changes was also verified. The selectivity of 
32 μm CFE over interferents such as ascorbic acid, DOPAC, and HVA was analysed by 
obtaining the cyclic voltammograms of these compounds and of DA in the presence of 
these compounds. The correlation between the CVs of DA and of interfering agents was 
made by matching the template of DA and obtaining a correlation coefficient using Invilog 
voltammetry software.  
4.3.2 Surgery (Study I-IV) 
For all experiments in Studies I-IV, the age of the mice from each genotype was from 3 to 5 
months. Mice were anaesthetized with chloral hydrate (Sigma-Aldrich, St. Louis, MO, USA) 
at a dose of 450 mg/kg i.p. in a volume of 10 ml/kg. A supplementary dose of 100 mg/kg 
was administered every 45-60 min to maintain anaesthesia. Rectal temperature was 
constantly monitored and maintained at 37°C using a heating lamp. The animal was fixed 
in the stereotaxic frame. Trepanations were made in the skull and a carbon fibre working 
electrode was lowered stereotaxically. When recordings were made in the dorsal striatum 
(Study I, III, IV), the most commonly used coordinates were AP –1.42 mm, LM –2.0-2.2 mm, 
DV 3.3 mm in reference to bregma according to the brain atlas of Franklin and Paxinos 
(2007). In experiments where multiple locations in the striatum were targeted (Study II), a 
CFE was lowered at coordinates AP ─1.42 mm, ML 1.8-3.0 mm, V 3.0 mm. In Study II, the 
CFE was lowered in the brain at an angle of 16˚ to avoid recording in the anterior 
commissure.  
A bipolar stimulating electrode (diameter 0.35 mm) was inserted into the medial 
forebrain bundle (MFB, AP: –1.7, ML: 1.1-1.2, DV: 5.1-5.3 mm vs. bregma). The exact depth 
of the stimulating electrode was adjusted for maximum DA release. An Ag/AgCl reference 
electrode was placed on the wet skull via a saline bridge. A stainless steel screw fixed in the 
skull served as the auxiliary electrode. 
4.3.3 Electrochemical techniques (Study I-IV) 
In Studies I-III, CPA was used to measure evoked DA overflow. A custom-made 
potentiostat maintained the working electrode at a constant potential of 0.4 V vs. Ag/AgCl 
reference electrode. The data from the potentiostat were digitized at 5 KHz and sent to a 
computer for offline analysis.  
In Study IV, FSCV was used for DA detection. As described in section 2.4.3, the typically 
used waveform used for DA detection in FSCV is scanning the voltage from ─0.4 V to 1.2 V 
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and back to ─0.4 V at 300-400 V/s (for a review, see Phillips et al., 2003). Increasing the scan 
rate can increase the sensitivity for DA detection and allow improved detection of naturally 
occurring DA transients, which are usually 100-200 nM in amplitude (Robinson and 
Wightman, 2002). One approach to improve the sensitivity is to use an electrode with larger 
dimensions of the exposed tip of carbon fibre (Bath et al., 2000). Another approach is to use 
higher scan rates, for example, as high as 2400 V/s (Keithley et al., 2011). However, cyclic 
scanning of voltage at high rates charges the double layer of the carbon fibre surface and 
produces a strong increase in background current (Keithley et al., 2011). If this increase in 
background current is greater than the increase in DA oxidation current/sensitivity of 
electrode, then higher scan rates prohibit detection of DA. Therefore, use of parameters of 
Vapp which increase DA oxidation without significant increase in background current is an 
ideal solution to boost the sensitivity of DA detection. For instance, studies have used Vapp 
with a wider voltage sweep from ─0.6 to 1.4 V (Phillips et al., 2003; Heien et al., 2004). 
However, Vapp with wider sweep also compromises the selectivity of sensor for DA over 
interfering compounds (Heien et al., 2004).  
In Study IV, we devised a novel waveform to overcome this challenge. We held the 
resting potential at 0.4 V similar to that in the typical waveform. The Vapp was lowered to 
─0.6 V before increasing to 1.2 V. The Vapp was reduced again to ─0.6 V before returning to 
─0.4 V. The scan rate for ─0.4 to ─0.6 V step was 133 V/s while the scan rate in the ─0.6 to 
1.2 V step was 514 V/s. The responses of 7 and 32 μm CFEs were tested using both typical 
and modified waveforms in vivo and in vitro.  
4.3.4 Drug treatments (Study II and III) 
In Study II, to assess the contribution of re-uptake to short-term plasticity of DA overflow, 
DA overflow was measured before and after intraperitoneal administration of the re-uptake 
inhibitor GBR12909 (Tocris Bioscience, Bristol, UK) at a dose of 10 mg/kg (in a volume of 10 
ml/kg). Recordings were made before and 45 min after drug administration. Haloperidol at 
a dose of 0.5 mg/kg (in a volume of 10 ml/kg) was administered intraperitoneally and 
recordings were made 20 min after drug injection.  
In Study III, methylphenidate hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was 
dissolved in saline and injected i.p. at doses of 1 or 5 mg/kg in a volume of 10 ml/kg. A 
specific DA re-uptake inhibitor, GBR12909 (Tocris Bioscience, Bristol, UK), was freshly 
dissolved in distilled water with a drop of TWEEN-20 (Sigma-Aldrich, St. Louis, MO, USA) 
and injected i.p. at the dose of 10 mg/kg. The measurements were made correspondingly 30 
and 45 min after the treatment at the peak effect of the drugs on evoked DA overflow.  
4.3.5 Experimental protocols (Study I-III) 
The MFB was stimulated using a computer-controlled interface. Constant current was 
maintained at 200-250 μA by a stimulus isolation unit (A365, World Precision Instruments, 
Aston, UK). In Study I, 2-s burst stimulation (1 ms bipolar pulse) was delivered at 
frequencies of 10, 20, 30, and 50 Hz 90 min after implantation of the CFE. The interval 
between two consecutive bursts was increased from 3 to 5 min with increasing frequency to 
allow sufficient time for refilling of presynaptic DA storage.  
Different subpopulations of DA neurons are known to fire in two modes – tonic and 
phasic. Both tonic and phasic neurons exhibit spontaneous spiking activity at frequencies of 
up to 20 Hz (Schultz et al., 1997; Hyland et al., 2002). However, neurons which primarily 
exhibit phasic firing activity such as the VTA neurons can fire at frequencies greater than 30 
Hz in awake animals (Hyland et al., 2002). Studies have shown that neurotransmitter 
release is adequately maintained by RRP and recycling pool at 10-30 Hz even following 
prolonged electrical stimulation (Richards et al., 2003). This suggests that electrical 
stimulation at these frequencies is well suited to study physiologically relevant DA release 
in intact animals. In addition, we also used higher frequency stimulation of 50 Hz that 
challenges the presynaptic machinery of neurotransmitter release, allowing investigation of 
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other factors such as vesicular mobilisation and re-uptake. For example, in vivo data shows 
that extracellular DA levels evoked by electrical stimulation at 10-30 Hz soon reach an 
equilibrium state, evident from the initial increase in DA signal which plateaus after a 
period of 600-800 ms of stimulation (Kawagoe et al., 1992; Garris and Wightman, 1994a; 
1995). The increase in DA release is balanced by increase in re-uptake to prevent the 
extracellular DA levels from increasing further. However, stimulation at higher frequencies 
(e.g. 50 Hz) disrupts this equilibrium since mobilisation of vesicles from the reserve pool 
significantly increases release (Yavich and MacDonald, 2000) and the peak DA levels do not 
reach a plateau since re-uptake cannot compensate for such a large increase in release 
(Garris and Wightman, 1994). Due to this phenomenon, even small changes in the rate of 
re-uptake or release can have a significant impact on the peak amplitude of evoked DA 
overflow. Since α-syn has been shown to be involved in vesicular organisation as well as 
trafficking of the DAT, even subtle changes in DAT function or vesicular mobilisation can 
be unmasked by using higher frequency stimulation. Therefore, the supraphysiological 
stimulation of 50 Hz, 2 s was employed to study presynaptic functions in greater detail. 
In Study II, two 2-s high-frequency bursts of 50 Hz, 100 p (100 bipolar pulses) were 
applied at an inter-stimulus interval of 5 s. Fig. 9 illustrates the track of the working 
electrode through the striatum. DA overflow was first recorded at the uppermost position 
of the working electrode (3 mm ventral from the bregma) after paired, high-frequency burst 
stimulation. The electrode was lowered by 300 μm immediately after recording and 10 min 
later, next stimulation and recording was made. Paired-burst facilitation (PBF) was 
calculated as the ratio of DA overflow following second stimulation to that following the 
first stimulation. This ratio was expressed as percentage and was used to quantify the 
variations in the short-term plasticity of DA overflow in striatal subregions.  
 
Figure 9. Illustration of the recording path of the working electrode in the striatum. The working 
electrode was inserted at an angle of 16˚and the first recording was made at approximately 3.0 
mm depth from the dura. The electrode was then lowered by 300 μm each time and a new 
recording was made at the next location 10 min later. The last recording was made at 5.4 mm 
from the dura in the ventral striatum. The points encircled in red indicate the positions where 
electrolytic lesions were made. The area shaded darker gray was considered as the dorsal 
striatum while the lighter gray was considered as the ventral striatum for subregional analysis 
of PBF.  
 
After recording at the lowest point at 5.4 mm, the working electrode was raised by 0.3 
mm and the first electrolytic lesion (6 V, 10 s) was made at 5.1 mm depth. The electrode was 
further raised and the second lesion was made at 3.0 mm (Fig. 9). Immediately thereafter, 
the brain was removed and frozen at –22°C. Brain sections were cut using a microtome. 
Only data from the brain samples in which the lesions were within desired regions of the 
striatum were included in the study. In separate sets of experiments, we tested the effects of 
re-uptake inhibitor and D2 antagonist on facilitation of DA overflow during repetitive high-
frequency stimulation. This stimulation consisted of six 2-s bursts at 50 Hz, delivered at an 
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inter-stimulus interval of 5 s. Three such trains of burst stimulation were delivered at 90 s 
inter-burst interval. Post-drug recordings were made 45 min after GBR12909 (10 mg/kg, 
i.p.) and 20 min after haloperidol (0.5 mg/kg, i.p.). To test D2 autoreceptor function, paired 
stimuli of 100 Hz, 5 bipolar pulses (pseudo-one pulse stimulation) were delivered at an 
inter-stimulus interval of 0.5 s to 5 s (Benoit-Marand et al., 2001; Kita et al., 2007) to the 
MFB. Each paired stimulus was separated by 2 min. Thereafter, a paired 50 Hz, 2 s 
stimulation was delivered at an inter-stimulus interval of 5 s. Although a high frequency of 
100 Hz was used in these experiments, the duration of stimulation was kept very brief to 50 
ms to evoke physiologically relevant extracellular concentrations of up to 300 nM.  
In Study III, two-second bursts of 1-ms bipolar pulses at 10–50 Hz were delivered to the 
MFB at a 3–4 min interstimulus intervals. Bursts at 10–30 Hz were delivered randomly 
while the 50 Hz stimulation was always made after stimulation at lower frequencies. 
Repeated-burst stimulation consisted of six, 2-s bursts at 50 Hz, delivered at an inter-
stimulus interval of 5 s, similar to that used in Study II. Post-drug recordings were made 30 
min after 1 or 5 mg/kg intraperitoneal doses of MPD.  
The primary purpose of using high frequency repetitive stimulation was to test the 
dynamics of vesicle mobilisation. As discussed in sections 2.5.3.1 and 2.5.3.2, mice lacking 
α-syn display a characteristic form of short-plasticity of DA overflow following repetitive 
stimulation (Yavich et al., 2004). Therefore, the high frequency stimulation protocol allowed 
further exploration of not only the role of α-syn in vesicle-mobilisation dependent plasticity 
but also the mechanisms of action of GBR12909 and MPD in mice with and without α-syn. 
In Study IV, 32 μm CFE was implanted and the first recording was made immediately 
after successfully adjusting the position of stimulating electrode in the MFB for maximal 
DA release. Thereafter, DA release was evoked every hour by delivering a 50 Hz, 2-s 
stimulation to the MFB.  
4.4 IN VIVO MICRODIALYSIS (STUDY I AND III) 
4.4.1 Cannula implantation 
Eight male mice from each group were used in these experiments. Mice were anaesthetized 
with a 1.5:1 mixture of ketamine (50 mg/ml, Intervet International B.V, Boxmeer, the 
Netherlands) and medetomidine (1 mg/ml, Orion Pharma, Turku, Finland) (2 ml/kg, i.p.). 
In addition, a local anaesthetic, lidocaine (10 mg/ml; Medipolar, Orion Corporation, Oulu, 
Finland), was applied to the skull. Mouse was mounted in a Kopf stereotaxic frame (David 
Kopf Instruments, Tujunga, CA, USA). A locally made microdialysis probe with an active 
membrane length of 2 mm was implanted into the right dorsal striatum (anteroposterior 
(AP) + 0.7 mm; lateromedial (LM) –1.8 mm; dorsoventral (DV) –3.9 mm versus bregma) and 
secured by three cranial screws and dental cement. Atipamezole hydrochloride (Orion 
Pharma, Turku, Finland, 0.5 mg/kg, s.c.) was used as an anti-sedative agent and carbiprofen 
(Vericore Ltd., Dundee, UK, 5 mg/kg, s.c.) for post-operative pain relief. Saline (1 ml, i.p.) 
was injected after the surgery to maintain fluid balance. 
4.4.2 In vivo microdialysis protocol 
In Study I, mice were allowed to recover from surgery for 3 three days before the 
microdialysis procedure. The microdialysis cannula was connected to a rotating liquid 
swivel (375/D/22QM, Instech Laboratories Inc., PA, USA). Artificial CSF (aCSF: 145 mM 
NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 1.0 mM MgCl2) was perfused at the rate of 2.2 μL/min 
(CMA/100 Microinjection Pump, Solna, Sweden). Perfusion was continued for 2 h. Four 
baseline samples were collected in the last 1 h were used as pretreatment baseline. The 
dialysate was introduced on-line into the HPLC injection loop and automatically injected 
every 15 minutes.  
In Study III, the microdialysis cannula was connected to a rotating liquid swivel 
(375/D/22QM, Instech Laboratories Inc., PA, USA) three days after implantation. aCSF was 
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perfused at the rate of 2.2 μL/min (CMA/100 Microinjection Pump, Solna, Sweden). 
Perfusion was continued for 2 h, and four baseline samples were collected. After collection 
of the baseline samples, mouse was injected first with saline (10 ml/kg, i.p.). After 1.5 h, 
mouse was injected a second time with MPD (1 mg/kg), and sample collection was 
continued for the next 3 hours. The dialysate was introduced online into the HPLC injection 
loop and automatically injected every 15 minutes. DA concentrations were measured from 
microdialysis samples using HPLC (Ihalainen and Tanila, 2004). After the experiment, the 
brain was removed from the skull and immersed in 4% paraformaldehyde. Coronal 
sections (50 μm) were cut and stained with cresyl violet for verification of the cannula 
placement. 
4.4.3 High performance liquid chromatography (HPLC) analysis of dopamine 
Extracellular concentration of DA was measured using an HPLC system consisting of a 
Shimadzu LC-9AD solvent delivery system (Shimadzu Corporation, Kyoto, Japan) and an 
ANTEC Decade electrochemical detector (Antec Leyden, Leyden, The Netherlands). A 
Coulochem 5011 detector cell (electrode 1 operated on +250 mV, electrode 2 on –300 mV) 
(ESA Inc., Chelmsford, MA, USA) was controlled by the Decade using the TWIN option. 
The mobile phase consisted of mQ water with 10.4 mM citric acid (2 g/l), 6.1 mM sodium 
acetate (5 g/l), 1.85 mM heptanesulphonic acid (375 mg/l), 0.3 mM EDTA and 12.5% 
methanol. Data acquisition and analysis was carried out by Shimadzu Class-VP software 
(Shimadzu, Duisburg, Germany). The detection limit for DA was 0.1 pg. Concentrations 
were expressed as pg/50 μl and were not corrected for “recovery” of the dialysis procedure.  
4.5 ESTIMATION OF KINETIC PARAMETERS OF DOPAMINE RELEASE 
AND RE-UPTAKE (STUDY I-IV) 
In Studies I and II, maximal rate of re-uptake (Vmax) was calculated by fitting linear 
regression to the descending part of the DA overflow curve using Clampfit 8.2 program 
(Molecular Devices, Sunnyvale, CA, USA). In case of the electrically evoked DA overflow 
curve, the ascending part reflects release and re-uptake while the descending part reflects 
the decline in DA concentration due to re-uptake (Ewing and Wightman, 1984). Some 
diffusion of DA into the extracellular space continues after the end of electrical stimulation 
(Garris et al., 1993). Therefore, linear regression was fitted on 20% to 50% part from the 
peak of the descending curve to eliminate interference due to diffusion (Stamford et al., 
1984b; Garris et al., 1993). Only peaks with concentration greater than 2 μM (i.e., 
concentrations 10 times higher than Km for DAT) (Garris and Wightman, 1994; Wu et al., 
2001) were used for this calculation, since at such high concentrations, the rate of decline is 
primarily dictated by DAT-mediated clearance of DA (Wu et al., 2001). The Vmax in wild-
type mice calculated by this method was in good agreement with the values reported in the 
literature (Salahpour et al., 2008). 
In Studies III and IV, Vmax, Km, and [DA]p were determined using the Michaelis-Menten 
based kinetic analysis, as explained in section 2.6.5. The equations for Michaelis-Menten 
model were solved by a custom-written algorithm using LabView 8.5 (National 
Instruments, USA) with Euler’s approach. Best-fit parameters between experimental data 
and the data simulated by the model were obtained using correlation coefficients. The 
validity of the model was verified by delivering stimulation at different frequencies and by 
pharmacological means. The validation proved that the Michaelis-Menten based model 
accurately simulated DA signals and showed a high level of correlation (r2> 0.97) with the 
real recordings, especially at higher frequencies. The best fit parameters of [DA]p, Km, and 
Vmax obtained for wild-type mice closely reflected the values reported in other studies (Wu 
et al., 2001). 
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4.6 EXTRAPOLATION ANALYSIS OF SUBREGIONAL DISTRIBUTION OF 
PAIRED-BURST FACILITATION IN THE STRIATUM (STUDY II) 
In Study II, the primary purpose was to investigate subregional differences in the short-
term plasticity of DA overflow (in form of PBF). However, methodological limitations in 
targeting specific areas and making several recordings in vivo necessitated an alternative 
approach to estimate spatial distribution of PBF at untargeted recording locations. Methods 
to estimate unknown values of a parameter at untargeted locations based on the known 
values in the surrounding region are routinely used in geological and environmental 
studies (Stein, 1999). Therefore, we decided to employ a similar extrapolation method to 
predict PBF where no measurements were made.  
To precisely locate the recording positions in the striatum, lesions were made in the 
brain as described in Fig. 9. The brains were immediately removed and frozen at ─20˚C. 20 
μm coronal brain sections were cut using a microtome to locate the striatal section where 
recordings were made. The sections were inspected for clear marking of lesions, and only 
the recordings locations which anatomically lied within the striatum were included in 
further analysis. The histological sections were photographed and superimposed on the 
coronal sections of mouse brain atlas (Franklin and Paxinos, 2007) using Corel Draw 11 
(Corel Inc., Ottawa, Canada). The first (3.0 mm) and second (5.1 mm) lesion sites were 
marked on the photograph. The remaining 7 recording sites were positioned 300 μm apart 
on the line connecting the two lesion marks. In total, 60-80 recordings locations from each 
genotype which lied within the striatal subregions were used to determine the spatial 
distribution of PBF. Such large number of actual recordings provided sufficient basis to 
employ extrapolation analysis to predict PBF in untargeted areas.  
Using actual recording locations and their real PBF values, subregional distribution of 
PBF in the striatum was determined by using software that generated 2D contour maps 
(3DField 3.0.0 by Vladimir Galouchko). Each recording location marked on the atlas was 
assigned its recorded PBF value. For extrapolation, the kriging approach was used which 
has been used to model spatiotemporal activation of auditory cortex in fMRI (Christensen 
and Yetkin, 2005). The software generated a map with coloured contours to predict PBF in 
neighbouring striatal areas based on the actual recordings. One important advantage of 
kriging over other methods such as linear or differential equations was that kriging does 
not assume a particular relation between neighbouring points unlike other methods. 
Although kriging estimates unknown values based on the weighted-averaging method, it 
also accounts for randomness and error in estimating unknown values. These attributes 
simultaneously provide greater reliability as well as flexibility in extrapolation analysis 
(Stein, 1999).  
4.7 DATA PRESENTATION AND STATISTICAL ANALYSES (STUDY I-IV) 
Stimulated DA release was presented in molar concentrations based on the post-calibration 
of working electrodes, except in Study II as specified in 4.3.1. Peak amplitudes of simulated 
DA overflow were calculated using custom-made software (LabView 8.5, Austin, TX, USA). 
Statistical analysis was performed using SPSS 16 (SPSS Inc., Chicago, IL, USA). 
In Study I, evoked DA overflow after stimulation at different frequencies was analysed 
by ANOVA for repeated measures (RM-ANOVA; 3 genotypes × 4 stimulation frequencies, 
Study I). Basal extracellular DA levels, mean optical density of DAT expression, and Vmax 
between three genotypes were analysed by one-way ANOVA followed by Tukey’s post-hoc 
test for multiple comparisons. 
In Study II, PBF was quantified by obtaining the ratio of DA overflow following the 
second stimulation to that following the first stimulation. The ratio was expressed as a 
percentage. DA overflow after first stimulation was always normalised to 100% regardless 
of whether the stimulation was delivered before or after a drug, since the objective was to 
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study the dynamics of relative increase or decrease in DA overflow. Subregion-specific PBF 
was analysed by ANOVA for repeated measures (RM-ANOVA) with genotypes as a 
between-subject factor and locations or subregion as a within-subject factor (Study II). The 
effects of treatments were analysed by RM-ANOVA (3 genotypes × 2 treatments). Time 
course of autoinhibition was also analysed by RM-ANOVA (6 inter-stimulus intervals × 2 
treatments × 3 genotypes).  
In Study III, to compare the effects of MPD and GBR12909 on peak DA overflow after 
single-burst stimulation at different frequencies, data were expressed as a percentage of 
pre-drug levels. Peak amplitudes of stimulated DA overflow were measured using Invilog 
Voltammetry System software. Changes in peak DA overflow and extracellular DA levels 
before and after treatment were analysed by two-way analysis of variance for repeated 
measures (two-way RM-ANOVA) with two within-subjects (treatments) and three 
between-subjects (genotypes) factors (Study III). The effects of MPD and GBR12909 on DA 
overflow following repeated-burst stimulation were compared by RM-ANOVA with 12 
within-subjects (2 treatments × 6 bursts) and 3 between-subjects (genotypes) factors. Percent 
increase in DA overflow at different stimulation frequencies was analysed by two-way RM-
ANOVA with Bonferroni post-hoc test (Table 1). Two-way RM-ANOVA with Bonferroni 
tests for multiple comparisons was used to study the effects of MPD (5 mg/kg) and 
GBR12909 (10 mg/kg) treatments. The effects of MPD (1 mg/kg) on Km and [DA]p were 
analysed by two-way RM-ANOVA followed by Bonferroni tests for multiple comparisons. 
Data are presented as mean ± S.E.M. 
In Study IV, differences between sensitivities of three types of CFEs were compared by 
one-way ANOVA followed by Tukey’s post-hoc test for multiple comparisons. Differences 
between signal-to-noise ratio, selectivity, and detection limit were compared by 
independent samples t-test. Differences between parameters obtained by standard and 
modified waveforms using the same electrode were compared by two-way mixed ANOVA 
with electrode type as a between-subject factor and waveform as a within-subject factor. 
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5 Results 
5.1 COMPENSATORY ALTERATIONS IN THE STRIATAL DOPAMINERGIC 
SYSTEM IN THE ABSENCE OF Α-SYN (STUDY I) 
5.1.1 Increased stimulated dopamine overflow in the dorsal striatum in mice lacking α-
syn 
Evoked DA overflow was studied in the dorsal striatum in wild-type (b6+) and two mouse 
lines with spontaneous (b6─) and targeted deletion (b6─ros) of the α-syn gene locus. 
Evoked DA overflow was measured using CPA (Fig. 10A). Electrical stimulation lasting 2 s 
was delivered to the MFB using a bipolar stimulating electrode at frequencies of 10-50 Hz. 
Statistical analysis revealed a significant genotype × frequency interaction (RM-ANOVA, 
F4,30 = 3.1, p = 0.03, n = 7 per group, Study I). The peak amplitude of DA overflow at 10-30 
Hz frequencies was not different between mice with and without α-syn. However, the DA 
overflow in b6−ros (p = 0.002) and b6− (p = 0.005) mice was significantly higher at 50 Hz 
stimulation than in b6+ mice (Tukey's post-hoc test). 
5.1.2 α-Syn deficient mice exhibit increased basal extracellular levels of dopamine in the 
dorsal striatum  
Due to the conflicting reports on striatal DA content in mice lacking α-syn, we measured 
basal extracellular DA levels in α-syn deficient mice (Fig. 10B). We found that the basal 
extracellular levels of DA were 75% and 69% higher in b6─ and b6─ros mice, respectively, 
than in b6+ mice (Study I). However, there was no difference in the basal levels between 
b6─ and b6─ros mice. (Fig. 10B, one-way ANOVA, F2,22 = 6.4, p = 0.007, n = 8 per group). In 
Tukey's post-hoc test, both b6−ros (p = 0.0004) and b6− (p = 0.0006) mice differed 
significantly from b6+ mice while there was no difference in the extracellular DA levels 
between b6− and b6−ros mice (p = 0.75). 
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Figure 10. Neurochemical alterations in the dorsal striatum in the absence of α-syn. A. 
Frequency-dependent increase in evoked DA overflow studied by in vivo voltammetry was 
significantly greater in mice lacking α-syn than in wild-type mice. At 50 Hz stimulation, evoked 
DA overflow in b6─ and b6─ros mice was significantly higher than in wild-type mice (n = 
7/group). B. Basal extracellular DA levels in the dorsal striatum studied by in vivo microdialysis 
were ~70% greater in α-syn deficient mice in comparison with wild-type mice (n = 8/group). C. 
Immunohistochemistry revealed that optical density of DAT staining in the dorsal striatum was 
significantly higher in wild-type mice than α-syn deficient mice, with no change observed in the 
nucleus accumbens (n = 4/group). D. Consistent with DAT expression, the maximal rate of 
DAT-mediated DA re-uptake was slower in b6─ros mice than in b6+ mice (n = 5-6/group). B6─ 
mice also displayed a tendency towards slower re-uptake in the dorsal striatum (Panels adapted 
from Study I with permission from Elsevier).  
 
5.1.3 Dopamine transporter expression is lower in the dorsal striatum in mice lacking α-
syn 
In order to understand the basis for the elevated extracellular basal levels of DA, we 
measured DAT expression in the striatum in the three lines using immunohistochemistry. 
We found that DAT expression was lower in the dorsal striatum in both lines lacking α-syn 
in comparison with wild-type mice (Fig. 10C, Study I). This difference was more prominent 
in the dorsolateral striatum than in the dorsomedial striatum (one-way ANOVA, F2,45 = 6.4, 
p = 0.003, n = 4 per group). Tukey's post-hoc test revealed a significant difference in b6− (p = 
0.035) and b6−ros (p = 0.002) mice in comparison with b6+ mice. However, there was no 
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difference in DAT expression in the ventral regions of the nucleus accumbens core and shell 
between mice with and without α-syn (p > 0.05).  
5.1.4 Decreased re-uptake of dopamine in the dorsal striatum in α-syn deficient mice 
Given the increase in extracellular DA levels and decreased DAT expression, we measured 
the functional re-uptake activity in the dorsal striatum of mice lacking α-syn (Fig. 10D, 
Study I). Right linear slope of the decay phase of DA signal was used to assess the maximal 
rate of re-uptake (Vmax). We found that the Vmax in b6─ros (2.69 ± 0.29 μM/s) mice was 
considerably lower than that of b6+ mice (4.70 ± 0.29 μM/s) (Study I, Fig. 10D, F2,14 =11.3, p = 
0.001, n = 5–6 per group). Tukey's post-hoc test revealed a significant difference between 
b6+ and b6−ros mice (p = 0.0009). However, the Vmax in b6─ mice (3.71 ± 0.29 μM/s) was not 
significantly different from that in b6+ (p = 0.056) or b6─ros (p = 0.08) mice.  
5.2 Α-SYN DEPENDENT ALTERATIONS IN THE SHORT-TERM PLASTICITY 
OF DOPAMINE RELEASE IN STRIATAL SUBREGIONS (STUDY II) 
5.2.1 Enhanced facilitation of stimulated dopamine overflow selectively in the 
dorsolateral striatum in α-syn deficient mice 
Earlier studies (Yavich et al., 2004) have shown that mice lacking α-syn display a specific 
form of plasticity in terms of enhanced facilitation of DA overflow in the dorsal striatum 
following repeated, high-frequency stimulation of the MFB. However, the mechanisms 
underlying this phenomenon were unknown. Further, no studies had reported on the effect 
of the absence of α-syn on the short-term plasticity of DA overflow in the ventral striatum, 
the region relatively unaffected in PD (Garris et al., 1997b; Kish et al., 1988). Therefore, we 
studied the short-term plasticity of DA overflow in three striatal subregions. A carbon fibre 
working electrode was inserted at an angle of 16° in the dorsal striatum (Fig. 9). We found 
that PBF in both mouse lines lacking α-syn was significantly higher than in the PBF in b6+ 
mice (Fig. 11A). RM-ANOVA revealed a significant subregion × genotype interaction (F2,75 = 
36.5, p = 0.001; Study II). The PBF in the ventral striatum was not different between the 
three lines. Furthermore, the PBF in the dorsal striatum was significantly higher in 
comparison with the PBF in the ventral striatum in b6− and b6–ros mice (RM-ANOVA, F1,75 
= 257, p = 0.001; Study II). 
To further elucidate the subregional variation in PBF in mice with and without α-syn, a 
two-dimensional map of PBF was generated. This approach allowed estimation of PBF at 
locations beyond the actual measurement locations. The actual values of PBF from the 
locations verified histologically served as input values for estimating the subregional 
distribution of PBF. The analysis revealed that PBF followed a dorsolateral-ventromedial 
gradient (Study II). In all three lines, PBF was the highest in the dorsolateral striatum and 
lowest in the ventral striatum (Fig. 11B). However, this difference was much more 
pronounced in b6─ and b6─ros mice (Study II). Statistical analysis revealed that PBF was 
selectively enhanced in the dorsolateral striatum in b6─ and b6─ros mice (RM-ANOVA, 
effect of subregion, F1,22 = 8.4, p = 0.008) but not b6+ mice (RM-ANOVA, effect of subregion, 
F1,22 = 0.13, p = 0.72). 
Since Study I reported alterations in re-uptake in the dorsal striatum in α-syn deficient 
mice, we measured the rate of re-uptake in the ventral striatum in three lines. We found no 
difference between the Vmax in b6+ mice (2.3 ± 0.23 μM/s), and in b6─ (2.37 ± 0.56 μM/s) and 
b6─ros (2.43 ± 0.39 μM/s) mice (One-way ANOVA, F2 = 0.1, p = 0.8, n = 6/group).  
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Figure 11. Subregional differences in the short-term plasticity of DA overflow in the striatum in 
wild-type and α-syn deficient mice. A. Mean PBF recorded at nine locations in dorsal and ventral 
striatum in three lines. PBF in α-syn deficient mice was significantly higher than that in control 
mice in the dorsal striatum. No difference in PBF was observed in the ventral striatum between 
the three lines B. Subregional distribution of PBF in the striatum in three lines. PBF at locations 
where no real recordings were made was extrapolated using statistical extrapolation analysis. 
The locations of actual recordings were positioned on the brain map (see section 4.7), and 
recorded PBF values at these locations were used as a basis to estimate the PBF in the 
surrounding region. Each coloured contour represents PBF values in the region shown by the 
corresponding colour indicated in the scale on the right side in panel B. This approach allowed 
precise evaluation of subregional distribution of PBF within striatal subregions in mouse brain. 
This data clearly reveals that in mice lacking α-syn, PBF was selectively altered in the 
dorsolateral striatum. The dorsomedial striatum was relatively less affected while there was no 
effect of the absence of α-syn in the ventral striatum (Panels adapted from Study II with 
permission from Elsevier).  
5.2.2 Role of re-uptake in short-term plasticity of dopamine overflow in striatal 
subregions in mice with and without α-syn 
Repetitive stimulation-dependent increase in neurotransmitter release has been shown to 
depend on re-uptake, which refills the readily releasable and recycling vesicle pools 
(Stevens and Wesseling, 1998; Wang and Kaczmarek, 1998). Furthermore, alterations in the 
refilling of vesicle pools have been suggested to play a role in short-term plasticity of DA 
overflow in mice lacking α-syn (Abeliovich et al., 2000; Yavich et al., 2004). Therefore, we 
investigated if differences in re-uptake underlie the genotypic or subregional differences in 
PBF in α-syn deficient mice. DA overflow was evoked by administering 50 Hz, 2-s 
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stimulation to the MFB (Fig. 12A), and PBF was recorded before and 45 min after GBR12909 
(10 mg/kg). In all three lines, peak DA overflow evoked after the second stimulation was 
always greater than that after the first stimulation. However, re-uptake inhibition 
eliminated the facilitation of DA overflow in all three lines in both striatal subregions (Fig. 
12). A statistically significant decrease was found in the PBF in both dorsolateral (Fig. 12B) 
and ventral (Fig. 12C) striatum in all three lines (RM-ANOVA, the main effect of treatment, 
F1,23 =2.78, p < 0.0001, n = 6 per group; Study II) 
However, a large amount of DA overflow following the first stimulation may exhaust 
vesicular storage and decrease the facilitation of DA overflow. To rule out the effect of the 
amount of DA overflow after the first stimulation on PBF, we delivered intense stimulation 
which exhausted vesicular storage. This experiment demonstrated that re-uptake inhibition 
eliminates the facilitation of DA overflow at different levels of emptiness of vesicular 
storage (data shown in Study II, Fig. 3D).  
 
Figure 12. Effect of specific re-uptake inhibitor GBR12909 (denoted as GBR, 10 mg/kg) on 
genotypic and subregional differences in PBF (Reprinted from Study II with permission from 
Elsevier). A. Recordings of evoked DA overflow following a paired stimulation of at 50 Hz 
frequency at an interstimulus interval of 5 s. DA overflow evoked by the second stimulation (~9 
μM) was nearly 3-fold greater than that evoked by the first stimulation (~3μM). However, for an 
equivalent amount of DA overflow evoked after the first stimulation (~3μM), DA overflow 
evoked by the second stimulation (~1.8 μM) was significantly lower after GBR12909 (10 mg/kg) 
treatment. B and C. GBR12909 treatment eliminated the facilitation of DA equally potently in all 
three lines in both subregions of dorsal and ventral striatum. Thus, although re-uptake is critical 
for the facilitation of DA overflow, it did not distinguish genotypic or subregional differences in 
PBF between the lines.  
5.2.3 Role of D2 autoreceptors in determining genotypic or subregional differences in 
paired-burst facilitation in wild-type and α-syn deficient mice  
D2 autoreceptors regulate the short-term dynamics of DA overflow following repetitive 
stimulation (Yavich, 1996; Benoit-marand et al., 2001; Kita et al., 2007). A study by 
Abeliovich et al. (2000) indicated that D2 autoreceptor function is not altered in α-syn 
deficient mice. However, the study did not analyse the D2-mediated autoinhibition at 
interstimulus intervals shorter than 2.5 s, during which the autoinhibition by D2 
autoreceptors is maximal (Benoit-Marand et al., 2001; Schmitz et al., 2002; Phillips et al., 
2002). Therefore, basal function of the D2 autoreceptors was tested by delivering 100 Hz, 5 
pulse paired stimulation (pseudo-one pulse) at interstimulus intervals between 0.5 to 5 s 
(Fig. 13A,B). Autoinhibition was quantified by measuring the ratio of peak DA overflow 
after second to that after first stimulation, and this ratio was referred to as paired-pulse 
depression (PPD). In all three lines, the maximal PPD was observed at 0.5 s interstimulus 
interval (Fig. 13C). PPD recovered gradually with increasing interstimulus interval and was 
nearly absent at 5 s interval. We found no difference in PPD between the three lines at any 
of the interstimulus intervals (RM-ANOVA, genotype × interstimulus interval interaction, 
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F2,11 = 2.6, p = 0.08, n = 4/group; Study II). Haloperidol which inhibits D2 autoreceptors and 
increases DA overflow (Yavich, 1996; Kita et al., 2007), significantly decreased 
autoinhibition at 0.5 (p = 0.0001, RM-ANOVA, the main effect of treatment, F1,11 = 26.3, n = 
4/group) and 1 s (p = 0.001) interstimulus intervals. However, there was no difference in 
PPD between the three lines after haloperidol treatment (Fig. 13D, RM-ANOVA, the main 
effect of treatment, F2,11 = 0.02, p = 0.09). We also found no difference in PPD between the 
three lines either before or after haloperidol treatment in the ventral striatum (data not 
shown). These data indicate that the basal function of D2 autoreceptors at physiologically 
relevant levels of DA overflow is not altered in mice lacking α-syn.  
 
Figure 13. D2 autoreceptor mediated paired-pulse depression in mice with and without α-syn 
(Panels adapted from Study II with permission from Elsevier). A. Original voltammetric 
recordings of DA overflow evoked by MFB stimulation in the dorsal striatum. The thick black line 
shows the interstimulus interval between paired stimuli at 100 Hz, 5 pulse stimulation. The first 
two recordings show that at interstimulus intervals of 0.5 and 1 s, DA overflow evoked following 
the second stimulation was significantly lower than that after the first stimulation, indicating 
depression of DA overflow. However, at 5 s interstimulus interval, the DA overflow following 
first and second stimuli was comparable, indicating complete recovery of short-term depression 
of DA overflow. B. A background subtracted cyclic voltammogram to reliably identify 
electrochemical signal as DA at small amplitudes of DA overflow. C and D. Paired-pulse 
depression (PPD) of DA overflow at varying interstimulus intervals in mice with and without α-
syn. Panel C shows that no significant difference was observed in PPD between mice with and 
without α-syn under control conditions. Panel D shows that haloperidol (0.5 mg/kg) decreased 
PPD mainly at 0.5 and 1 s interstimulus intervals by inhibiting D2 autoreceptor-mediated 
inhibition of DA release. However, haloperidol treatment also did not reveal any differences 
between the genotypes. 
 
D2 autoreceptors have also been shown to modulate PBF (Yavich, 1996; Kita et al., 2007). 
In order to assess the effect of D2 receptor inhibition on PBF, we measured PBF in dorsal 
and ventral striatum in the three lines. Haloperidol had no effect on the PBF in b6+ mice in 
the dorsal striatum (Fig. 14; p = 0.45). However, haloperidol significantly decreased the PBF 
in b6─ (p = 0.004) and b6─ros (p = 0.008) mice in the dorsal striatum (Fig. 14A; RM-
ANOVA, the main effect of treatment, F1,23 = 2.72, n = 4/group). Haloperidol did not change 
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the PBF in all three lines in the ventral striatum (data not shown). We delivered high-
frequency, repetitive stimulation also in the case of D2 autoreceptor blockade to examine 
PBF at varying levels of vesicular storage. Repeated six bursts at 50 Hz, 2-s stimulation 
showed that haloperidol decreased PBF after the first massive set of stimulation (Fig. 14B), 
possibly as a result of depletion of vesicle pools. However, repetitive stimulation during the 
second and third sets of massive bursts restored the facilitation of DA overflow (statistics 
not shown). These results showed that although D2 autoreceptors modify PBF in all three 
lines, they do not distinguish the genotypic or subregional differences in PBF in these lines.  
 
 
Figure 14. Effect of haloperidol (0.5 mg/kg, i.p.) on the dynamics of facilitation of DA overflow 
in mice with and without α-syn (Reprinted from Study II with permission from Elsevier). The 
effect of haloperidol, which blocks presynaptic D2 autoreceptors and decreases the 
autoinhibition of DA release following repetitive stimulation, was studied by stimulating the MFB 
with six 2-s bursts at 50 Hz frequency at a 5-s interstimulus interval. The trains of six bursts 
were repeated after 60 s to test the dynamics of facilitation of DA overflow at gradually 
declining storage of DA in presynaptic vesicles. Panel A shows that haloperidol (0.5 mg/kg) 
significantly decreased the facilitation of DA overflow in α-syn deficient mice but did not change 
the PBF in wild-type mice. Panel B shows that although haloperidol decreased the facilitation of 
DA overflow during the first train of six bursts, possibly due to exhaustion of vesicle pools, the 
dynamics of increase in DA overflow following repetitive stimulation was again evident in the 
second and third trains of burst stimulation. Thus, although haloperidol modulates PBF, it does 
not interfere with the mechanism of vesicular refilling necessary for the facilitation of DA 
overflow.  
5.3 METHYLPHENIDATE MODIFIES DOPAMINE NEUROTRANSMISSION 
VIA AN Α-SYN DEPENDENT MECHANISM (STUDY III) 
5.3.1 Effect of methylphenidate on stimulated dopamine overflow depends on the 
presence of α-syn  
Studies I and II clearly showed that α-syn plays an important role in modulating DA 
release, re-uptake, and vesicular mobilisation. Psychostimulants are a class of drugs that 
also affects DA release, re-uptake, and vesicular mobilisation (Sulzer et al., 2005). In 
particular, methylphenidate (MPD) is the most commonly prescribed drug for treatment of 
ADHD. MPD exerts its pharmacological effects by interacting with the DAT (Pan et al., 
1984) and VMAT2, and by redistributing presynaptic vesicles (Volz et al., 2007a; 2008a). α-
Syn also interacts with these proteins and plays a role in vesicular compartmentalisation 
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(Abeliovich et al., 2000; Cabin et al., 2002). Therefore, we investigated if α-syn may play a 
role in modulating the pharmacological action of MPD on DA neurotransmission. 
 
Figure 15. Effect of MPD (1 mg/kg) on frequency-dependent DA overflow in the dorsal striatum 
in wild-type and α-syn deficient mouse lines (Reprinted from Study III with permission from the 
American Society for Pharmacology & Experimental Therapeutics). A. Representative original 
voltammetric recordings of evoked DA overflow from the dorsal striatum of a b6─ mouse. 2-s 
bursts of stimulation at 10-50 Hz frequencies were delivered to the MFB. The black line 
indicates recording before drug while the dashed line indicates DA overflow after MPD 
administration. B, C, and D. Effect of MPD on evoked DA overflow in b6+, b6─, and b6─ros 
mice, respectively. MPD significantly increased DA overflow in b6+ mice at 10 Hz stimulation 
but did not increase it in α-syn deficient mouse lines. However, at 50 Hz, MPD significantly 
increased DA overflow in all three lines.  
 
We used a therapeutically equivalent dose of MPD (1 mg/kg), which corresponds to the 
dose that has been shown to improve the symptoms of ADHD in humans (Volkow et al., 
2001). We first tested the effect of this dose (1 mg/kg) on evoked DA overflow in mice with 
and without α-syn at 10-50 Hz frequencies of stimulation (Fig. 15A, Study III). MPD 
produced a significant frequency-dependent increase in all three lines (RM-ANOVA, the 
main effect of treatment, F1,15 = 7.1, p = 0.017, n = 6/group; Fig. 15B,C,D). Fig. 15A illustrates 
original recordings before and after MPD from b6─ mouse. At 10 Hz stimulation, MPD-
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induced increase in DA overflow was significantly smaller in b6─ (two-way RM-ANOVA, 
Bonferroni post-hoc test, p = 0.017) and b6─ros (p = 0.011) mice than in b6+ mice (shown in 
table 1 in Study III).  
We also tested the effect of MPD on the dynamics of DA overflow following repetitive, 
high-frequency burst stimulation to the MFB in wild-type and α-syn deficient mice. We 
used similar massive stimulation comprising six 50-Hz, 2-s bursts at an interstimulus 
interval of 5 s as used in Study II (Fig. 12). The experiments revealed that MPD produced 
no change in the dynamics of DA overflow following repetitive stimulation in b6+ mice 
(Fig. 16A). In contrast, MPD decreased the enhanced facilitation of DA overflow in mice 
lacking α-syn (Fig. 16B,C). The effect of MPD on decreasing the facilitation of DA overflow 
was significant in b6─ and b6─ros mice (two-way RM-ANOVA, F2,15 = 4.5, p = 0.019, n = 
6/group). MPD treatment “normalised” the DA overflow in mice lacking α-syn such that 
there was no difference in the facilitation of DA overflow between untreated wild-type 
mice and MPD-treated α-syn deficient mice (two-way RM-ANOVA, F2,15 = 8.3, p = 0.74).  
 
Figure 16. Effect of MPD (1 mg/kg) on the dynamics of facilitation of DA overflow in three lines 
(Panels adapted from Study III with permission from the American Society for Pharmacology & 
Experimental Therapeutics). A. MPD did not significantly change the facilitation of DA overflow 
in b6+ mice following repetitive burst stimulation. B and C. MPD significantly decreased the 
facilitation of DA overflow in both b6─ and b6─ros mice, indicating that vesicle mobilisation-
dependent facilitation of DA overflow is attenuated in mice lacking α-syn following MPD 
administration. 
5.3.2 Re-uptake independent effect of methylphenidate on the dynamics of dopamine 
overflow 
We showed in Study II that the facilitation of DA overflow following repeated-burst 
stimulation relies on re-uptake. Therefore, we examined whether the different effect of 
MPD in α-syn deficient mice could be attributed to a difference in re-uptake in mice lacking 
α-syn. In order to test this, we used the specific re-uptake inhibitor GBR 12909 to first 
understand the effect of the classic re-uptake inhibitor on the dynamics of DA overflow. 
Consistent with Study II, we found that the effect of GBR 12909 (10 mg/kg) on the dynamics 
of DA overflow following repeated stimulation was not different between mice with and 
without α-syn (two-way RM-ANOVA, F2,15 = 15.0, p = 0.6; data shown in Study III, Fig. 3D). 
Moreover, the effect of GBR 12909 on the dynamics of the facilitation of DA overflow was 
completely different from that of MPD in all three lines (two-way RM-ANOVA, F2,15 = 25.0, 
p = 0.0001). Further, these experiments revealed that there is a fundamental difference 
between the actions of MPD and GBR 12909, and that MPD facilitates DA overflow through 
mechanisms in addition to re-uptake inhibition (Fig. 75C). However, before investigating 
this difference, first we tested whether different effects of MPD (1 mg/kg) and GBR 12909 
(10 mg/kg) could be due to their different potencies as re-uptake inhibitors. In order to 
achieve the same degree of re-uptake inhibition, we increased the dose of MPD (Fig. 75). 
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Based on pilot studies, we found that 5 mg/kg dose of MPD produced a comparable 
increase in peak DA overflow (Fig. 17A) to that produced by 10 mg/kg dose of GBR 12909. 
The effect of the two drugs on increasing peak DA overflow was not different (two-way 
RM-ANOVA, F1,6 = 0.7, p = 4-5/group). Kinetic analysis, which permits Michaelis-Menten 
based estimation of the parameters of Km and Vmax, confirmed the equivalent potency of the 
two drugs at the doses used (Fig. 17B). Both MPD (5 mg/kg) and GBR 12909 (10 mg/kg) 
produced a nearly 20-fold increase in the apparent affinity of DA for re-uptake by the DAT. 
However, the effect of the two drugs on the facilitation of DA overflow was significantly 
different (two-way RM-ANOVA, F1,6 = 88.0, p = 0.0001; Fig. 17C).  
 
Figure 17. Comparison of the effects of MPD (5 mg/kg, i.p.) and GBR12909 (10 mg/kg, i.p.) on 
the facilitation of DA overflow and kinetic parameters of DA release and re-uptake (Reprinted 
from Study III with permission from the American Society for Pharmacology & Experimental 
Therapeutics). A. Both MPD (5 mg/kg) and GBR12909 (10 mg/kg) produced a comparable 
increase in evoked DA overflow in the dorsal striatum following stimulation of the MFB. B. Both 
drugs at the doses used produced an equivalent increase in the Km, indicating a potent inhibition 
of DA re-uptake. C. Although both MPD and GBR12909 produced equivalent increase in peak DA 
overflow and inhibition of re-uptake, their effects on the facilitation of DA overflow were 
opposite. MPD at the dose of 5 mg/kg maintained the facilitation of DA overflow while 
GBR12909 eliminated the facilitation. D. MPD (5 mg/kg) significantly increased DA release per 
pulse, an indication of DA release probability. However, GBR12909 produced no such change. 
 
To examine the primary reason for the maintenance of facilitation of DA overflow 
following MPD treatment even at high doses, we analysed the effect of MPD on DA release 
per pulse [DA]p of stimulation, which is a reflection of DA release probability. We found 
that while GBR 12909 produced no change in [DA]p, MPD at an equivalent dose 
significantly increased [DA]p (two-way RM-ANOVA, Bonferroni post-hoc test for the effect 
of MPD on [DA]p, F1,3 = 4.1, p = 0.025; see Fig. 15D). When we applied the same calculations 
to the data obtained at the lower of MPD at 1 mg/kg, we observed a similar phenomenon 
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(Fig. 18, Study III). MPD significantly increased [DA]p in the wild-type mice (two-way RM-
ANOVA, F1,5 = 26.3, p = 0.004, Fig. 18A). In contrast, MPD treatment significantly decreased 
[DA]p in b6─ros mice (p = 0.011) and approached significance in b6─ mice (p = 0.064). A 
significant genotype × treatment interaction was observed (F2,15 = 15.4, p = 0.009). Although 
MPD (1 mg/kg) significantly increased the Km (F1,13 = 39.0, p = 0.001) in all three lines also at 
the lower dose, the effect was not different between the three lines (F2,15 = 12.1, p = 0.14).  
 
Figure 18. Effect of MPD (1 mg/kg) on the kinetic parameters of DA release and re-uptake in 
mice with and without α-syn (Reprinted from Study III with permission from the American 
Society for Pharmacology & Experimental Therapeutics). A. MPD at the dose of 1 mg/kg 
significantly increased DA release probability in wild-type mice. In contrast, it significantly 
decreased DA release probability in b6─ros mice and showed a trend towards decreased [DA]p 
in b6─ mice. B. MPD (1 mg/kg) significantly enhanced the Km for DA re-uptake, indicating 
potent re-uptake inhibition at this dose. However, the increase in Km was not different between 
the lines.  
5.3.3 Effect of methylphenidate on extracellular dopamine levels 
Study I showed that mice lacking α-syn display increased extracellular DA levels and 
slower re-uptake (b6─ros mice) in the dorsal striatum. Therefore, we used in vivo 
microdialysis to understand whether MPD affects the extracellular levels differently in the 
three lines (Fig. 19; Study III). Consistent with Study I, extracellular DA levels were 
elevated in b6─ and b6─ros mice. 30 min after injection, MPD (1 mg/kg) produced a strong 
(~40%) increase in the extracellular levels of DA in all three lines (two-way RM-ANOVA, 
F1,21 = 14.0, p = 0.001, n = 7-8/group; Fig. 19). However, this increase was not different 
between the lines with and without α-syn (two-way RM-ANOVA, genotype × treatment 
interaction, F2,1 = p = 0.74; Study III, Fig. 19 inset).  
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Figure 19. Effect of MPD (1 mg/kg) on the extracellular levels of DA in the dorsal striatum in 
three lines (Reprinted from Study III with permission from the American Society for 
Pharmacology & Experimental Therapeutics). Effect of MPD on basal levels of extracellular DA in 
the dorsal striatum was studied by in vivo microdialysis. An intraperitoneal saline injection 
produced no change in extracellular DA levels in all three lines. MPD (1 mg/kg) significantly 
increased extracellular DA levels by approximately 50% in the three lines. The peak effect of 
MPD was observed 30 min after injection. However, this increase was not different between the 
lines (see inset).  
5.4 CHARACTERISATION OF A 32 μM CARBON FIBRE ELECTRODE AND 
OPTIMISATION OF FAST-SCAN CYCLIC VOLTAMMETRY FOR IN VIVO 
DETECTION OF DOPAMINE (STUDY IV) 
5.4.1 Modification of applied voltage in fast-scan cyclic voltammetry for enhanced 
sensitivity of dopamine detection 
Studies I, II, and III provided strong evidence that α-syn plays an important role in 
modulating DA neurotransmission in the striatum. Results from Study III show that mice 
lacking α-syn may display altered response to psychostimulants such as MPD. Further, 
unpublished work performed in the lab revealed interesting behavioural differences 
between wild-type and α-syn deficient mice in relation to the effects of psychostimulants. 
However, further investigating the mechanisms underlying these differences warranted 
recording of endogenous DA release in freely moving animals. FSCV is a preferred 
technique for detecting endogenous subsecond changes in DA concentration, since FSCV 
can reliably identify changes in DA concentration from changes in other compounds in the 
brain (Robinson and Wightman, 2002). The use of FSCV to detect DA using chronically 
implanted CFEs in freely moving rodents was first established in a study by Clark et al. 
(2010). However, the major limiting factor in this approach is the low sensitivity and 
deterioration of performance of CFEs. To reliably measure subsecond DA release in mice 
with and without α-syn over a period of 3 months, we first decided to improve the working 
electrodes to achieve higher sensitivity for DA detection. As a first step in this direction, we 
made modifications to the parameters of applied voltage (Vapp) to boost the sensitivity of 
CFEs for DA. Second, we employed a new CFE with a larger diameter of 32 μm and a 
longer exposed length of 300 μm. The greater surface area of the 32 μm CFE allows more 
DA molecules to come in contact with the CFE producing larger oxidation current, and in 
turn, greater sensitivity for DA detection. The most commonly used Vapp (Fig. 20A) 
comprises a triangular waveform with the Vapp swept forward and backward from ─0.4 V 
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to 1.2 V at a scan rate of 300-400 V/s (Phillips et al., 2003). In our modified waveform (Fig. 
20B), Vapp was briefly reduced to ─0.6 V from the resting potential of ─0.4 V. Vapp was 
increased to 1.2 V and decreased to ─0.6 V, before returning again to ─0.4 V. Previous 
studies have used a waveform with a wider sweep from ─0.6 V to 1.4 V to increase the 
sensitivity for DA detection (Phillips et al., 2003; Heien et al., 2003). However, the studies 
reported that waveforms with holding potential of ─0.6 V decreased the selectivity for DA 
detection, which can seriously compromise DA detection in freely moving animals. Further, 
a resting potential of ─0.6 V produces a steady, non-specific upward trend in the electrical 
signal which can also impair selective DA detection. Therefore, we maintained the holding 
potential at ─0.4 V, which did not produce any trend in the electrical signal, and briefly 
lowering the Vapp to ─0.6 V provided additional time and greater negative voltage for 
complete reduction of DA. The modified waveform significantly increased the sensitivity of 
7 and 32 μm CFEs for DA detection by ~64% (two-way ANOVA, the main effect of 
waveform, F1,9 = 17.3, p = 0.002; See Fig. 21A, Study IV). The modified waveform also 
produced a 12% increase in the background current. However, the increase in sensitivity 
(~65%) was far greater than the increase in background current (See Fig. 21B). 
 
 
Figure 20. Modifications of the parameters of applied voltage in comparison with the typically 
used parameters for DA detection using FSCV (Reprinted from Study IV with permission from 
Elsevier). Panel A shows a typical triangular waveform with applied voltage (Vapp) scanned 
forward and backward from ─0.4 to 1.2 V at a rate of 400 V/s. Panel B shows the modified 
waveform, in which Vapp was briefly reduced to ─0.6 V from ─0.4 V before scanning the voltage 
to 1.2 V. Vapp was again reduced to ─0.6 V before returning to ─0.4 V. The modified waveform 
produced a minor 12% increase in the background current. Panels C and D show the typically 
observed background currents for 7 and 32 μm CFEs, respectively. 
5.4.2 32 μm CFEs displayed significantly greater sensitivity for dopamine detection in 
vitro 
CFEs of 7 and 32 μm were calibrated in a flow injection system to compare the sensitivities 
for DA detection. We observed that the sensitivities of both types of CFEs depended on the 
concentrations used for calibration (data shown in Study IV). At physiologically relevant 
concentrations (Phillips et al., 2003) from 100 to 500 nM, the sensitivities of 7 and 32 μm 
CFEs were 24.2 and 107 nA/μM, respectively (Study IV, Fig. 3A). At greater concentrations 
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from 1 to 3 μM, the sensitivity of 7 μm CFE was 5.9 nA/μM while the 32 μm CFE displayed 
a sensitivity of 53.52 nA/μM (Study IV, Fig. 3A). Both electrodes displayed excellent 
linearity (r2 > 0.99) within both low and high concentration ranges. The 32 μm CFEs also 
displayed significantly greater signal-to-noise (S/N) ratio than 7 μm CFEs (Student’s t-test, 
p = 0.02). The detection limit of 32 μm CFEs (40 nM) was also lower than that of 7 μm CFEs 
(133 nM; Student’s t-test, t6 = 3.7, p = 0.009; Study IV, Fig. 5A,B).  
 
 
 
Figure 21. Comparison of the sensitivities of 7 and 32 μm CFEs with standard and modified 
waveform (Adapted from Study IV with permission from Elsevier). A. The 32 μm CFE displayed 
14-fold more sensitivity to DA than the conventionally used 7 μm CFE. Further, the modified 
waveform significantly increased the sensitivity of both types of CFEs by approximately 65%. B. 
Representative background-subtracted cyclic voltammogram (CV) of DA obtained using 32 μm 
CFE with standard (dashed line) and modified (black line) waveforms. 
5.4.3 Ability of 32 μm CFEs to detect dopamine in the presence of interfering compounds 
and changes in pH 
In vivo detection of DA is confounded by the presence of interfering compounds which are 
electrochemically active and contribute to the electrochemical signal produced at voltages 
commonly used to detect DA (Wiedemann et al., 1990). The primary interferents are 
ascorbic acid and DA metabolites such as DOPAC and HVA (Kuhr et al., 1986), which are 
present at much greater quantities in the extracellular fluid than that of DA. Hence the 
ability of a CFE to detect DA in preference over these compounds is crucial for reliable 
detection. Furthermore, it has also been shown that pH changes occur following 
neurotransmitter release in the microenvironment surrounding the electrode and may 
influence the net amplitude of oxidation current of DA (Runnels et al., 1999). Therefore, we 
tested the performance of 32 μm CFE in presence of interferents at physiologically relevant 
concentrations and under changing pH conditions.  
The 32 μm CFE displayed characteristic CVs of 200 μM ascorbic acid, 20 μM DOPAC 
and 5 μM HVA comparable to that of the 7 μm CFE (See figures in Study IV). The electrode 
could also adequately detect DA in the presence of DOPAC and HVA. Similarly, the 32 μm 
CFE could successfully detect DA in the presence of acidic (pH 7.2) and basic (pH 7.6) shifts 
in the pH of aCSF. The selectivity of 7 and 32 μm CFEs for DA over interfering compounds 
was not significantly different from each other (p > 0.05; Study IV, Fig. 7). However, the 32 
μm CFE displayed a significantly enhanced selectivity for DA over DOPAC when the 
modified waveform was used (Independent samples t-test, t4 = 7.4, p = 0.017; Study IV, 
Table 1).  
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5.4.4 In vivo detection of dopamine in mouse dorsal striatum using 32 μm CFE 
After in vitro evaluation of the electrode, we used the 32 μm CFE in vivo to measure 
electrically evoked DA overflow in the dorsal striatum of C57Bl/6J mice (n = 4). DA 
overflow evoked by stimulation of the MFB was measured over a period of 5 h following 
implantation of the electrode. The 32 μm CFE could successfully capture the rapid 
dynamics of rise and decline of extracellular DA levels (Fig. 22A,B). The temporal 
resolution of the CFE was comparable to that of the 7 μm CFE. The recordings made using 
32 μm CFEs yielded a mean Vmax for DA re-uptake of 6.2 ± 0.9 μM/s and a Km of 0.46 ± 0.21 
μM. The values reported in the literature are in agreement with these values (Salahpour et 
al., 2008; Study III). Furthermore, the sensitivity of the electrode assessed in post-calibration 
was ~84% of the sensitivity obtained during pre-calibration. These data suggest that the 32 
μm CFE is highly suitable for in vivo detection of DA in rodent brain. 
In addition, this study also provides a novel waveform that enhances the sensitivity for 
DA detection by approximately 65%. Since it has been reported that applied waveforms 
with a wider voltage sweep irreversibly alter the properties of the CFE (Keithley et al., 
2011), we measured the background current as an indicator of the change in the surface 
properties of CF. The application of the modified waveform during 5-h implantation did 
not produce any change in the background current of the electrode (Fig. 22A,B). Moreover, 
the modified waveform did not compromise the selectivity of DA detection in the presence 
of interfering compounds. In fact, the 32 μm CFE displayed greater selectivity for DA over 
DOPAC when combined with the modified waveform.  
This work provided highly useful tools in the forms of a novel waveform and a superior 
working electrode to study subsecond DA release to further investigate the role of α-syn in 
modulation of behaviour and striatal DA neurotransmission. Preliminary studies using α-
syn deficient mice have been performed using an implantable version of 32 μm CFE 
secured on the skull using dental cement. The unpublished results indicate that the new 
waveform and the 32 μm CFE could successfully detect subsecond DA release in freely 
moving α-syn deficient mice over a period of 3 months post-implantation (data not shown).  
 
 
 
Figure 22. Application of the modified waveform and 32 μm CFE for DA detection in vivo 
(Adapted from Study IV with permission from Elsevier). A. Real-time measurement of evoked 
DA overflow in the dorsal striatum of wild-type mouse following stimulation of the MFB. The 
black line indicates DA overflow recorded by the 32 μm CFE while the dashed line indicates DA 
overflow measured using 7 μm CFE. Due to the significantly greater sensitivity of 32 μm CFE, 
the electrode produced a very high oxidation current, thus allowing reliable detection of DA 
overflow at very low concentrations in the range of nanomolars. B. Background-subtracted CVs 
taken at the peaks of recordings shown in panel A. The black line shows the CV taken using 32 
μ CFE while the dashed line shows CV obtained using 7 μ CFE.  
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6 Discussion 
6.1 SIGNIFICANT ALTERATIONS IN THE STRIATAL DOPAMINERGIC 
SYSTEM IN THE ABSENCE OF Α-SYN  
In this work, we showed for the first time that significant alterations occur in the striatal 
dopaminergic system following α-syn deletion. The major findings show that mice lacking 
α-syn display increased extracellular DA levels and decreased re-uptake of DA in the 
dorsolateral striatum.  
Earlier studies using α-syn deficient mice have reported a tendency for increased DA 
overflow in these mice in comparison with wild-type mice (Abeliovich et al., 2000; Senior et 
al., 2008). α-Syn has been described as a negative regulator of DA release (Abeliovich et al., 
2000; for a review, see Sidhu et al., 2004b). However, there were no significant differences in 
DA release after single-pulse stimulation in mice lacking α-syn (Abeliovich et al., 2000; 
Senior et al., 2008). Consistent with these studies, we also did not find a significant effect of 
the absence of α-syn on DA overflow at lower stimulation frequencies (Fig. 10). However, 
at a higher frequency (50 Hz) when DA overflow is more sensitive to organisation of vesicle 
pools and re-uptake, we found a significant increase in evoked DA overflow in α-syn 
deficient mice. At lower stimulation frequencies, extracellular DA concentration is 
determined mainly by the affinity of the DAT for DA (Garris et al., 2003), and is less 
sensitive to re-uptake. However, with higher frequencies, the duration between two 
consecutive pulses is much shorter, which allows less time for re-uptake than at lower 
frequencies (Chergui et al., 1994; Garris and Wightman, 1994). Therefore, the extracellular 
DA concentration at higher frequencies is determined by the maximal re-uptake (Vmax) 
(Garris et al., 2003). These data allow one to draw a conclusion that in mice lacking α-syn, 
the affinity for DA re-uptake (Km) is not affected when Vmax is low, which may explain 
increased DA overflow at the frequency of 50 Hz. The increased stimulated DA overflow 
can also be explained on the basis of increased DA release probability in these mice (Senior 
et al., 2008). Mice lacking α-syn have impaired compartmentalization of DA vesicles 
(Abeliovich et al., 2000; Cabin et al., 2002). Furthermore, α-syn plays an important role in 
the formation of SNARE-complex assembly by interacting with CSPα (Chandra et al., 2005), 
synaptobrevin-2 and vesicle associated membrane protein-2 (VAMP-2) (Burré et al., 2010). 
Formation of SNARE-complex assembly is a critical step preceding vesicle fusion and 
exocytosis. Therefore, the absence of α-syn may impair this process. For instance, α-syn is 
known to tether vesicles and attenuate release (Nemani et al., 2010). In the absence of α-syn, 
the missing negative regulation of DA release may lead to enhanced DA overflow and may 
even contribute to elevated extracellular DA levels.  
An earlier study reported no change in DAT expression (Dauer et al., 2002) or re-uptake 
(Senior et al., 2008) in α-syn deficient mice. The discrepancy may have arisen due to the 
different genetic backgrounds of animals used in the two studies. The mice used by Dauer 
et al. (2002) were of 129/Sv background while the α-syn deficient mice used by Abeliovich 
et al. (2000) and Senior et al. (2008) were generated using a cross between C57BL/6J and 
129Sv/j, and bred by backcrossing on pure C57Bl/6J mice. The wild-type line used by 
Abeliovich et al. (2008) was also a cross of 129/Sv and C57Bl/6J mice derived from the cross 
used to generate α-syn deficient line. On the other hand, the wild-type line used by Senior 
was derived from the original intercross of C57BL/6J mice used to produce α-syn and γ-syn 
double knockout mice (Senior et al., 2008). The b6─ mice in our study were from pure 
C57Bl/6J background and b6─ros mice were backcrossed onto C57Bl/6J mice. Abeliovich et 
al. (2000) showed that mice lacking α-syn do not display any alterations in the density of 
dopaminergic terminals. Therefore, the decreased DAT expression found in our study is 
61 
 
unlikely to be due to innervation density of dopaminergic neurons (Abeliovich et al., 2000; 
Chandra et al., 2004; Roberson et al., 2004). Importantly, our finding of decreased DAT 
expression in b6─ mice was recently validated by another study (Bellucci et al., 2011) using 
both immunohistochemistry and western blot analysis showing a robust 30% reduction in 
DAT expression in the striatum. Another source of the discrepancy in rate of re-uptake 
between a previous ex vivo study (Senior et al., 2008) and our findings could be due to 
differences in methodology. In in vivo environment, a microelectrode is surrounded by a 
much denser network of DA neurons (Garris and Wightman, 1994) and diffusion of DA is 
limited only to the extracellular fluid. Hence, even the smallest change in the rate of re-
uptake could affect the peak amplitude and re-uptake in vivo (Moquin and Michael, 2009; 
2011). Secondly, a recent study (Kile et al., 2012) demonstrated that at commonly used 
sampling rates, FSCV underestimates rates of DA re-uptake by as much as 18% compared 
to CPA, providing further proof that our approach is more capable of detecting smaller 
changes in rates of re-uptake. In addition to decreased DAT expression, deficits in 
trafficking of the DAT may also explain lower re-uptake. DAT membrane expression is 
highly dynamic, and the presence of DA in the extracellular space promotes rapid transport 
of DAT to the membrane via a number of mechanisms including D2 receptor activation, 
changes in ionic gradients, and intracellular enzymatic activity associated with DA release 
(for a review, see Mortensen and Amara, 2003). Since α-syn has been shown to play an 
important role in trafficking DAT to the membrane, the absence of α-syn may impair the 
transport of DAT, which may affect re-uptake.   
The findings on tissue content of DA in α-syn mice have also been inconsistent in the 
literature. The study by Abeliovich et al (2000) showed an 18% reduction in striatal DA 
content while Chandra et al. (2004) reported no change in DA content. However, no studies 
had so far reported extracellular DA levels in these mice. We show for the first time that α-
syn deficient mice display increased extracellular DA levels in the dorsal striatum. The 
most obvious explanation for the elevated extracellular DA levels in these mice could be 
decreased re-uptake. In addition, since α-syn also regulates presynaptic recruitment 
(Yavich et al., 2004) and exocytosis (Cabin et al., 2002; Larsen et al., 2006), impairment in 
these mechanisms may also lead to increased release and can produce elevated basal 
extracellular DA levels. As discussed earlier in this section, α-syn participates in vesicle 
fusion by interacting with the SNARE-complex (Burré et al., 2010). α-Syn is known to 
negatively regulate neurotransmitter release by tethering vesicles (Nemani et al., 2010). 
Therefore, one may speculate that the absence of α-syn may allow a greater fusion of 
vesicles with the membrane, possibly causing more leakage of DA in the extracellular 
space.  
This study also highlights the important role of α-syn in maintaining homeostasis in the 
dopaminergic system. Although extracellular concentrations similar to those evoked by 50 
Hz stimulation cannot be triggered physiologically, our finding that re-uptake can be 
affected in the absence of α-syn is important in the pathological context. Given the 
importance of re-uptake in functioning of the dopaminergic system (Garris et al., 1997a; 
Jones et al., 1998; 1999), loss of function of α-syn may have serious implications. A close 
relation between disruption of re-uptake and vulnerability of DA neurons has been 
reported in several studies involving proteins implicated in PD, such as PINK1 (Lu et al., 
2006), Parkin (Jiang et al., 2004), and DJ-1 (Goldberg et al., 2004) which have been shown to 
disrupt the re-uptake mechanism. Therefore, we suggest that the contribution of α-syn to 
disruption of re-uptake either alone or synergistically with other proteins may play an 
important role in determining the vulnerability of DA neurons to PD. Moreover, drugs of 
abuse such as cocaine, which significantly increase DA concentration in the synaptic cleft, 
have also been shown to increase the expression of α-syn (Brenz-Verca et al., 2003). 
Therefore, effect of α-syn on DA clearance from the extracellular space at high 
concentrations may be relevant after DAT blockade or downregulation following chronic 
drug abuse.  
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Overall, this study shows that in the absence of α-syn, permanent alterations occur in the 
dopaminergic system in the dorsal striatum. These changes include a reduction in DAT 
expression and a 70% increase in the basal extracellular DA levels. Although functional 
redundancy between the synucleins has been proposed (Chandra et al., 2004; Senior et al., 
2008), it is clear that β- or γ-syn could not prevent the elevation in extracellular DA levels or 
decreased surface expression of the DAT.    
6.2 SUBREGION SPECIFIC ROLE OF Α-SYN IN THE SHORT-TERM 
PLASTICITY OF DOPAMINE OVERFLOW IN THE STRIATUM 
Mice lacking α-syn have been shown to display specific alterations in short-term plasticity 
in the dorsal striatum, characterised by enhanced facilitation of DA overflow (Abeliovich et 
al., 2000; Cabin et al., 2002; Yavich et al., 2004). However, the mechanisms underlying these 
changes are not fully known. Furthermore, striatal subregions are differentially vulnerable 
to neurodegeneration in the course of PD (Kish et al., 1988; Morrish et al., 1996), and so far 
there is no evidence on a subregion-specific role of α-syn in the striatum. In Study II, we 
investigated possible α-syn-dependent alterations in the short-term plasticity of DA 
overflow in striatal subregions, and the mechanisms which may underlie these variations.  
When we investigated short-term plasticity in the form of PBF, we found enhanced PBF 
in the dorsal striatum in mice lacking α-syn consistent with earlier studies (Abeliovich et 
al., 2000; Yavich et al., 2004). However, earlier studies reported DA neurotransmission only 
from one particular location in the dorsal striatum, which does not take into account the 
well-known heterogeneity of DA neurotransmission (Garris and Wightman, 1994) and the 
plasticity of DA overflow in the striatum (Cragg, 2000). Therefore, we designed 
experiments to measure DA overflow from over 9 locations in the striatum in a 
dorsoventral fashion in each mouse. We found that PBF in both α-syn deficient lines was 
significantly enhanced specifically in the dorsolateral striatum. The PBF in α-syn deficient 
mice was higher also in the dorsomedial striatum but not in the ventral striatum in 
comparison with wild-type mice. We found no differences in the re-uptake of DA (Study II) 
and DAT expression (Study I) in the ventral striatum between the lines. This suggests that 
the ventral striatum is unaffected by the loss of α-syn. The gradient of distribution of PBF in 
striatal subregions very closely correlated with the gradient of degeneration of 
dopaminergic neurons (Kish et al., 1988; Morrish et al., 1996; Garris et al., 1997b). For 
instance, the dorsolateral striatum (or caudate nucleus) is significantly more vulnerable to 
degeneration than the dorsomedial striatum ( or putamen) in the course of PD, while the 
ventral striatum is largely unaffected in PD (Kish et al., 1988; Morrish et al., 1996; Garris et 
al., 1997b; Kirik et al., 2003). Our findings show that deletion of α-syn produces subregion-
specific alterations in the short-term plasticity of DA overflow, which reflect the 
pathological pattern of degeneration of DA neurons in the striatum.  
To understand the basis for these subregional alterations, we first investigated the 
mechanisms underlying PBF. One of the first candidates that can explain the subregional 
distribution of PBF was the DAT, which also shows a similar gradient of expression in the 
striatum (Lindvall and Björklund, 1978). Therefore, we investigated if differences in re-
uptake can explain the genotypic and/or subregional variation in PBF. When we tested PBF 
in the two subregions after administration of GBR 12909 (10 mg/kg), we found no 
differences in the PBF between the lines (Fig. 12). Therefore, re-uptake is not a 
distinguishing factor for PBF between mice with and without α-syn. However, re-uptake is 
an important player in the short-term plasticity of DA overflow. Our data show that re-
uptake inhibition eliminated PBF and produces successively decreased amount of DA 
overflow following each stimulation. During intense or prolonged stimulation, 
maintenance of DA release is dependent on the rate of refilling of DA vesicles (Yavich, 
1996; Yavich and MacDonald, 2000; Daniel et al., 2009). Re-uptake inhibition decreases the 
amount of DA available for refilling of vesicles since recycled DA is the primary source for 
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refilling of depleted vesicles (Wang and Kaczmarek, 1998; Stevens and Wesseling, 1999). 
However, this phenomenon was never tested in in vivo models in the dopaminergic system. 
In Study II, we show that refilling of vesicles through re-uptake is critical for sustaining 
neurotransmitter release following prolonged stimulation. The importance of re-uptake is 
highlighted by the fact that GBR12909 eliminated the facilitation of DA overflow in all three 
mouse lines and in both subregions.  
The second important presynaptic factor modulating the short-term dynamics of DA 
overflow is the contribution of D2 autoreceptors (Yavich, 1996; Kita et al., 2007). Testing the 
basal function of D2 autoreceptors was important since earlier studies (Jones et al., 1999b) 
showed that increase in extracellular DA levels desensitises D2 autoreceptors causing a 
complete loss of D2-autoreceptor mediated autoinhibition. Since both α-syn deficient mice 
showed a 70% increase in basal extracellular DA levels, we conducted experiments using 
protocols that directly test D2 autoreceptor function (Benoit-Marand et al., 2001; Kita et al., 
2007). The results (Fig. 13) revealed no differences in the basal function of D2 autoreceptors 
between mice with and without α-syn. Thus, we show that a 70% increase in the basal 
extracellular DA levels is not sufficient to desensitise D2 autoreceptors. Next, we also 
studied the contribution of D2 autoreceptors to PBF. Although D2 autoreceptor inhibition 
by haloperidol significantly decreased the PBF in b6─ and b6─ros mice, it is unlikely that 
D2 autoreceptor function is a distinguishing factor for genotypic differences in PBF. D2 
autoreceptor-mediated autoinhibition of DA release is most effective at interstimulus 
intervals shorter than 5 s (Kita et al., 2007) and is most visible at physiologically relevant 
electrical stimulation (Kita et al., 2007). It has been shown that increasing intensity of 
stimulation evokes a large amount of DA overflow that saturates DA autoreceptors. Hence, 
the autoreceptors no longer respond to the additional amount of DA release following 
subsequent stimulation (Kita et al., 2007). However, although D2 autoreceptor inhibition 
decreased PBF, it did not completely eliminate the appearance of PBF unlike in the case of 
GBR12909. Initially, during the first burst stimulation, it is possible that the large amount of 
DA overflow produced following the first stimulation may have depleted DA storage and 
less DA was available for future release (Study II). However, during the third train of burst 
stimulation, when most of the presynaptic DA was exhausted, PBF was restored. Therefore, 
we concluded that D2 autoreceptors affect PBF but do not interfere with the mechanism of 
vesicular refilling.  
Since it is clear that neither re-uptake nor D2 autoreceptors could distinguish the 
subregional or genotypic differences in PBF, other factors contributing to striatal 
heterogeneity can be considered. It is well known that the innervation density of 
dopaminergic neurons is much greater in the dorsal striatum than in the ventral striatum 
(Lindvall and Björklund, 1978). The dynamics of DA release and re-uptake are faster in the 
dorsal than the ventral striatum (Garris et al., 1994a,b; Jones et al., 1995a,b,c). In addition, 
the properties and organisation of the subtypes of DA neurons, their expressions of 
proteins such as DAT, TH, VMAT2, and other molecular factors affecting their function also 
show differences (For reviews, see Björklund and Dunnett, 2007a,b; Sulzer, 2007; Liss and 
Roeper, 2008). These factors may predispose the more vulnerable nigral DA neurons to 
degeneration than neurons originating from the VTA.  
The role of α-syn in determining subregional differences in PBF remains an interesting 
question. α-Syn has been shown to modulate the compartmentalisation of DA vesicle pools 
in earlier studies (Abeliovich et al., 2000; Murphy et al., 2000; Cabin et al., 2002). One study 
(Lee et al. 2008) showed that α-syn is localised only in a subpopulation of DA vesicles, and 
proposed that it may modulate vesicle recycling. Indeed earlier studies have shown that α-
syn recruits DA vesicles, and binds and dissociates from the vesicles in different vesicle 
pools in an activity- and stimulation-dependent manner (Fortin et al., 2005; Tao-Cheng, 
2006; For a review, see Bellani et al., 2010). Therefore, α-syn dependent alterations in PBF 
suggest that the function of α-syn in vesicle mobilisation may vary depending on the 
subregion or subtype of striatal neurons. Moreover, the protective role of α-syn in DA 
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storage might be critical in areas with denser dopaminergic innervation such as the dorsal 
striatum. When α-syn function is disrupted, this region may become preferentially 
vulnerable to degeneration in the course of PD. This argument is strengthened by the 
evidence that although the mice lacking VMAT2 with impaired DA storage display 
significant loss of DA neurons, progressive loss is observed only in the presence of α-syn 
(Caudle et al., 2007). Overexpression of α-syn also reported significant degeneration of DA 
neurons selectively in the dorsal striatum but not in the ventral striatum (Kirik et al., 2003). 
Further, the presence of α-syn specifically increases the vulnerability of neurons with 
greater expression of DAT levels in the dorsal striatum (González-Hernández et al., 2004; 
Lehmensiek et al., 2006). These studies may allow one to conclude that α-syn plays a 
subregion-specific role in modulating DA neurotransmission and in determining the 
differential vulnerability of striatal neurons.  
Apart from α-syn, another interesting argument is the greater requirement of 
nigrostriatal neurons for Ca2+ and K+ influx. The A8 and A9 populations of nigrostriatal 
neurons are tonically active (Schultz et al., 1998) and rely on high levels of Ca2+ influx 
(Kuznetsov et al., 2006). Studies have shown that high Ca2+ influx may exacerbate oxidative 
stress in neurons. For instance, A10 VTA neurons and some proportion of A9 nigral 
neurons which contain the protein calbindin are significantly more resistant to 
neurotoxicity due to their ability to effectively buffer intracellular Ca2+ (Liang et al., 1996a,b; 
Damier et al., 1999). The role of Ca2+ is particularly interesting in the context of α-syn 
deficient mice. The study by Abeliovich et al. (2000) showed that faster recovery of DA 
release from paired-pulse depression in α-syn deficient mice could be mimicked in wild-
type mice by stimulating DA release in a Ca2+ rich medium, suggesting that Ca2+ influx in 
the dorsal striatum of α-syn deficient mice might be altered. Moreover, dysfunction in the 
G-coupled inwardly rectifying K+ (GIRK) and ATP sensitive K+ (K-ATP) channels, which is 
linked to vulnerability to PD, may also be another cause of selective vulnerability of SN 
neurons (for a review, see Sulzer, 2007). GIRK channel expression is greater in the nigral 
neurons and their dysfunction in the presence of α-syn selectively increases the death of 
nigral neurons (Mendez et al., 2005; Chung et al., 2005). Similarly, activation of K-ATP 
channels causes death of nigral neurons but spares the VTA neurons (Liss et al., 1999; Liss 
et al., 2005).   
Thus, the question about a subregion specific role of α-syn in short-term plasticity of DA 
overflow and in PD remains an interesting area for future research. Our results show that 
the absence of α-syn accentuates the subregional differences in PBF in the striatum. Short-
term plasticity of DA overflow dependent on vesicular mobilisation is specifically affected 
in mice lacking α-syn. In contrast, short-term plasticity dependent on re-uptake or D2 
autoreceptors is not altered, since GBR12909 or haloperidol did not distinguish the 
genotypic or subregional differences in PBF. Strong evidence suggests that α-syn plays both 
protective (Kholodilov et al., 1999; Hashimoto et al., 2002; Chandra et al., 2005) and 
detrimental (Stefanis et al., 2001; Snyder et al., 2003; Nemani et al., 2010) roles in the 
pathology of PD. Therefore, the precise consequence of the absence of α-syn on 
vulnerability of DA neurons is hard to estimate. However, this work strongly suggests that 
the dorsolateral striatum will likely be most affected by the loss or toxicity of α-syn.   
6.3 ROLE OF Α-SYN IN MEDIATING THE PHARMACOLOGICAL ACTION OF 
PSYCHOSTIMULANTS SUCH AS METHYLPHENIDATE 
Despite the numerous functions of α-syn in the dopaminergic system and its involvement 
in addiction (Mash et al., 2003; Liang et al., 2003; Boyer and Dreyer, 2007), the role of α-syn 
in the action of psychostimulants is relatively unexplored. α-Syn modulates redistribution 
of DA vesicles (Fortin et al., 2005) and re-uptake (Study I). These functions are shared by 
several psychostimulants, especially MPD (Pan et al., 1987; Volz et al., 2007a,b; Volz, 2008). 
MPD is the most commonly prescribed drug in the treatment of ADHD (Volkow et al., 
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2001). Despite belonging to the psychostimulant class of drugs, MPD produces a 
paradoxical calming effect in individuals suffering from ADHD (Volkow et al., 2001). It is 
unclear why drugs such as MPD and amphetamine derivatives are effective in ADHD 
treatment but not other classic re-uptake inhibitors such as cocaine or GBR12909 which 
only inhibit the DAT without acting as releasers. Since MPD and α-syn share common 
molecular targets (Sandoval et al., 2002; Volz et al., 2007a,b; 2008; Study I), we investigated 
the role of α-syn in mediating the effects of MPD.  
We studied the effect of MPD at a physiologically relevant dose of 1 mg/kg (Volkow et 
al., 2001), which corresponds to the therapeutically effective dose of MPD in humans. We 
found that MPD increases evoked DA overflow in a frequency-dependent manner in mice 
with and without α-syn. At 10 Hz stimulation frequency, when only docked or vesicles 
from the RRP are released (Richards et al., 2003), MPD-induced increase in peak DA 
overflow was significantly lower in mice lacking α-syn. The most plausible explanation for 
this finding could be decreased number of vesicles in the RRP in α-syn deficient mice 
(Murphy et al., 2000; Cabin et al., 2002). At 50 Hz stimulation, MPD significantly increased 
evoked DA in wild-type mice but not in b6─ and b6─ros mice. A part of the explanation for 
this phenomenon may be the differential effect of MPD on [DA]p in mice with and without 
α-syn. MPD significantly increased [DA]p in control mice while decreased it in α-syn 
deficient mice. [DA]p plays an important role in determining the peak amplitude of DA 
overflow especially at higher frequencies of stimulation, during which even a small 
increase in DA release probability can lead to a significant overall increase in the peak 
amplitude (Kawagoe et al., 1993; Kawagoe and Wightman, 1994). Moreover, MPD enhances 
release by increasing the vesicular content of DA through VMAT2 mediated refilling of 
vesicles (Volz et al., 2007a). Given the fact that α-syn and VMAT2 directly interact with 
each other (Guo et al., 2008), the absence of α-syn may attenuate the effect of MPD on 
vesicle refilling in mice lacking α-syn. For instance, the possibility that MPD may decrease 
the [DA]p by decreasing the vesicular content of DA in addition to affecting the 
mobilisation of presynaptic vesicles cannot be ruled out.  
The involvement of D2 autoreceptors in mediating the effect of MPD has also been 
shown (Sandoval et al., 2002). However, Study II showed that neither the basal function of 
D2 autoreceptors nor the response to D2 antagonist following intense stimulation is altered 
in mice lacking α-syn. Therefore, it is unlikely that the different effect of MPD in α-syn 
deficient mice can be attributed to D2 autoreceptors. 
The differences in the effects of MPD and GBR12909 can also be explained on the basis of 
changes in [DA]p. GBR12909 decreased DA re-uptake while produced no change in [DA]p. 
The net effect of this was decreased vesicular refilling due to lower re-uptake. On the other 
hand, MPD decreased re-uptake but at the same time increased [DA]p. Therefore, the net 
effect was no change in the facilitation of DA overflow in comparison with pre-drug 
recording. The effect of MPD on increasing DA release probability can be seen more clearly 
at the higher dose of 5 mg/kg. At this dose, MPD produced inhibition of re-uptake as potent 
as that of GBR12909 (~20 times increase in Km) but still maintained the facilitation of DA 
overflow. Thus, this study highlights two important facts. First, the short-term plasticity of 
DA overflow is highly dependent on re-uptake as well as DA release probability. Molecular 
alterations or pharmacological agents which alter this balance can thus dramatically alter 
the plasticity of DA overflow. Second, increasing release probability is an important 
mechanism of action of MPD that can have therapeutic relevance in ADHD. In fact, phasic 
increase in DA overflow, which is more characteristic of DA releasers, has been reported in 
humans in imaging studies following MPD administration (Volkow et al., 2008; 2012; 
Goldstein et al., 2010). In contrast, typical re-uptake blockers produce a tonic increase in DA 
overflow that is much less dependent on cue-specific firing of DA neurons (Venton et al., 
2003). MPD is known to upregulate the function of VMAT2 and increase the rate of 
vesicular refilling (Volz et al., 2008). A study showed that α-syn directly binds with VMAT2 
and modulates its function (Guo et al., 2008). Therefore, in the absence of α-syn, the rate of 
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refilling of vesicles via VMAT2 may be altered in α-syn deficient mice following MPD 
treatment. This may affect the vesicular content of DA and influence the facilitation of DA 
overflow.  
It is important to note that MPD produced a similar increase in Km in all three lines but 
affected release in only α-syn deficient mice. This phenomenon can be seen further in in 
vivo microdialysis data where the net increase in basal extracellular DA levels (~50%) was 
similar in mice with and without α-syn. Therefore, it is clear that MPD affects the release 
component differently depending on the genetic makeup of the mouse line. Volkow et al. 
(2002) showed in humans that the increases in extracellular DA levels were different for the 
same level of DAT occupancy by MPD. These data strongly suggest that for the same level 
of re-uptake inhibition, MPD can modulate release differently. This study provides a 
compelling argument for investigating the role of presynaptic proteins in mediating the 
pharmacological action of MPD. Despite our results on the involvement of α-syn in the 
effect of MPD on DA overflow, postulating a direct role for α-syn in ADHD is tenuous. In 
fact, a study by Peña-Oliver (2012) showed that b6─ mice show decreased impulsivity in 
contrast to the ADHD phenotype. It is likely that MPD-mediated decrease in evoked DA 
overflow or decreased impulsivity in b6─ mice might actually be an indirect consequence 
of alterations in the dopaminergic system following α-syn deletion instead of a direct 
molecular role for α-syn. However, given the recent evidence on the involvement of 
presynaptic proteins such as SNAP-25 (Zhang et al., 2011) in ADHD, other presynaptic 
proteins such as α-syn can be investigated in relation to cognitive and neuropsychiatric 
disorders.  
In summary, Study III suggests an involvement of α-syn in affecting the action of MPD. 
We show that re-uptake inhibition is only a part of the pharmacological spectrum of MPD 
action. MPD exerts its therapeutic effect also by increasing or decreasing the release 
probability of DA depending on the presence of α-syn. This dual mode of action of MPD 
may distinguish it from other re-uptake inhibitors, and may help explain why MPD is 
efficacious in treating ADHD but not other re-uptake inhibitors. A recent study (Avelar et 
al., 2013) showed that amphetamine also increases DA neurotransmission by not only 
inhibiting re-uptake but also by increasing [DA]p, suggesting a common mechanism of 
action among amphetamine derivatives. Further, the selectivity of MPD in mice lacking α-
syn highlighted that α-syn can be a modulator of the action of MPD. MPD is also used for 
treatment in early stages of PD and improves symptoms such as gait imbalance, freezing, 
and cognitive dysfunction (Devos et al., 2007; for a review, Devos et al., 2012). Therefore, 
investigation of the precise interaction between α-syn and MPD deserves further attention.  
6.4 IMPORTANCE OF Α-SYN IN STRIATAL DOPAMINE 
NEUROTRANSMISSION 
Overall, our findings suggest that α-syn is an important player in the regulation of striatal 
dopaminergic activity. The role of α-syn appears to be considerably more important in the 
dorsal areas of the striatum than the ventral areas. The absence of α-syn produces 
fundamental alterations in DA homeostasis in the dorsal striatum. Critical aspects of DA 
neurotransmission such as basal extracellular DA levels, re-uptake, and release are affected 
by the absence of α-syn. The primary source of these alterations appears to be the role of α-
syn in presynaptic vesicle organization. Specific studies targeted at testing the dynamics of 
vesicle mobilisation indeed show that α-syn deficient mice display a distinct form of short-
term plasticity of DA overflow. This form of plasticity is not a result of increased 
extracellular DA levels or decreased DAT expression in these mice but possibly due to the 
function of α-syn in redistribution and mobilisation of DA vesicles. However, it highlights 
that the role of DAT is critical in maintaining DA neurotransmission during sustained 
demand. For example, in the event of dysregulation of presynaptic storage and decreased 
DA content as reported in models of PD, the role of DAT in replenishing the vesicle pool 
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might be crucial. Moreover, depending on the role of α-syn, DAT function might be altered, 
thus further compromising adequate recycling of DA. Furthermore, these changes are 
highly localised to the dorsolateral area of the striatum, which is most vulnerable to 
degeneration in PD. The dorsomedial striatum is much less affected by the absence of α-syn 
while no changes were observed in the ventral striatum in release or re-uptake.  
We also showed that the presence of α-syn may affect the pharmacological effects of 
drugs such as MPD on DA neurotransmission. Several other psychostimulants such as 
cocaine and amphetamines also target vesicle pools and interact with α-syn. In addition, α-
syn mutations modify the effect of levodopa on DA neurotransmission, which is 
particularly relevant in the treatment of PD (Oksman et al., 2009). Increased expression of 
α-syn in SN neurons was observed in mice following exposure to amphetamine and 
MDMA treatments (Fornai et al., 2005). Moreover, a recent study indicated that 
methamphetamine directly binds with the N-terminus of α-syn and produces 
conformational change (Tavassoly and Lee, 2012). These studies point to a much wider role 
for α-syn in mediating effects of centrally acting drugs.  
6.5 LIMITATIONS PERTAINING TO Α-SYN DEFICIENT MOUSE MODEL 
AND VOLTAMMETRIC TECHNIQUES  
An important challenge in using inbred or genetically engineered mice is the influence of 
the strain on gene deletion. Particularly, the influence of mouse backgrounds on the effects 
of gene deletions is well known (Morice et al., 2004). In this study, we used two α-syn 
deficient mouse lines. The b6─ mice belonged to C57Bl/6J background and carry a 
spontaneous deletion of the SNCA gene locus. On the other hand, the genetically 
engineered b6─ros mouse line was a cross between C57BL/6J and 129Sv/j mouse lines. 
Several studies have reported contradictory alterations in different aspects in α-syn 
knockout mice. For instance, studies have reported increased (Abeliovich et al., 2000; 
Yavich et al., 2004; Fortin et al., 2005) and decreased (Cabin et al., 2002) DA release in these 
mice. Also, studies have reported attenuated (Abeliovich et al., 2000) or no effect (Cabin et 
al., 2002) of psychostimulants on open-field locomotor activity. Some studies have reported 
drastic reduction in SNARE complexes (Burré et al., 2010) while others found no such 
change (Anwar et al., 2011). Most of these discrepancies have been attributed to differences 
in genetic backgrounds of mice (for a review, see Venda et al., 2010). Therefore, the findings 
in this work may also have been influenced by the genetic background. However, since we 
used two mouse lines lacking α-syn and observed similar changes in both mouse lines, we 
can corroborate that the findings are indeed related to the deficiency of α-syn. The primary 
contradictory finding of decreased re-uptake in α-syn deficient mice may be attributed to 
different genetic backgrounds. However, a recent validation (Bellucci et al., 2011) of 
decreased DAT expression in the same mouse line we used (b6─, C57BL/6J OlaHasd Harlan 
mice) provides strength to our finding.  
Another important consideration is the technical challenge associated with targeting 
areas in the dorsal striatum with in vivo voltammetry. In the dorsal striatum, DA overflow 
and D2-mediated autoinhibition can vary considerably depending on the location of the tip 
of the CFE (Phillips et al., 2003; Moquin and Michael, 2009; 2011). Robust differences in 
peak DA overflow and rates of re-uptake can be found within the same areas of the dorsal 
striatum (Moquin and Michael, 2009; 2011). In this work, no dramatic variation between 
and within mouse lines were observed as far as evoked DA overflow was concerned. One 
advantage could be the stimulation protocol used in our study. Since we used a strong 
stimulation of 50 Hz lasting 2 s, which evoked supraphysiological levels of DA overflow, 
minor differences in the local dynamics of DA neurotransmission such as diffusion of DA 
to the electrode and autoinhibition may have been masked (Wightman and Zimmerman, 
1990; Cragg and Rice, 2004; Kita et al., 2007). However, the influence of such factors cannot 
be completely ruled out. Another methodological consideration is that the location of the 
68 
 
stimulating electrode may also influence peak amplitude of evoked DA overflow (Kuhr et 
al., 1984). However, all care was taken to make sure that the stimulating electrode was 
lowered precisely in all animals and highest possible release was targeted to determine 
peak DA overflow. 
6.6 FUTURE DIRECTIONS 
This work, carried out primarily using voltammetric techniques, allowed a detailed 
characterisation of the role of α-syn in the striatal subregions. It showed that α-syn plays an 
important role in modulating DA release, re-uptake, DAT expression, and extracellular DA 
levels. However, due to the discrepancy in the literature over tissue DA content, it would 
be useful to measure DA content in striatal tissues of the mice used in this study for more 
reliable interpretation of our findings. Moreover, correlating changes in DAT expression to 
those in TH may also help to elucidate the precise cause of decreased DAT expression in α-
syn deficient mice. Further, although evidence suggests that TH activity is not altered in α-
syn deficient mice (Abeliovich et al., 2000), directly monitoring in vivo DA overflow 
following AADC inhibition by 3-hydroxybenzyl hydrazine (NSD-1015) and its effects of l-
DOPA accumulation may provide further insight into the synthesis and handling of 
presynaptic DA in α-syn deficient mice. To further probe the specific mechanisms of 
vesicular DA storage in α-syn deficient mice, studying the effect of VMAT inhibitor 
tetrabenazine on vesicle refilling and facilitation of DA overflow can be carried out. 
α-Syn mediates vesicle redistribution and plasticity of DA release associated with 
vesicular organization. In addition, α-syn may play a role in mediating therapeutic effects 
of psychotropic agents including psychostimulants and re-uptake inhibitors like MPD. To 
validate whether this phenomenon is specific to MPD or also other dopaminergic drugs, 
evoked DA overflow in the dorsal striatum can be studied following amphetamine 
treatment. Further, testing the effects of amphetamine and MPD on DA neurotransmission 
in the ventral striatum, the region unaffected by α-syn deletion, may also elucidate 
subregion-specific and/or drug-specific effects of α-syn on DA neurotransmission. In 
addition, behavioural experiments such as measuring the effect of MPD on psychomotor 
stimulation in wild-type and α-syn deficient mice may provide a better understanding of 
the phenomenon reported in this work.  
The results of this work pave the way for future studies pertaining to the role of α-syn at 
neurochemical and behavioural levels. This work also took the first step to enable 
simultaneous study of DA neurotransmission at neurochemical and behavioural levels by 
further developing the technique of FSCV in freely moving mice. Subsecond DA release 
plays an important role in the modulation of many behaviours, including motor function, 
reward, goal-directed behaviour, and cognitive locomotor response to therapeutic and 
addictive drugs. However, how DA modulates this behaviour, especially in connection 
with α-syn, is poorly understood. One major advance in studying the role of DA has been 
the use of in vivo voltammetry in freely moving animals (Garris et al., 1997a; Yavich and 
Tiihonen, 2000a). However, a major challenge in this approach is the low concentrations of 
endogenously released DA (100-500 nM). Detecting DA at such low concentrations in freely 
moving animals is difficult due to electrical artifacts produced by movements and changes 
in other chemicals which also contribute to the electrical signal (Phillips et al., 2003; for a 
review, see Wightman, 2006; Robinson et al., 2008). Therefore, the best way to overcome 
this limitation is development of sensors with a higher sensitivity and selectivity for DA. 
Our developments of FSCV techniques from Study IV would be highly useful in studying 
the role of α-syn in modulating subsecond DA release in freely moving α-syn deficient 
mice.  
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7 Conclusions 
The primary aim of this work was to investigate the role of α-syn in the striatal 
dopaminergic system. Alterations in electrically evoked DA overflow, basal extracellular 
DA levels, and DAT expression were studied in wild-type and mouse lines lacking α-syn. 
Different pharmacological tools were used to probe the mechanisms of action of α-syn. The 
results indicate the following main conclusions: 
 
1. α-Syn plays an important role in maintaining dopaminergic homeostasis in the 
dorsal striatum. The absence of α-syn produces significant increase in electrically 
evoked and basal extracellular DA levels, and a modest decrease in DAT expression 
in the dorsal striatum.  
 
2. α-Syn may play a subregion specific role in the striatum. Loss of α-syn alters the 
short-term plasticity of DA overflow selectively in the dorsolateral striatum. The 
dorsomedial striatum is relatively less affected while no changes are found in the 
ventral striatum in the absence of α-syn. The dorsolateral-ventromedial pattern of α-
syn-dependent short-term plasticity correlates precisely with the degeneration 
pattern of DA neurons in the course of PD. We suggest that these alterations may be 
a result of α-syn-mediated regulation of vesicle pools and this may be particularly 
crucial in the dorsolateral striatum. 
 
3. The presence of α-syn may modify pharmacological actions of psychostimulants 
such as MPD. We found that MPD modulates overflow and compartmentalization of 
presynaptic DA via an α-syn dependent mechanism of vesicle mobilisation. Further, 
we showed MPD affects DA neurotransmission not only by inhibiting re-uptake but 
also by differentially increasing or decreasing DA release probability depending on 
the presence of α-syn. These findings suggest a wider role for α-syn in modulating 
the effects of psychostimulants and drugs of abuse. 
 
4. We showed that carbon fibre electrodes with a relatively larger diameter of 32 μm 
can be successfully used for in vivo detection of DA with fast-scan cyclic 
voltammetry, yielding a 14-fold greater sensitivity than conventional electrodes. 
Further, the novel waveform of applied voltage can boost the sensitivity of all types 
of carbon fibre electrodes by ~65%.  
 
In summary, the functions of α-syn are of critical importance for proper functioning of 
the dopaminergic system. α-Syn regulates crucial aspects of DA neurotransmission 
including release, re-uptake, and extracellular DA levels, short-term plasticity of DA 
overflow, and mediates the therapeutic actions of psychotropic agents.  
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in the Regulation of Dopamine 
Neurotransmission in the Striatum
The presynaptic protein alpha-
synuclein (α-syn) plays a crucial role 
in dopamine neurotransmission and 
pathology of Parkinson’s disease. 
However, its precise functions in the 
dopaminergic system are unknown. 
This thesis shows that α-syn plays an 
important role in the dorsal region 
of the striatum, where it modulates 
striatal neurochemistry, short-term 
plasticity of dopamine release, and 
may mediate the pharmacological 
action of psychostimulants.
